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Summary 
Aminoglycosides are valuable and effective broad-spectrum bactericidal antibiotics 
against Gram-positive and Gram-negative pathogens, with several members of natural and 
semisynthetic origin occupying prominent roles in clinical practice since 1950. Nobel-prize 
winning crystallographic studies on the ribosome have revealed how their diverse 
polyaminated sugar framework is tailored to target a RNA helix within the decoding centre 
of the bacterial 30S subunit. By interfering with the affinity and kinetics of the tRNA 
selection and proof-reading steps, they induce error-prone protein synthesis, and 
translocation inhibition and lead to a lethal cycle of antibiotic uptake and membrane stress. 
In retaliation, bacterial pathogens have evolved and disseminated a number of enzymatic 
and efflux resistance mechanisms. These include N-acetyl-transferases, 
O-phosphotransferases and O-nucleotidyltransferases, which target the core hydroxyl and 
amino groups of aminoglycosides promiscuously; methyltransferases, which target the 
ribosomal binding-site; and energy-dependent drug efflux pumps for aminoglycoside-
selective elimination, in Gram-negative pathogens.  
The most problematic infectious pathogens which are currently resilient to most 
unrelated antibiotic classes and in the verge of pan-resistance have been defined ‘ESKAPE’ 
bacteria, a mnemonic for Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae. 
The world-wide spread of aminoglycoside resistance to current clinical standards, such as 
tobramycin, amikacin and gentamicin, ranges from 20 to 60% of clinical isolates. Hence, 
the contemporary 4,6-disubstituted-2-deoxystreptamine aminoglycosides are currently 
inadequate as broad-spectrum anti-infective therapies. 
The 4,5-disubstituted class of aminoglycosides are a challenging framework for 
medicinal chemistry, which includes butirosin, neomycin and paromomycin. Exploring the 
potential of these alternatives, colleagues in the Hanessian group and collaborators of 
Achaogen Inc. have demonstrated that paromomycin and neomycin analogs modified by 
deoxygenation of positions 3' and 4', as well as N1-substituted analogs possesing the 
-hydroxy--aminobutyryl amide (HABA) chain of butirosin, could produce promising 
antibiotics. Chapter 4 of this dissertation features the conception and development of an 
expedient semi-synthetic strategy to access novel aminoglycosides of the 4,5-disubstituted 
class, inspired from biosynthetic modifications of the sisomicin subfamily, that surmount 
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the wide-spread bacterial resistance mechanisms. This synthetic methodology relies on a 
novel Tsuji palladium-catalyzed hydrogenolysis developed on model monosaccharides, 
which was applied to generate a library of aminoglycosides comprising ring A hybrids of 
the neomycin and sisomicin families. The structure-activity relationships of this new class 
were assessed against a panel of 26 bacterial strains expressing modifying enzymes and 
efflux systems to provide an overview of ESKAPE pathogens. Two novel hybrid 
aminoglycoside analogs exhibited excellent antibacterial coverage, and may be promising 
candidates for preclinical development. 
Aminoglycoside therapy is also invariably associated with a probability of 
nephrotoxic complications. Aminoglycoside toxicity has been largely correlated with the 
number of amino groups, and more loosely with the extent of deoxygenation. A long 
standing hypothesis in the field states that because the foremost interactions are effected by 
ammonium group salts, the tuning of pKa parameters could provide a higher target 
dissociation rate, more effective clearance and overall less nephrotoxic analogs. Chapter 5 
in this dissertation features the conception and asymmetric synthesis of isosteric 
-substituted N1-HABA chains, modified by mono- and bis-fluorination. These chains 
covering a range of -N-pKa values from 10 to 7.5 were applied to advanced tetra-
deoxygenated neomycin antibiotics. In spite of the important reduction in -N-pKa, 
broad-spectrum antimicrobial activity was not significantly disrupted for isosteric 
fluorinated analogs. Furthermore, structure-toxicity relationships, assessed by Achaogen’s 
proprietary luciferase-coupled apoptosis assay, revealed that the novel ,-difluoro-N1-
HABA chain is less harmful in a Human Kidney 2 cell-line model and promising for the 
development as new generation neomycin antibiotics with improved therapeutic properties. 
The final chapter in this dissertation features the proposal and validation of the 
concise biomimetic synthesis and self-assembly of aminoglycoside 66-40C, a remarkable 
C2-symmetric 16-membered macrocyclic bis-imine dimer. The proposed structure was 
spectroscopically characterized as an anti-parallel s-trans-bis-azadiene macrocyclic system. 
Calculations indicate the anomeric effect of the -glycosidic bond between rings A and B is 
important for pre-organization of the monomeric sisomicin 6'-aldehyde and favors the 
observed macrocycle product. Self-assembly in aqueous solutions was studied through the 
dimerization of three diverse analogs and cross-over experiments, which demonstrated the 
generality and stability of the macrocyclic motif of aminoglycoside 66-40C. 
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Résumé 
            Les antibiotiques aminoglycosidiques sont des agents bactéricides de grande valeur 
et d’efficacité à large spectre contre les pathogènes Gram-positifs et Gram-négatifs, dont 
plusieurs membres naturels et semisynthétiques sont importants dans l’histoire clinique 
depuis 1950. Des travaux crystallographiques sur le ribosome, récompensés par le prix 
Nobel, ont démontré comment leurs diverses structures polyaminées sont adaptées pour 
cibler une hélice d’ARN dans le centre de codage de la sous-unité 30S du ribosome 
bactérien. Leur interférence avec l’affinité et la cinétique des étapes de sélection et 
vérification des tARN induit la synthèse de protéines à basse fidélité, et l’inhibition de la 
translocation, établissant un cercle vicieux d’accumulation d’antibiotique et de stress sur la 
membrane. En réponse à ces pressions, les pathogènes bactériens ont évolué et disséminé 
une panoplie de mécanismes de résistance enzymatiques et d’expulsion : tels que les 
N-acétyltransférases, les O-phosphotransférases et les O-nucleotidyltransférases qui ciblent 
les groupements hydroxyle et amino sur le coeur des aminoglycosides; des méthyl-
transférases, qui ciblent le site de liaison ribosomale; et des pompes d’expulsion actives 
pour l’élimination sélective des aminoglycosides, qui sont utilisés par les souches Gram-
négatives. 
            Les pathogènes les plus problématiques, qui présentent aujourd’hui une forte 
résilience envers la majorité des classes d’antibiotiques sur le bord de la pan-résistance ont 
été nommés des bactéries ESKAPE, une mnémonique pour Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa et Enterobacteriaceae. La distribution globale des souches avec des 
mécanismes de résistance envers les standards cliniques aminoglycosides, tels que la 
tobramycine, l’amikacine et la gentamicine, est comprise entre 20 et 60% des isolées 
cliniques. Ainsi, les aminoglycosides du type 4,6-disubstitués-2-deoxystreptamine sont 
inadéquats comme thérapies anti-infectieuses à large spectre. 
            Cependant, la famille des aminoglycosides 4,5-disubstitués, incluant la butirosine, 
la neomycine et la paromomycine, dont la structure plus complexe, pourrait constituter une 
alternative. Des collègues dans le groupe Hanessian et collaborateurs d’Achaogen Inc. ont 
démontré que certains analogues de la paraomomycine et neomycine, modifiés par 
désoxygénation sur les positions 3’ et 4’, et par substitution avec la chaîne N1--hydroxy--
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aminobutyramide (HABA) provenant de la butirosine, pourrait produire des antibiotiques 
très prometteurs. Le Chapitre 4 de cette dissertation présente la conception et le 
développement d’une stratégie semi-synthétique pour produire des nouveaux 
aminoglycosides améliorés du type 4,5-disubstitués, inspiré par des modifications 
biosynthétiques de la sisomicine, qui frustrent les mécanismes de résistance bactérienne 
distribuées globalement. Cette voie de synthèse dépend d’une réaction d’hydrogénolyse de 
type Tsuji catalysée par palladium, d’abord développée sur des modèles monosaccharides 
puis subséquemment appliquée pour générer un ensemble d’aminoglycosides hybrides 
entre la neomycine et la sisomicine. Les études structure-activité des divers analogues de 
cette nouvelle classe a été évalué sur une gamme de 26 souches bactériennes exprimant des 
mécanismes de résistance enzymatique et d’expulsion qui englobe l’ensemble des 
pathogènes ESKAPE. Deux des antibiotiques hybrides ont une couverture antibacterienne 
excellente, et cette étude a mis en évidence des candidats prometteurs pour le 
développement préclinique. 
            La thérapie avec les antibiotiques aminoglycosidiques est toujours associée à une 
probabilité de complications néphrotoxiques. Le potentiel de toxicité de chaque 
aminoglycoside peut être largement corrélé avec le nombre de groupements amino et de 
désoxygénations. Une hypothèse de longue date dans le domaine indique que les 
interactions principales sont effectuées par des sels des groupements ammonium, donc 
l’ajustement des paramètres de pKa pourrait provoquer une dissociation plus rapide avec 
leurs cibles, une clairance plus efficace et globalement des analogues moins 
néphrotoxiques. Le Chapitre 5 de cette dissertation présente la conception et la synthèse 
asymétrique de chaînes N1-HABA -substitutées par mono- et bis-fluoration. Des chaînes 
qui possèdent des -N-pKa dans l’intervale entre 10 et 7.5 ont été appliquées sur une 
neomycine tétra-désoxygénée pour produire des antibiotiques avancés. Malgré la réduction 
considérable du -N-pKa, le large spectre bactéricide n’a pas été significativement affecté 
pour les analogues fluorés isosteriques. De plus, des études structure-toxicité évaluées avec 
une analyse d’apoptose propriétaire d’Achaogen ont démontré que la nouvelle chaîne 
,-difluoro-N1-HABA est moins nocive sur un modèle de cellules de rein humain HK2 et 
elle est prometteuse pour le développement d’antibiotiques du type neomycine avec des 
propriétés thérapeutiques améliorées. 
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            Le chapitre final de cette dissertation présente la proposition et validation d’une 
synthèse biomimétique par assemblage spontané du aminoglycoside 66-40C, un dimère 
C2-symétrique bis-imine macrocyclique à 16 membres. La structure proposée du 
macrocycle a été affinée par spectroscopie nucléaire à un système trans,trans-bis-azadiène 
anti-parallèle. Des calculs indiquent que l’effet anomérique de la liaison -glycosidique 
entre les anneaux A et B fournit la pré-organisation pour le monomère 6’-aldéhydo 
sisomicine et favorise le produit macrocyclique observé. L’assemblage spontané dans l’eau 
a été étudié par la dimérisation de trois divers analogues et par des expériences 
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"Compound 4.18 (JPM4-189)"  1  1  D:  Hanessian
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Acq. Operator   : rd                             Seq. Line :  15
Acq. Instrument : Chemstation 8                   Location : Vial 10
Injection Date  : 12/15/2008 10:13:48 PM               Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20081215RD-AG\557\05-25-95B_20M.M
Last changed    : 10/24/2008 3:35:56 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 12/16/2008 8:35:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  



























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   8.658 MM    0.1969   13.33785    1.12922   0.2611
   2   9.803 BB    0.3603   61.65374    2.80684   1.2070
   3  10.800 MM    0.1505 5015.08398  555.31445  98.1797
   4  12.330 MM    0.2800   17.99119    1.07085   0.3522
Totals :                  5108.06677  560.32136
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20081215RD-AG\557\RD_000015.D
Sample Name: JPM4-189
Chemstation 8 12/16/2008 8:50:10 AM rd Page 1 of 1
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"Compound 4.19 (JPM4-191)"  1  1  D:  Hanessian
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Acq. Operator   : rd                             Seq. Line :  17
Acq. Instrument : Chemstation 8                   Location : Vial 11
Injection Date  : 12/15/2008 10:55:45 PM               Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20081215RD-AG\557\05-25-95B_20M.M
Last changed    : 10/24/2008 3:35:56 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 12/16/2008 8:35:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.714 MM    0.1799  101.51895    9.40456   2.0827
   2  10.856 BV    0.2273  150.06935    9.34979   3.0788
   3  11.599 MM    0.1430 4622.69629  538.71045  94.8385
Totals :                  4874.28459  557.46480
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20081215RD-AG\557\RD_000017.D
Sample Name: JPM4-191
Chemstation 8 12/16/2008 8:51:32 AM rd Page 1 of 1
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"Compound 4.21 (JPM4-169)"  1  1  D:  Hanessian
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Acq. Operator   : rd                             Seq. Line :  14
Acq. Instrument : Chemstation 8                   Location : Vial 9
Injection Date  : 12/15/2008 9:52:48 PM                Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20081215RD-AG\557\05-25-95B_20M.M
Last changed    : 10/24/2008 3:35:56 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 12/16/2008 8:35:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  





























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  10.192 BB    0.1923  111.17039    8.09142   2.2071
   2  10.926 BV    0.2445  150.17834    9.29495   2.9815
   3  11.674 VB    0.1313 4749.79053  558.00244  94.2971
   4  12.997 MM    0.4246   25.90739    1.01685   0.5143
Totals :                  5037.04665  576.40566
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20081215RD-AG\557\RD_000014.D
Sample Name: JPM4-169
Chemstation 8 12/16/2008 8:48:48 AM rd Page 1 of 1
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"Compound 4.23 (JPM4-193)"  1  1  D:  Hanessian
149
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Acq. Operator   : rd                             Seq. Line :  18
Acq. Instrument : Chemstation 8                   Location : Vial 12
Injection Date  : 12/15/2008 11:16:43 PM               Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20081215RD-AG\557\05-25-95B_20M.M
Last changed    : 10/24/2008 3:35:56 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 12/16/2008 8:35:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  





























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.723 BB    0.1310   23.25134    2.74062   0.3931
   2  10.185 MM    0.1403   12.68547    1.50671   0.2145
   3  10.939 BB    0.2216   61.72415    3.79780   1.0435
   4  11.679 MM    0.1413 5817.34863  686.23798  98.3489
Totals :                  5915.00959  694.28311
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20081215RD-AG\557\RD_000018.D
Sample Name: JPM4-193
Chemstation 8 12/16/2008 8:52:20 AM rd Page 1 of 1
151
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"Compound 4.25 (JPM5-17)"  1  1  D:  Hanessian
152
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Acq. Operator   : rd                             Seq. Line :  16
Acq. Instrument : Chemstation 4                   Location : Vial 71
Injection Date  : 1/28/2009 11:48:42 PM                Inj :   1
                                                Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20090128RD-AG\20090128RD-AG\05-30-75B_210_30M.M
Last changed    : 1/23/2009 12:23:25 PM by rc
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 1/28/2009 8:43:05 AM by rc
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  
























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.277 MF    0.2662 1937.68665  121.29505  96.9886
   2  10.629 FM    0.2323    9.60944 6.89434e-1   0.4810
   3  12.757 MM    0.4517   50.55310    1.86522   2.5304
Totals :                  1997.84919  123.84971
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090128RD-AG\20090128RD-AG\RD-AG000016.D
Sample Name: JPM-5-17
Chemstation 4 1/29/2009 9:18:34 AM rc Page 1 of 1
154
4.28 





























































































































































































































































"Compound 4.27 (JPM5-19)"  1  1  D:  Hanessian
155
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Acq. Operator   : rd                             Seq. Line :  17
Acq. Instrument : Chemstation 4                   Location : Vial 72
Injection Date  : 1/29/2009 12:19:31 AM                Inj :   1
                                                Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20090128RD-AG\20090128RD-AG\05-30-75B_210_30M.M
Last changed    : 1/23/2009 12:23:25 PM by rc
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 1/28/2009 8:43:05 AM by rc
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  




























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.947 MM    0.2289   17.42037    1.26856   0.7351
   2   9.402 MM    0.8175   59.04083    1.20362   2.4913
   3  12.816 BB    0.2729 2134.35278  121.52830  90.0615
   4  15.819 BB    0.2858  159.06853    7.80302   6.7121
Totals :                  2369.88251  131.80350
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090128RD-AG\20090128RD-AG\RD-AG000017.D
Sample Name: JPM-5-19
Chemstation 4 1/29/2009 9:19:18 AM rc Page 1 of 1
157
4.30 











































































































































































































































































































































Acq. Operator   : rd                             Seq. Line :  20
Acq. Instrument : Chemstation 8                   Location : Vial 26
Injection Date  : 2/27/2009 7:42:50 PM                 Inj :   1
                                                Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20090227RD-AG\596\05-25-95B_20M.M
Last changed    : 2/23/2009 10:45:33 AM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 2/27/2009 4:35:05 PM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  































                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   3.586 MM    0.1975   12.38992    1.04543   0.4474
   2   8.450 MM    0.3210   33.89148    1.40172   1.2237
   3   9.690 MF    0.1877 2705.54370  240.25909  97.6908
   4  10.541 FM    0.1758    9.77732 9.27024e-1   0.3530
   5  11.444 MM    0.2507    7.89570 5.24878e-1   0.2851
Totals :                  2769.49811  244.15814
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090227RD-AG\596\RD-AG000020.D
Sample Name: JPM-5-29
Chemstation 8 3/2/2009 4:40:03 PM rd Page 1 of 1
160
4.33 
































































































































































































































































































































































































































































"Compound 4.34 (JPM5-59)"  1  1  D:  Hanessian
161
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Acq. Operator   : rd                             Seq. Line :   7
Acq. Instrument : Chemstation 8                   Location : Vial 32
Injection Date  : 3/6/2009 5:33:26 PM                  Inj :   1
                                                Inj Volume : 2 µl
Acq. Method     : C:\Chem32\1\DATA\20090306RD-AG\603\05-25-95B_20M.M
Last changed    : 2/23/2009 10:45:33 AM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 3/9/2009 8:54:44 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  




























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1   9.492 MM    0.1651   28.48261    2.87491   1.3127
   2  10.628 MM    0.3154   55.44510    2.92964   2.5553
   3  11.324 MF    0.1457 2082.21240  238.20245  95.9642
   4  12.132 FM    0.1330    3.64138 4.56144e-1   0.1678
Totals :                  2169.78150  244.46314
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090306RD-AG\603\RD-AG000007.D
Sample Name: JPM-5-59
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"Compound 5.4 (JPM5-129)"  2  1  D:  Hanessian
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"Compound 5.4 (JPM5-129)"  6  1  D:  Hanessian
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"Compound 5.4 (JPM5-129)"  1  1  D:  Hanessian
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"Compound 5.4 (JPM5-129)"  1  1  D:  Hanessian
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"Compound 5.4 (JPM5-129)"  3  1  D:  Hanessian
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"Compound 5.4 (JPM5-129)"  4  1  D:  Hanessian
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"Compound 5.6 (JPM5-137)"  2  1  D:  Hanessian
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"Compound 5.6 (JPM5-137)"  6  1  D:  Hanessian
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"Compound 5.6 (JPM5-137)"  1  1  D:  Hanessian
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"Compound 5.6 (JPM5-137)"  1  1  D:  Hanessian
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"Compound 5.6 (JPM5-137)"  4  1  D:  Hanessian
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"Compound 5.6 (JPM5-137)"  5  1  D:  Hanessian
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"Compound 5.8 (JPM5-127)"  1  1  D:  Hanessian
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"Compound 5.8 (JPM5-127)"  2  1  D:  Hanessian
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"Compound 5.8 (JPM5-127)"  4  1  D:  Hanessian
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"Compound 5.8 (JPM5-127)"  5  1  D:  Hanessian
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"Compound 5.11 (JPM5-177)"  1  1  D:  Hanessian
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"Compound 5.11 (JPM5-177)"  3  1  D:  Hanessian
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"Compound 5.11 (JPM5-177)"  4  1  D:  Hanessian
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"Compound 5.11 (JPM5-177)"  4  1  D:  Hanessian
231
=====================================================================
Acq. Operator   : rd                             Seq. Line :  18
Acq. Instrument : Chemstation 8                   Location : Vial 27
Injection Date  : 7/20/2009 9:12:11 PM                 Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\Chem32\1\DATA\20090720RD-AG\680\05-30-75B_30M.M
Last changed    : 6/3/2009 4:40:11 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 7/22/2009 10:16:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  

























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  15.447 MM    0.6713   46.90804    1.16453   0.9562
   2  16.729 MF    0.2652 4632.53711  291.16046  94.4355
   3  17.946 FM    0.2025  226.05675   18.60634   4.6082
Totals :                  4905.50189  310.93133
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090720RD-AG\680\RD-AG000018.D
Sample Name: JPM-5-177
Chemstation 8 7/22/2009 11:34:37 AM rd Page 1 of 1
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"Comopund 5.12 (JPM5-175)"  1  1  D:  Hanessian
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"Comopund 5.12 (JPM5-175)"  3  1  D:  Hanessian
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"Comopund 5.12 (JPM5-175)"  4  1  D:  Hanessian
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"Comopund 5.12 (JPM5-175)"  4  1  D:  Hanessian
236
=====================================================================
Acq. Operator   : rd                             Seq. Line :  16
Acq. Instrument : Chemstation 8                   Location : Vial 26
Injection Date  : 7/20/2009 8:10:03 PM                 Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\Chem32\1\DATA\20090720RD-AG\680\05-30-75B_30M.M
Last changed    : 6/3/2009 4:40:11 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 7/22/2009 10:16:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  






























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  15.474 MM    0.3494   24.63910    1.17544   0.5217
   2  16.836 MF    0.2682 4607.08398  286.30731  97.5469
   3  17.968 FM    0.2321   78.56721    5.64193   1.6635
   4  21.320 MM    0.5934   12.65054 3.55318e-1   0.2679
Totals :                  4722.94083  293.48000
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090720RD-AG\680\RD-AG000016.D
Sample Name: JPM-5-175
Chemstation 8 7/22/2009 11:33:54 AM rd Page 1 of 1
237





































































































































































































































































































































"Compound 5.13 (JPM5-179)"  1  1  D:  Hanessian
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"Compound 5.13 (JPM5-179)"  2  1  D:  Hanessian
239
=====================================================================
Acq. Operator   : rd                             Seq. Line :  19
Acq. Instrument : Chemstation 8                   Location : Vial 28
Injection Date  : 7/20/2009 9:43:15 PM                 Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\Chem32\1\DATA\20090720RD-AG\680\05-30-75B_30M.M
Last changed    : 6/3/2009 4:40:11 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 7/22/2009 10:16:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  


























                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  15.013 MM    0.5230  116.93092    3.72629   1.9854
   2  16.809 MF    0.2806 5681.50732  337.45233  96.4659
   3  17.955 FM    0.2955   91.21282    5.14437   1.5487
Totals :                  5889.65107  346.32299
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090720RD-AG\680\RD-AG000019.D
Sample Name: JPM-5-179
Chemstation 8 7/22/2009 11:35:13 AM rd Page 1 of 1
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"Compound 5.14 (JPM5-151)"  2  1  D:  Hanessian
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"Compound 5.14 (JPM5-151)"  4  1  D:  Hanessian
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"Compound 5.14 (JPM5-151)"  1  1  D:  Hanessian
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"Compound 5.14 (JPM5-151)"  1  1  D:  Hanessian
244
=====================================================================
Acq. Operator   : rd                             Seq. Line :  14
Acq. Instrument : Chemstation 8                   Location : Vial 24
Injection Date  : 7/20/2009 7:07:57 PM                 Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\Chem32\1\DATA\20090720RD-AG\680\05-30-75B_30M.M
Last changed    : 6/3/2009 4:40:11 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 7/22/2009 10:16:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  



































                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  15.258 MM    0.3037  306.18039   16.80083   5.5798
   2  16.607 MF    0.2830 4914.58496  289.43253  89.5632
   3  17.967 FM    0.2625  218.36775   13.86411   3.9795
   4  20.841 MM    0.7193   43.64676    1.01128   0.7954
   5  22.063 MM    0.2028    4.50189 3.69911e-1   0.0820
Totals :                  5487.28175  321.47865
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090720RD-AG\680\RD-AG000014.D
Sample Name: JPM-5-151
Chemstation 8 7/22/2009 11:32:24 AM rd Page 1 of 1
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"Compound 5.15 (JPM5-154)"  1  1  D:  Hanessian
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"Compound 5.15 (JPM5-154)"  3  1  D:  Hanessian
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"Compound 5.15 (JPM5-154)"  4  1  D:  Hanessian
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"Compound 5.15 (JPM5-154)"  4  1  D:  Hanessian
249
=====================================================================
Acq. Operator   : rd                             Seq. Line :  15
Acq. Instrument : Chemstation 8                   Location : Vial 25
Injection Date  : 7/20/2009 7:38:59 PM                 Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\Chem32\1\DATA\20090720RD-AG\680\05-30-75B_30M.M
Last changed    : 6/3/2009 4:40:11 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 7/22/2009 10:16:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  








































                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  14.370 MM    0.1714    1.87630 1.82448e-1   0.0356
   2  14.654 MM    0.1760    2.66441 2.52376e-1   0.0506
   3  15.296 MM    0.3664   21.96153 9.99039e-1   0.4167
   4  16.747 MF    0.2795 5161.20850  307.72284  97.9206
   5  17.978 FM    0.3309   67.04270    3.37640   1.2720
   6  21.103 MM    0.2527   16.05596    1.05881   0.3046
Totals :                  5270.80940  313.59191
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090720RD-AG\680\RD-AG000015.D
Sample Name: JPM-5-154
Chemstation 8 7/22/2009 11:33:09 AM rd Page 1 of 1
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"Compound 5.16 (JPM5-149)"  1  1  D:  Hanessian
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"Compound 5.16 (JPM5-149)"  3  1  D:  Hanessian
252
=====================================================================
Acq. Operator   : rd                             Seq. Line :  12
Acq. Instrument : Chemstation 8                   Location : Vial 23
Injection Date  : 7/20/2009 6:05:50 PM                 Inj :   1
                                                Inj Volume : 20 µl
Different Inj Volume from Sequence !     Actual Inj Volume : 5 µl
Acq. Method     : C:\Chem32\1\DATA\20090720RD-AG\680\05-30-75B_30M.M
Last changed    : 6/3/2009 4:40:11 PM by rd
Analysis Method : C:\CHEM32\1\METHODS\INT_30MIN.M
Last changed    : 7/22/2009 10:16:51 AM by rd
                  (modified after loading)
Method Info     : Integration method.
Sample Info     : 20x dilution
                  








































                         Area Percent Report                         
=====================================================================
Sorted By             :      Signal
Multiplier            :      1.0000
Dilution              :      1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: ADC1 A, ADC1 CHANNEL A
Peak RetTime Type  Width     Area      Height     Area  
  #   [min]        [min]   [mAU*s]     [mAU]        %
----|-------|----|-------|----------|----------|--------|
   1  11.174 MM    0.2023    2.59703 2.13988e-1   0.0467
   2  11.711 MM    0.2642    5.41364 3.41519e-1   0.0974
   3  14.991 MM    0.5720  164.35103    4.78857   2.9557
   4  16.751 MF    0.2783 5267.21338  315.49460  94.7261
   5  17.989 FM    0.2848   34.01289    1.99023   0.6117
   6  21.129 MM    0.6513   86.87753    2.22310   1.5624
Totals :                  5560.46549  325.05200
=====================================================================
                          *** End of Report ***
Data File C:\CHEM32\1\DATA\20090720RD-AG\680\RD-AG000012.D
Sample Name: JPM-5-149
Chemstation 8 7/22/2009 11:31:29 AM rd Page 1 of 1
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Operation Time 6/25/2010 03:57:02
Model DoseResp
Equation
y = A1 + (A2-A1)/(1 + 10 (^(LOGx0-
x)*p))
Report Status New Analysis Report
Multi-Data Fit Mode






















All datasets were fitted successfully.
Some parameter values were fixed.
Statistics
5.10 (H) - C003932 5.11 (F) - C004675 5.12 (diF) - C004674
Number of Points 8 8 8
Degrees of Freedom 4 5 4
Reduced Chi-Sqr 1.41584 31.70456 1.13534
Residual Sum of Squares 5.66335 158.52281 4.54137
Adj. R-Square 0.99945 0.98935 0.99998
Fit Status Succeeded(100) Succeeded(100) Succeeded(100)
Fit Status Code : 
100 : Fit converged
ANOVA
DF Sum of Squares Mean Square F Value Prob>F
5.10 (H) - C003932
Regression 4 1.81625E12 4.54063E11 3.20702E11 0
Residual 4 5.66335 1.41584
Uncorrected Total 8 1.81625E12
Corrected Total 7 18085.95701
5.11 (F) - C004675
Regression 3 1.79344E12 5.97814E11 1.88558E10 0
Residual 5 158.52281 31.70456
Uncorrected Total 8 1.79344E12
Corrected Total 7 20841.06038
5.12 (diF) - C004674
Regression 4 1.21371E12 3.03429E11 2.67258E11 0
Residual 4 4.54137 1.13534
Uncorrected Total 8 1.21371E12
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NL Fit (DoseResp) (6/25/2010 03:57:02)
Fitted Curves Plot
5.10 (H) - C003932
0 1 2 3
2 0 00 00
4 0 00 00
6 0 00 00














lo g co nc
5.10 (H) - C003 932
DoseR esp F it  o f 5.10 (H) - C0
5.11 (F) - C004675
0 1 2 3
2 0 00 00
4 0 00 00
6 0 00 00














lo g co nc
5.11 (F) - C0 04675
DoseR esp F it  o f 5.11 (F) - C0
5.12 (diF) - C004674
0 1 2 3
2 0 00 00
4 0 00 00















lo g co nc
5.12 (diF ) - C004 674
DoseR esp F it  o f 5.12 (diF ) - C
Residual vs. Independ
5.10 (H) - C003932



























I nde pende nt  Varia ble
Resid ual of  5.10 (H) - C0 0393 2
5.11 (F) - C004675


























I nde pende nt  Varia ble
Resid ual of  5.11 (F ) - C0046 75
5.12 (diF) - C004674



























I nde pende nt  Varia ble
Resid ual of  5.12 (di F) - C00 4674
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Operation Time 6/25/2010 03:59:40
Model DoseResp
Equation
y = A1 + (A2-A1)/(1 + 10 (^(LOGx0-
x)*p))
Report Status New Analysis Report
Multi-Data Fit Mode






















Fitting failed on some of the datasets.
Some parameter values were fixed.
Statistics
5.13 (OH) - C004676 Gentamicin Amikacin
Number of Points 8 8 8
Degrees of Freedom 5 4 4
Reduced Chi-Sqr 1.32014 3.67143 2.36441
Residual Sum of Squares 6.60068 14.68571 9.45763
Adj. R-Square 0.99828 0.99415 0.9649
Fit Status Succeeded(100) Succeeded(100) Reduced chi-sq(1)
Fit Status Code : 
100 : Fit converged
1 : Chi-sqr is reduced.
ANOVA
DF Sum of Squares Mean Square F Value Prob>F
5.13 (OH) - C004676
Regression 3 1.41831E12 4.72771E11 3.58123E11 0
Residual 5 6.60068 1.32014
Uncorrected Total 8 1.41831E12
Corrected Total 7 5369.67704
Gentamicin
Regression 4 1.22321E12 3.05802E11 8.32924E10 0
Residual 4 14.68571 3.67143
Uncorrected Total 8 1.22321E12
Corrected Total 7 4393.62396
Amikacin
Regression 4 4.61716E11 1.15429E11 4.88194E10 0
Residual 4 9.45763 2.36441
Uncorrected Total 8 4.61716E11
256
NL Fit (DoseResp) (6/25/2010 03:59:40)
Fitted Curves Plot
5.13 (OH) - C004676
0 1 2 3
2 0 00 00
4 0 00 00
















lo g co nc
5.13 (OH) - C0 0467 6
DoseR esp F it  o f 5.13 (OH) - C
Gentamicin
0 1 2 3
2 0 00 00
4 0 00 00








lo g co nc
Ge nta mi cin
DoseR esp F it  o f Ge nta mi cin
Amikacin
0 1 2 3
1 8 00 00
2 4 00 00







lo g co nc
Ami kacin
DoseR esp F it  o f Ami kacin
Residual vs. Independ
5.13 (OH) - C004676




























I nde pende nt  Varia ble
Resid ual of  5.13 (OH ) - C004 676
Gentamicin



















I nde pende nt  Varia ble
Resid ual of  G entam icin
Amikacin


















I nde pende nt  Varia ble
Resid ual of  Am ikacin
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Operation Time 6/25/2010 03:41:42
Model DoseResp
Equation
y = A1 + (A2-A1)/(1 + 10 (^(LOGx0-
x)*p))
Report Status New Analysis Report
Multi-Data Fit Mode






















All datasets were fitted successfully.
Statistics
5.10 (H) - C003932 5.14 (F) - C004672 5.15 (diF) - C004673
Number of Points 8 8 8
Degrees of Freedom 4 4 4
Reduced Chi-Sqr 1.16765 5.30064 0.97621
Residual Sum of Squares 4.67062 21.20258 3.90482
Adj. R-Square 0.99885 0.99601 0.99984
Fit Status Succeeded(100) Succeeded(100) Succeeded(100)
Fit Status Code : 
100 : Fit converged
ANOVA
DF Sum of Squares Mean Square F Value Prob>F
5.10 (H) - C003932
Regression 4 1.79214E12 4.48035E11 3.83705E11 0
Residual 4 4.67062 1.16765
Uncorrected Total 8 1.79214E12
Corrected Total 7 7136.12239
5.14 (F) - C004672
Regression 4 1.6406E12 4.10149E11 7.73772E10 0
Residual 4 21.20258 5.30064
Uncorrected Total 8 1.6406E12
Corrected Total 7 9292.72475
5.15 (diF) - C004673
Regression 4 1.19846E12 2.99616E11 3.06919E11 0
Residual 4 3.90482 0.97621
Uncorrected Total 8 1.19846E12
258
NL Fit (DoseResp) (6/25/2010 03:41:42)
Fitted Curves Plot
5.10 (H) - C003932
0 1 2 3
2 0 00 00
4 0 00 00
6 0 00 00














lo g co nc
5.10 (H) - C003 932
DoseR esp F it  o f 5.10 (H) - C0
5.14 (F) - C004672
0 1 2 3
2 0 00 00
4 0 00 00














lo g co nc
5.14 (F) - C0 04672
DoseR esp F it  o f 5.14 (F) - C0
5.15 (diF) - C004673
0 1 2 3
2 0 00 00
4 0 00 00















lo g co nc
5.15 (diF ) - C004 673
DoseR esp F it  o f 5.15 (diF ) - C
Residual vs. Independ
5.10 (H) - C003932




























I nde pende nt  Varia ble
Resid ual of  5.10 (H) - C0 0393 2
5.14 (F) - C004672


























I nde pende nt  Varia ble
Resid ual of  5.14 (F ) - C0046 72
5.15 (diF) - C004673




























I nde pende nt  Varia ble
Resid ual of  5.15 (di F) - C00 4673
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Operation Time 6/25/2010 03:50:59
Model DoseResp
Equation
y = A1 + (A2-A1)/(1 + 10 (^(LOGx0-
x)*p))
Report Status New Analysis Report
Multi-Data Fit Mode






















Fitting failed on some of the datasets.
Statistics
5.16 (OH) - C004671 Gentamicin Amikacin
Number of Points 8 8 8
Degrees of Freedom 4 4 4
Reduced Chi-Sqr 5.70338 0.36076 2.50386
Residual Sum of Squares 22.81354 1.44305 10.01545
Adj. R-Square 0.99799 0.99742 0.9891
Fit Status Succeeded(100) Succeeded(100) Reduced chi-sq(1)
Fit Status Code : 
100 : Fit converged
1 : Chi-sqr is reduced.
ANOVA
DF Sum of Squares Mean Square F Value Prob>F
5.16 (OH) - C004671
Regression 4 1.5795E12 3.94876E11 6.92353E10 0
Residual 4 22.81354 5.70338
Uncorrected Total 8 1.5795E12
Corrected Total 7 19899.24456
Gentamicin
Regression 4 1.07317E12 2.68292E11 7.43678E11 0
Residual 4 1.44305 0.36076
Uncorrected Total 8 1.07317E12
Corrected Total 7 980.22355
Amikacin
Regression 4 4.38856E11 1.09714E11 4.38179E10 0
Residual 4 10.01545 2.50386
Uncorrected Total 8 4.38856E11
260
NL Fit (DoseResp) (6/25/2010 03:50:59)
Fitted Curves Plot
5.16 (OH) - C004671
0 1 2 3
2 0 00 00
4 0 00 00
















lo g co nc
5.16 (OH) - C0 0467 1
DoseR esp F it  o f 5.16 (OH) - C
Gentamicin
0 1 2 3
2 0 00 00
4 0 00 00








lo g co nc
Ge nta mi cin
DoseR esp F it  o f Ge nta mi cin
Amikacin
0 1 2 3
2 1 00 00
2 8 00 00







lo g co nc
Ami kacin
DoseR esp F it  o f Ami kacin
Residual vs. Independ
5.16 (OH) - C004671




























I nde pende nt  Varia ble
Resid ual of  5.16 (OH ) - C004 671
Gentamicin




















I nde pende nt  Varia ble
Resid ual of  G entam icin
Amikacin



















I nde pende nt  Varia ble
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Figure 6.8. Sequential LCMS injections of aqueous solutions incubated 72 h in the following 
conditions: (A) sisamine dimer 6.13 alone, (B) aminoglycoside 66-40C 6.1 alone, (C) 1:1 mixture of 
free bases, (D) 1:1 mixture of lyophilized acetate salts, (E) 1:1 mixture in pH 4 excess acetic acid, 
then lyophilized, (F) positive control, (G) cross-over product 6.21 isolated by preparative TLC. See 
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"Aminoglycoside 66-40 C (6.1)"  1  1  D:  Hanessian
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"Aminoglycoside 66-40 C (6.1)"  3  1  D:  Hanessian
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"Aminoglycoside 66-40 C (6.1)"  13  1  D:  Hanessian
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"Aminoglycoside 66-40 C (6.1)"  7  1  D:  Hanessian
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"Aminoglycoside 66-40 C (6.1)"  5  1  D:  Hanessian
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"Aminoglycoside 66-40 C (6.1)"  6  1  D:  Hanessian
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"Compound 6.13 (JPM6-19)"  1  1  D:  Hanessian
319



















































"Compound 6.13 (JPM6-19)"  3  1  D:  Hanessian
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"Compound 6.13 (JPM6-19)"  8  1  D:  Hanessian
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"Compound 6.13 (JPM6-19)"  4  1  D:  Hanessian
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"Compound 6.13 (JPM6-19)"  5  1  D:  Hanessian
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"Compound 6.13 (JPM6-19)"  6  1  D:  Hanessian
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"Compound 6.15 (JPM6-23)"  1  1  D:  Hanessian
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"Compound 6.15 (JPM6-23)"  8  1  D:  Hanessian
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"Compound 6.15 (JPM6-23)"  13  1  D:  Hanessian
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"Compound 6.15 (JPM6-23)"  2  1  D:  Hanessian
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"Compound 6.15 (JPM6-23)"  4  1  D:  Hanessian
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"Compound 6.15 (JPM6-23)"  5  1  D:  Hanessian
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"Compound 6.20 (JPM5-57)"  1  1  D:  Hanessian
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"Compound 6.20 (JPM5-57)"  2  1  D:  Hanessian
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"Compound 6.20 (JPM5-57)"  10  1  D:  Hanessian
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"Compound 6.20 (JPM5-57)"  12  1  D:  Hanessian
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"Compound 6.20 (JPM5-57)"  102  1  D:  Hanessian
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"Compound 6.20 (JPM5-57)"  103  1  D:  Hanessian
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      Table 1.  Crystal data and structure refinement for C15 H19 N O5.  
   
   
      Identification code               HAN451  
   
      Empirical formula                 C15 H19 N O5  
   
      Formula weight                    293.31  
   
      Temperature                       150(2)K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       P212121  
   
      Unit cell dimensions              a = 4.7348(2) Å     = 90°  
                                        b = 10.7188(5) Å     = 90°  
                                        c = 28.7574(12) Å     = 90°  
   
      Volume                            1459.48(11)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.335  g/cm3  
   
      Absorption coefficient            0.837 mm-1  
   
      F(000)                            624  
   
      Crystal size                      0.20 x 0.08 x 0.06 mm  
   
      Theta range for data collection   3.07 to 72.61°  
   
      Index ranges                      -5  h  5, -12  k  13, -35    35  
   
      Reflections collected             19773  
   
      Independent reflections           2875 [Rint = 0.039]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.95 and 0.92  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    2875 / 0 / 193  
   
      Goodness-of-fit on F2             1.070  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0337, wR2 = 0.0870  
   
      R indices (all data)              R1 = 0.0381, wR2 = 0.0892  
   
      Absolute structure parameter      -0.07(19)  
  342 
   
      Extinction coefficient            0.0034(4)  
   
      Largest diff. peak and hole       0.145 and -0.176 e/Å3  
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         Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C15 H19 N O5.  
   
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          O(1)         9297(3)       -734(1)        277(1)       34(1)  
          O(2)         9929(3)       -257(1)       -714(1)       42(1)  
          O(3)         6714(3)       -460(1)        965(1)       35(1)  
          O(4)        12534(2)       2952(1)       1108(1)       32(1)  
          O(5)         8913(2)       3408(1)       1595(1)       31(1)  
          N(1)         8233(3)       2007(1)       1042(1)       28(1)  
          C(1)         6887(4)       -611(2)        -27(1)       33(1)  
          C(2)         5674(4)        674(2)        -25(1)       30(1)  
          C(3)         6548(3)       1559(2)        263(1)       27(1)  
          C(4)         8822(3)       1318(1)        615(1)       27(1)  
          C(5)         9083(4)        -83(2)        702(1)       30(1)  
          C(6)         7812(5)      -1025(2)       -508(1)       40(1)  
          C(7)         7076(5)      -1654(2)       1174(1)       46(1)  
          C(8)        10090(3)       2793(2)       1236(1)       25(1)  
          C(9)        10744(4)       4293(2)       1830(1)       35(1)  
          C(10)        8926(4)       4998(2)       2168(1)       31(1)  
          C(11)        9042(4)       4762(2)       2643(1)       42(1)  
          C(12)        7356(5)       5432(2)       2947(1)       52(1)  
          C(13)        5561(5)       6340(2)       2784(1)       51(1)  
          C(14)        5433(4)       6578(2)       2311(1)       47(1)  
          C(15)        7097(4)       5906(2)       2006(1)       37(1)  
         ________________________________________________________________  
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         Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C15 H19 N O5.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          H(2)         9174           386          -826          63  
          H(1)         6587          1901          1179          33  
          H(1A)        5393         -1199            83          39  
          H(2A)        4211           867          -239          36  
          H(3)         5715          2364           246          33  
          H(4)        10654          1624           485          32  
          H(5)        10829          -242           888          36  
          H(6A)        8540         -1889          -488          48  
          H(6B)        6139         -1037          -715          48  
          H(7A)        7600         -2264           935          70  
          H(7B)        5304         -1912          1322          70  
          H(7C)        8571         -1609          1409          70  
          H(9A)       11605          4872          1602          42  
          H(9B)       12274          3849          1996          42  
          H(11)       10283          4140          2759          51  
          H(12)        7441          5263          3271          63  
          H(13)        4417          6801          2994          61  
          H(14)        4198          7204          2196          56  
          H(15)        6985          6070          1682          45  
         ________________________________________________________________  
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    Table 4.  Anisotropic parameters (Å2 x 103) for C15 H19 N O5.  
   
         The anisotropic displacement factor exponent takes the form:  
   
                 -2 2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(1)     40(1)      35(1)      27(1)      -4(1)      -2(1)       9(1)  
    O(2)     42(1)      51(1)      33(1)       3(1)       5(1)       9(1)  
    O(3)     45(1)      30(1)      31(1)       7(1)       7(1)       2(1)  
    O(4)     23(1)      39(1)      34(1)      -5(1)       3(1)      -1(1)  
    O(5)     28(1)      37(1)      30(1)      -9(1)       5(1)      -3(1)  
    N(1)     23(1)      36(1)      25(1)      -4(1)       6(1)      -3(1)  
    C(1)     35(1)      33(1)      30(1)      -2(1)      -2(1)      -2(1)  
    C(2)     26(1)      39(1)      25(1)       2(1)       0(1)       1(1)  
    C(3)     27(1)      31(1)      24(1)       3(1)       2(1)       2(1)  
    C(4)     25(1)      32(1)      23(1)      -1(1)       4(1)       1(1)  
    C(5)     32(1)      36(1)      23(1)      -1(1)       1(1)       4(1)  
    C(6)     50(1)      35(1)      35(1)      -6(1)      -2(1)       2(1)  
    C(7)     65(1)      33(1)      41(1)       9(1)      -4(1)      -3(1)  
    C(8)     24(1)      28(1)      23(1)       2(1)       2(1)       2(1)  
    C(9)     29(1)      38(1)      38(1)     -10(1)       0(1)      -5(1)  
    C(10)    32(1)      30(1)      30(1)      -3(1)       1(1)      -6(1)  
    C(11)    48(1)      48(1)      31(1)       0(1)      -5(1)      -2(1)  
    C(12)    65(2)      64(1)      29(1)      -8(1)       6(1)     -14(1)  
    C(13)    48(1)      55(1)      49(1)     -25(1)      17(1)     -13(1)  
    C(14)    43(1)      37(1)      60(1)      -8(1)       5(1)       5(1)  
    C(15)    42(1)      36(1)      33(1)       1(1)       2(1)      -1(1)  
    _______________________________________________________________________  
 
  346 
  
      Table 5.  Bond lengths [Å] and angles [°] for C15 H19 N O5  
    ______________________________________________________________________  
  
    O(1)-C(5)              1.4105(18)  
    O(1)-C(1)              1.4438(19)  
    O(2)-C(6)              1.427(2)  
    O(3)-C(5)              1.4116(19)  
    O(3)-C(7)              1.425(2)  
    O(4)-C(8)              1.2262(18)  
    O(5)-C(8)              1.3465(18)  
    O(5)-C(9)              1.4513(19)  
    N(1)-C(8)              1.339(2)  
    N(1)-C(4)              1.4607(18)  
    C(1)-C(2)              1.492(2)  
    C(1)-C(6)              1.518(2)  
    C(2)-C(3)              1.325(2)  
    C(3)-C(4)              1.501(2)  
    C(4)-C(5)              1.527(2)  
    C(9)-C(10)             1.502(2)  
    C(10)-C(15)            1.384(2)  
    C(10)-C(11)            1.390(2)  
    C(11)-C(12)            1.386(3)  
    C(12)-C(13)            1.374(3)  
    C(13)-C(14)            1.386(3)  
    C(14)-C(15)            1.381(3)  
   
    C(5)-O(1)-C(1)         115.00(12)  
    C(5)-O(3)-C(7)         112.80(15)  
    C(8)-O(5)-C(9)         115.44(13)  
     
 
    C(8)-N(1)-C(4)         122.84(13)  
    O(1)-C(1)-C(2)         112.71(14)  
    O(1)-C(1)-C(6)         107.30(14)  
    C(2)-C(1)-C(6)         112.67(14)  
    C(3)-C(2)-C(1)         122.88(15)  
    C(2)-C(3)-C(4)         121.49(15)  
    N(1)-C(4)-C(3)         110.07(13)  
    N(1)-C(4)-C(5)         112.06(12)  
    C(3)-C(4)-C(5)         109.74(13)  
    O(1)-C(5)-O(3)         112.28(13)  
    O(1)-C(5)-C(4)         110.52(12)  
    O(3)-C(5)-C(4)         107.72(13)  
    O(2)-C(6)-C(1)         114.33(15)  
    O(4)-C(8)-N(1)         125.65(14)  
    O(4)-C(8)-O(5)         123.57(15)  
    N(1)-C(8)-O(5)         110.78(13)  
    O(5)-C(9)-C(10)        106.70(13)  
    C(15)-C(10)-C(11)      118.85(17)  
    C(15)-C(10)-C(9)       119.70(15)  
    C(11)-C(10)-C(9)       121.44(17)  
    C(12)-C(11)-C(10)      120.30(19)  
    C(13)-C(12)-C(11)      120.45(17)  
    C(12)-C(13)-C(14)      119.53(18)  
    C(15)-C(14)-C(13)      120.16(19)  
    C(14)-C(15)-C(10)      120.70(17)  
   
    
______________________________________________________________________  
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         Table 6.  Torsion angles [°] for C15 H19 N O5.  
  ______________________________________________________________________________  
  
  C(5)-O(1)-C(1)-C(2)       38.87(18)  
  C(5)-O(1)-C(1)-C(6)      163.48(14)  
  O(1)-C(1)-C(2)-C(3)       -6.7(2)  
  C(6)-C(1)-C(2)-C(3)     -128.27(18)  
  C(1)-C(2)-C(3)-C(4)       -0.8(2)  
  C(8)-N(1)-C(4)-C(3)     -125.35(16)  
  C(8)-N(1)-C(4)-C(5)      112.23(17)  
  C(2)-C(3)-C(4)-N(1)     -144.10(15)  
  C(2)-C(3)-C(4)-C(5)      -20.3(2)  
  C(1)-O(1)-C(5)-O(3)       58.49(17)  
  C(1)-O(1)-C(5)-C(4)      -61.81(18)  
  C(7)-O(3)-C(5)-O(1)       74.08(16)  
  C(7)-O(3)-C(5)-C(4)     -164.00(13)  
  N(1)-C(4)-C(5)-O(1)      172.66(13)  
  C(3)-C(4)-C(5)-O(1)       50.05(17)  
  N(1)-C(4)-C(5)-O(3)       49.66(16)  
  C(3)-C(4)-C(5)-O(3)      -72.95(15)  
  O(1)-C(1)-C(6)-O(2)      -64.55(19)  
   
  C(2)-C(1)-C(6)-O(2)       60.1(2)  
  C(4)-N(1)-C(8)-O(4)       -6.6(3)  
  C(4)-N(1)-C(8)-O(5)      173.14(13)  
  C(9)-O(5)-C(8)-O(4)        0.0(2)  
  C(9)-O(5)-C(8)-N(1)     -179.76(13)  
  C(8)-O(5)-C(9)-C(10)     171.96(13)  
  O(5)-C(9)-C(10)-C(15)    -75.22(19)  
  O(5)-C(9)-C(10)-C(11)    105.06(19)  
  C(15)-C(10)-C(11)-C(12)   -0.2(3)  
  C(9)-C(10)-C(11)-C(12)   179.55(17)  
  C(10)-C(11)-C(12)-C(13)   -0.3(3)  
  C(11)-C(12)-C(13)-C(14)    0.4(3)  
  C(12)-C(13)-C(14)-C(15)    0.0(3)  
  C(13)-C(14)-C(15)-C(10)   -0.5(3)  
  C(11)-C(10)-C(15)-C(14)    0.6(3)  
  C(9)-C(10)-C(15)-C(14)  -179.13(17)  
   
  
______________________________________________________________________________  
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   Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C15 H19 N O5.  
   ______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(2)-H(2)      O(4)#1     0.84        2.11       2.9441(18)  176.4  
     N(1)-H(1)      O(4)#2     0.88        2.23       2.8885(18)  130.9  
   
   ______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 x-1/2,-y+1/2,-z    #2 x-1,y,z      
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ORTEP view of the C15 H19 N O5 compound with the numbering 
scheme adopted. Ellipsoids drawn at 30% probability level. 
Hydrogen atoms are represented by sphere of arbitrary size.  
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      Table 1.  Crystal data and structure refinement for C11 H12 F N3 O3.  
   
   
      Identification code               bent32  
   
 
      Empirical formula                 C11 H12 F N3 O3  
   
      Formula weight                    253.24  
   
      Temperature                       150K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       P212121  
   
      Unit cell dimensions              a = 5.4945(1) Å     = 90°  
                                        b = 10.4751(2) Å     = 90°  
                                        c = 21.0798(3) Å     = 90°  
   
      Volume                            1213.26(4)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.386  g/cm3  
   
      Absorption coefficient            0.965 mm-1  
   
      F(000)                            528  
   
      Crystal size                      0.21 x 0.18 x 0.05 mm  
   
      Theta range for data collection   4.19 to 72.33°  
   
      Index ranges                      -6  h  6, -12  k  12, -25    25  
   
      Reflections collected             14268  
   
      Independent reflections           2387 [Rint = 0.037]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9529 and 0.8008  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    2387 / 0 / 165  
   
      Goodness-of-fit on F2             1.076  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0268, wR2 = 0.0686  
   
      R indices (all data)              R1 = 0.0278, wR2 = 0.0694  
   
  353 
      Absolute structure parameter      0.03(12)  
   
      Extinction coefficient            0.0082(6)  
   
      Largest diff. peak and hole       0.146 and -0.207 e/Å3  
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         Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C11 H12 F N3 O3.  
   
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          F(1)         4405(1)       8115(1)       1707(1)       30(1)  
          O(1)         6514(2)       6126(1)       2737(1)       35(1)  
          O(2)         3656(2)       4940(1)       2242(1)       29(1)  
          O(3)         3091(2)       8004(1)       2964(1)       27(1)  
          N(1)          -82(2)       9049(1)       1202(1)       39(1)  
          N(2)         1550(2)       9766(1)       1012(1)       38(1)  
          N(3)         2882(3)      10431(1)        769(1)       57(1)  
          C(1)         4491(2)       5978(1)       2531(1)       26(1)  
          C(2)         2495(2)       6994(1)       2547(1)       25(1)  
          C(3)         2189(2)       7549(1)       1883(1)       26(1)  
          C(4)          233(2)       8560(1)       1853(1)       30(1)  
          C(5)         2597(3)       7727(1)       3625(1)       34(1)  
          C(6)         3477(2)       8853(1)       3999(1)       31(1)  
          C(7)         5574(3)       8786(1)       4365(1)       40(1)  
          C(8)         6457(3)       9869(2)       4666(1)       49(1)  
          C(9)         5265(3)      11023(2)       4597(1)       48(1)  
          C(10)        3161(3)      11092(1)       4245(1)       44(1)  
          C(11)        2258(3)      10011(1)       3948(1)       36(1)  
         ________________________________________________________________  
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         Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C11 H12 F N3 O3.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          H(2)         4783          4402          2208          44  
          H(2A)         930          6594          2684          30  
          H(3)         1787          6847          1579          31  
          H(4A)       -1325          8195          2004          36  
          H(4B)         673          9274          2138          36  
          H(5A)        3465          6943          3758          41  
          H(5B)         830          7598          3692          41  
          H(7)         6408          7996          4408          48  
          H(8)         7882          9818          4919          58  
          H(9)         5898         11769          4793          58  
          H(10)        2326         11882          4205          53  
          H(11)         797         10062          3708          44  
         ________________________________________________________________  
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    Table 4.  Anisotropic parameters (Å2 x 103) for C11 H12 F N3 O3.  
   
         The anisotropic displacement factor exponent takes the form:  
   
                 -2 2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    F(1)     21(1)      32(1)      36(1)       3(1)       3(1)      -1(1)  
    O(1)     25(1)      32(1)      49(1)       2(1)      -5(1)       2(1)  
    O(2)     28(1)      22(1)      39(1)      -2(1)       2(1)       2(1)  
    O(3)     30(1)      24(1)      28(1)      -1(1)       2(1)      -3(1)  
    N(1)     32(1)      39(1)      46(1)       8(1)     -11(1)      -5(1)  
    N(2)     44(1)      33(1)      38(1)       2(1)      -9(1)      -6(1)  
    N(3)     71(1)      57(1)      43(1)      11(1)     -12(1)     -26(1)  
    C(1)     24(1)      24(1)      30(1)       4(1)       4(1)       0(1)  
    C(2)     20(1)      22(1)      33(1)      -2(1)       2(1)      -3(1)  
    C(3)     20(1)      25(1)      32(1)      -2(1)       0(1)      -3(1)  
    C(4)     22(1)      30(1)      38(1)       2(1)      -2(1)       0(1)  
    C(5)     42(1)      30(1)      31(1)       2(1)       7(1)      -2(1)  
    C(6)     35(1)      33(1)      27(1)       0(1)       7(1)       0(1)  
    C(7)     38(1)      47(1)      35(1)      -2(1)       2(1)       8(1)  
    C(8)     40(1)      72(1)      34(1)      -8(1)       1(1)      -6(1)  
    C(9)     64(1)      46(1)      35(1)     -10(1)      12(1)     -16(1)  
    C(10)    66(1)      32(1)      34(1)      -2(1)      10(1)       4(1)  
    C(11)    42(1)      36(1)      32(1)      -1(1)       4(1)       5(1)  
    _______________________________________________________________________  
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      Table 5.  Bond lengths [Å] and angles [°] for C11 H12 F N3 O3  
    ______________________________________________________________________  
  
 
    F(1)-C(3)              1.4043(13)  
    O(1)-C(1)              1.2034(15)  
    O(2)-C(1)              1.3278(15)  
    O(3)-C(2)              1.4149(13)  
    O(3)-C(5)              1.4487(14)  
    N(1)-N(2)              1.2359(17)  
    N(1)-C(4)              1.4756(17)  
    N(2)-N(3)              1.1331(18)  
    C(1)-C(2)              1.5286(15)  
    C(2)-C(3)              1.5248(16)  
    C(3)-C(4)              1.5099(16)  
    C(5)-C(6)              1.4990(18)  
    C(6)-C(7)              1.388(2)  
    C(6)-C(11)             1.3905(18)  
    C(7)-C(8)              1.388(2)  
    C(8)-C(9)              1.383(2)  
    C(9)-C(10)             1.376(2)  
    C(10)-C(11)            1.385(2)  
   
    C(2)-O(3)-C(5)         113.92(8)  
    N(2)-N(1)-C(4)         115.25(11)  
     
 
    N(3)-N(2)-N(1)         171.25(14)  
    O(1)-C(1)-O(2)         126.17(11)  
    O(1)-C(1)-C(2)         124.40(11)  
    O(2)-C(1)-C(2)         109.41(10)  
    O(3)-C(2)-C(3)         108.15(9)  
    O(3)-C(2)-C(1)         111.61(9)  
    C(3)-C(2)-C(1)         108.97(9)  
    F(1)-C(3)-C(4)         108.07(9)  
    F(1)-C(3)-C(2)         107.89(9)  
    C(4)-C(3)-C(2)         112.59(9)  
    N(1)-C(4)-C(3)         111.43(10)  
    O(3)-C(5)-C(6)         106.74(9)  
    C(7)-C(6)-C(11)        119.17(12)  
    C(7)-C(6)-C(5)         121.32(12)  
    C(11)-C(6)-C(5)        119.38(12)  
    C(6)-C(7)-C(8)         120.15(14)  
    C(9)-C(8)-C(7)         120.12(15)  
    C(10)-C(9)-C(8)        120.01(14)  
    C(9)-C(10)-C(11)       120.12(14)  
    C(10)-C(11)-C(6)       120.39(14)  
   
    
______________________________________________________________________  
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         Table 6.  Torsion angles [°] for C11 H12 F N3 O3.  
  ______________________________________________________________________________  
  
 
  C(5)-O(3)-C(2)-C(3)      159.17(10)  
  C(5)-O(3)-C(2)-C(1)      -80.98(12)  
  O(1)-C(1)-C(2)-O(3)      -14.47(16)  
  O(2)-C(1)-C(2)-O(3)      167.21(9)  
  O(1)-C(1)-C(2)-C(3)      104.89(13)  
  O(2)-C(1)-C(2)-C(3)      -73.43(11)  
  O(3)-C(2)-C(3)-F(1)       60.31(11)  
  C(1)-C(2)-C(3)-F(1)      -61.18(11)  
  O(3)-C(2)-C(3)-C(4)      -58.86(12)  
  C(1)-C(2)-C(3)-C(4)      179.65(9)  
  N(2)-N(1)-C(4)-C(3)      -73.97(14)  
  F(1)-C(3)-C(4)-N(1)       62.87(12)  
  C(2)-C(3)-C(4)-N(1)     -178.07(9)  
   
 
  C(2)-O(3)-C(5)-C(6)      176.42(10)  
  O(3)-C(5)-C(6)-C(7)     -106.92(13)  
  O(3)-C(5)-C(6)-C(11)      68.91(15)  
  C(11)-C(6)-C(7)-C(8)      -1.00(19)  
  C(5)-C(6)-C(7)-C(8)      174.83(13)  
  C(6)-C(7)-C(8)-C(9)       -0.7(2)  
  C(7)-C(8)-C(9)-C(10)       1.9(2)  
  C(8)-C(9)-C(10)-C(11)     -1.2(2)  
  C(9)-C(10)-C(11)-C(6)     -0.5(2)  
  C(7)-C(6)-C(11)-C(10)      1.65(19)  
  C(5)-C(6)-C(11)-C(10)   -174.27(12)  
   
  
______________________________________________________________________________  
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   Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C11 H12 F N3 O3.  
   ______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(2)-H(2)      O(3)#1     0.84        1.91       2.7379(11)  169.1  
   
   ______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 -x+1,y-1/2,-z+1/2      
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ORTEP view of the C11 H12 F N3 O3 compound with the numbering 
scheme adopted. Ellipsoids drawn at 30% probability level. 
Hydrogen atoms are represented by sphere of arbitrary size.  
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Structure solved and refined in the laboratory of X-ray 
diffraction Université de Montréal by Benoît Deschênes 
Simard.  
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      Table 1.  Crystal data and structure refinement for C11 H12 F N3 O3.  
   
   
      Identification code               bent27  
   
 
      Empirical formula                 C11 H12 F N3 O3  
   
      Formula weight                    253.24  
   
      Temperature                       150K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       P212121  
   
      Unit cell dimensions              a = 5.5106(2) Å     = 90°  
                                        b = 10.4989(4) Å     = 90°  
                                        c = 21.1010(9) Å     = 90°  
   
      Volume                            1220.80(8)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.378  g/cm3  
   
      Absorption coefficient            0.959 mm-1  
   
      F(000)                            528  
   
      Crystal size                      0.22 x 0.18 x 0.05 mm  
   
      Theta range for data collection   4.19 to 72.38°  
   
      Index ranges                      -6  h  6, -12  k  12, -26    26  
   
      Reflections collected             16014  
   
      Independent reflections           2389 [Rint = 0.038]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9532 and 0.7983  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    2389 / 3 / 165  
   
      Goodness-of-fit on F2             1.057  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0299, wR2 = 0.0780  
   
      R indices (all data)              R1 = 0.0312, wR2 = 0.0792  
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      Absolute structure parameter      -0.05(14)  
   
      Extinction coefficient            0.0109(8)  
   
      Largest diff. peak and hole       0.140 and -0.209 e/Å3  
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         Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C11 H12 F N3 O3.  
   
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          F(1)         5599(1)       1889(1)       8293(1)       34(1)  
          O(1)         3483(2)       3878(1)       7265(1)       39(1)  
          O(2)         6345(2)       5063(1)       7757(1)       33(1)  
          O(3)         6904(2)       2002(1)       7034(1)       31(1)  
          N(1)        10084(2)        953(1)       8797(1)       43(1)  
          N(2)         8465(3)        237(1)       8986(1)       43(1)  
          N(3)         7133(3)       -430(2)       9229(1)       61(1)  
          C(1)         5507(3)       4027(1)       7468(1)       30(1)  
          C(2)         7500(2)       3011(1)       7452(1)       29(1)  
          C(3)         7813(2)       2457(1)       8116(1)       30(1)  
          C(4)         9768(3)       1445(1)       8145(1)       34(1)  
          C(5)         7386(3)       2277(1)       6373(1)       38(1)  
          C(6)         6512(3)       1150(1)       5999(1)       36(1)  
          C(7)         4413(3)       1216(2)       5634(1)       44(1)  
          C(8)         3525(3)        130(2)       5334(1)       52(1)  
          C(9)         4727(4)      -1019(2)       5403(1)       52(1)  
          C(10)        6826(4)      -1089(2)       5754(1)       48(1)  
          C(11)        7735(3)         -5(1)       6050(1)       40(1)  
         ________________________________________________________________  
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         Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C11 H12 F N3 O3.  
   
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
 
          H(2)         5227          5604          7788          50  
          H(2A)        9060          3410          7314          34  
          H(3)         8214          3157          8420          36  
          H(4A)        9328           733          7859          41  
          H(4B)       11321          1810          7994          41  
          H(5A)        9146          2408          6305          46  
          H(5B)        6514          3057          6240          46  
          H(7)         3582          2003          5590          53  
          H(8)         2098           178          5082          63  
          H(9)         4099         -1764          5206          62  
          H(10)        7656         -1877          5795          57  
          H(11)        9195           -54          6288          48  
         ________________________________________________________________  
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    Table 4.  Anisotropic parameters (Å2 x 103) for C11 H12 F N3 O3.  
   
         The anisotropic displacement factor exponent takes the form:  
   
                 -2 2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    F(1)     26(1)      35(1)      40(1)       3(1)       3(1)      -1(1)  
    O(1)     29(1)      35(1)      54(1)       1(1)      -6(1)       2(1)  
    O(2)     31(1)      25(1)      44(1)      -2(1)       1(1)       2(1)  
    O(3)     34(1)      27(1)      34(1)      -2(1)       2(1)      -3(1)  
    N(1)     35(1)      42(1)      51(1)       8(1)     -11(1)      -4(1)  
    N(2)     48(1)      36(1)      45(1)       2(1)     -10(1)      -7(1)  
    N(3)     74(1)      59(1)      51(1)      11(1)     -12(1)     -28(1)  
    C(1)     28(1)      27(1)      34(1)       4(1)       4(1)      -1(1)  
    C(2)     23(1)      24(1)      39(1)      -3(1)       2(1)      -3(1)  
    C(3)     24(1)      27(1)      38(1)      -2(1)       0(1)      -4(1)  
    C(4)     26(1)      33(1)      43(1)       2(1)      -2(1)       0(1)  
    C(5)     46(1)      33(1)      36(1)       2(1)       6(1)      -1(1)  
    C(6)     38(1)      37(1)      32(1)       0(1)       6(1)       0(1)  
    C(7)     41(1)      50(1)      41(1)      -2(1)       1(1)       7(1)  
    C(8)     43(1)      75(1)      38(1)      -9(1)       1(1)      -7(1)  
    C(9)     66(1)      49(1)      41(1)     -10(1)      12(1)     -16(1)  
    C(10)    68(1)      36(1)      39(1)      -3(1)       9(1)       3(1)  
    C(11)    45(1)      38(1)      36(1)      -1(1)       3(1)       5(1)  
    _______________________________________________________________________  
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      Table 5.  Bond lengths [Å] and angles [°] for C11 H12 F N3 O3  
    ______________________________________________________________________  
  
 
    F(1)-C(3)              1.4089(15)  
    O(1)-C(1)              1.2050(17)  
    O(2)-C(1)              1.3299(16)  
    O(3)-C(2)              1.4178(15)  
    O(3)-C(5)              1.4490(16)  
    N(1)-N(2)              1.2328(18)  
    N(1)-C(4)              1.4812(19)  
    N(2)-N(3)              1.1365(19)  
    C(1)-C(2)              1.5317(17)  
    C(2)-C(3)              1.5266(18)  
    C(3)-C(4)              1.5140(18)  
    C(5)-C(6)              1.501(2)  
    C(6)-C(7)              1.390(2)  
    C(6)-C(11)             1.392(2)  
    C(7)-C(8)              1.394(2)  
    C(8)-C(9)              1.384(3)  
    C(9)-C(10)             1.376(3)  
    C(10)-C(11)            1.391(2)  
   
    C(2)-O(3)-C(5)         114.05(10)  
    N(2)-N(1)-C(4)         115.36(12)  
     
 
    N(3)-N(2)-N(1)         171.49(16)  
    O(1)-C(1)-O(2)         126.24(13)  
    O(1)-C(1)-C(2)         124.41(12)  
    O(2)-C(1)-C(2)         109.31(11)  
    O(3)-C(2)-C(3)         108.21(10)  
    O(3)-C(2)-C(1)         111.6(1)  
    C(3)-C(2)-C(1)         109.04(10)  
    F(1)-C(3)-C(4)         107.96(10)  
    F(1)-C(3)-C(2)         107.87(10)  
    C(4)-C(3)-C(2)         112.61(11)  
    N(1)-C(4)-C(3)         111.45(12)  
    O(3)-C(5)-C(6)         106.88(11)  
    C(7)-C(6)-C(11)        119.26(14)  
    C(7)-C(6)-C(5)         121.26(14)  
    C(11)-C(6)-C(5)        119.35(14)  
    C(6)-C(7)-C(8)         120.24(15)  
    C(9)-C(8)-C(7)         119.81(16)  
    C(10)-C(9)-C(8)        120.33(16)  
    C(9)-C(10)-C(11)       120.10(16)  
    C(10)-C(11)-C(6)       120.23(15)  
   
    
______________________________________________________________________  
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         Table 6.  Torsion angles [°] for C11 H12 F N3 O3.  
  ______________________________________________________________________________  
  
 
  C(5)-O(3)-C(2)-C(3)     -159.25(11)  
  C(5)-O(3)-C(2)-C(1)       80.78(13)  
  O(1)-C(1)-C(2)-O(3)       14.82(18)  
  O(2)-C(1)-C(2)-O(3)     -167.21(10)  
  O(1)-C(1)-C(2)-C(3)     -104.66(15)  
  O(2)-C(1)-C(2)-C(3)       73.31(13)  
  O(3)-C(2)-C(3)-F(1)      -60.27(12)  
  C(1)-C(2)-C(3)-F(1)       61.29(12)  
  O(3)-C(2)-C(3)-C(4)       58.76(13)  
  C(1)-C(2)-C(3)-C(4)     -179.68(10)  
  N(2)-N(1)-C(4)-C(3)       74.07(16)  
  F(1)-C(3)-C(4)-N(1)      -62.77(14)  
   
 
   
  C(2)-C(3)-C(4)-N(1)      178.25(10)  
  C(2)-O(3)-C(5)-C(6)     -176.53(11)  
  O(3)-C(5)-C(6)-C(7)      106.98(15)  
  O(3)-C(5)-C(6)-C(11)     -68.76(17)  
  C(11)-C(6)-C(7)-C(8)       1.1(2)  
  C(5)-C(6)-C(7)-C(8)     -174.62(14)  
  C(6)-C(7)-C(8)-C(9)        0.5(2)  
  C(7)-C(8)-C(9)-C(10)      -1.6(3)  
  C(8)-C(9)-C(10)-C(11)      0.9(2)  
  C(9)-C(10)-C(11)-C(6)      0.8(2)  
  C(7)-C(6)-C(11)-C(10)     -1.8(2)  
  C(5)-C(6)-C(11)-C(10)    174.06(13)  
   
  
______________________________________________________________________________  
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   Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C11 H12 F N3 O3.  
   ______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(2)-H(2)      O(3)#1     0.84        1.92       2.7458(13)  169  
   
   ______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 -x+1,y+1/2,-z+3/2      
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ORTEP view of the C11 H12 F N3 O3 compound with the numbering 
scheme adopted. Ellipsoids drawn at 30% probability level. 
Hydrogen atoms are represented by sphere of arbitrary size.  
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The following website materials, which were referenced in Chapter 3, were 
annexed for preservation by request of the dissertation jury, because of the importance 
of their content: 
1. IDSA Report: Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, a Public 
Health Crisis Brews. July 19, 2004. (PDF)
http://www.idsociety.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=5554,
also freely available at http://www.idsociety.org/10x20.htm (accessed June 2, 2010). 
2. Statement of the Infectious Diseases Society of America Before the Food and Drug 
Administration Part 15 Hearing Panel on Antimicrobial Resistance. Apr. 28, 2008. 
(PDF)
http://www.idsociety.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=11150,
also freely available at http://www.idsociety.org/10x20.htm (accessed June 2, 2010). 
3. ECDC/EMEA JOINT TECHNICAL REPORT. The bacterial challenge: time to 
react. Stockholm, September 2009. (PDF).  
http://www.ema.europa.eu/pdfs/human/antimicrobial_resistance/EMEA-576176-
2009.pdf. ISBN 978-92-9193-193-4 (accessed June 2, 2010). 
4. IDSA’s 10 X ’20 INITIATIVE: ID Experts Call for 10 Novel Antibacterial Drugs by 
2020 - Letter to President Barack Obama and Prime Minister Fredrik Reinfeldt.
Nov. 20, 2009. (PDF).
http://www.idsociety.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=15752,
also available at http://www.idsociety.org/10x20.htm (accessed June 2, 2010). 
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Day 1 A 34-year-old New Hampshire expectant mother visits her doctor’s office complaining of severe stomach pain,
vomiting, diarrhea, fever, and chills. She is diagnosed with an intestinal infection, given intravenous fluids and a
prescription for a fluoroquinolone—an antibiotic—and is sent home. 
Day 2 At a Massachusetts hospital’s emergency room, a 2-year-old boy with a severe case of diarrhea, vomiting,
dehydration, and fever is given fluids and administered a cephalosporin, another type of antibiotic, and is
admitted to the hospital. 
Day 4 The boy’s lab results come back identifying the cause of his illness as Salmonella, a common foodborne bacterial
infection, but, in this instance, the “bug” is highly resistant to the antibiotics commonly used to treat such
infections, including cephalosporins and fluoroquinolones. 
The baby boy dies of dehydration and bloodstream infection. As for the 34-year-old woman, the Salmonella
infection results in a miscarriage of an otherwise normal baby followed by the woman’s death. 
Day 5 325 people are dead. Thousands—many of them children, the elderly, and other vulnerable individuals—jam
emergency rooms across the Northeast complaining of similar symptoms. Cases have been reported in 15 states
along the East Coast and in the Mid-Atlantic region. Isolated cases are reported in other states, including Texas
and California. Fourteen cases are reported in Mexico and 27 cases in Canada.
Day 6 1,730 deaths and 220,000 illnesses have occurred in the United States. The epidemic expands in other countries. 
Canada, Mexico, and Europe close their borders to U.S. food imports, and travel initiated from the United States is
banned around the globe. Economic losses to the U.S. and global economies soon reach tens of billions of dollars.
The Food and Drug Administration and Centers for Disease Control and Prevention identifiy the source of the
infections as a milk distribution facility located in New York state. They confirm that the Salmonella not only
causes severe illness, but also is resistant to all available antibiotics. Doctors can only provide supportive care, not
specific, antibiotic treatment.
Day 7 The number of deaths and illnesses continues to climb.
Think it can’t happen? Think again. In 1985, milk contaminated with Salmonella typhimurium infected 200,000 people
across the Midwest. What distinguishes that case from our scenario is the development of a fully antibiotic-resistant strain
of the bacteria as compared to the one that is only partially drug-resistant. Such “bad bugs” are evolving. Some are
already here. 
Had bioterrorism prompted this scenario, infection rates could have been significantly higher, as several sources 
could have been intentionally contaminated. The toll on human lives and the U.S. economy would have been
substantially worse.
Can we avert this catastrophe? If we act now, the answer is yes.
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Antibiotic-Resistant Bacterial
Pathogens: Why We Are Concerned
Antibiotics and other antimicrobial drugs have saved
millions of lives and eased patients’ suffering. Although
they have been dubbed “miracle drugs,” antibiotics are
not always effective. Over time, bacteria can develop
resistance to existing drugs, making infections difficult if
not impossible to treat. 
A multi-pronged approach is needed to limit the impact of
antibiotic resistance on patients and the public. These
efforts include educating physicians, patients, and parents
about the appropriate use of antibiotics, developing and
applying infection control and immunization policies and
practices to prevent transmission, surveying clinical and
prescription data, and developing safer alternatives to
antibiotic uses in agriculture. 
The purpose of this document, however, is to call
attention to a frightening twist in the antibiotic resistance
problem that has not received adequate attention from
federal policymakers: The pharmaceutical pipeline for new
antibiotics is drying up.
Until recently, research and development (R&D) efforts
have provided new drugs in time to treat bacteria that
became resistant to older antibiotics. That is no longer the
case. Unfortunately, both the public and private sectors
appear to have been lulled into a false sense of security
based on past successes. The potential crisis at hand is the
result of a marked decrease in industry R&D, government
inaction, and the increasing prevalence of resistant
bacteria. Infectious diseases physicians are alarmed by the
prospect that effective antibiotics may not be available to
treat seriously ill patients in the near future. 
Why Policymakers 
Should be Concerned Too
Policymakers already have recognized the urgent need to
spur R&D related to biodefense. While this concern is
appropriate, it is important to keep things in perspective.
There has not been a single case of smallpox anywhere on
the planet since the 1970s, but drug-resistant bacterial
infections kill tens of thousands of Americans every year,
and an epidemic could harm millions.
Why should policymakers care about antibiotic
resistance and the lack of new antibiotics to treat
resistant infections? 
• Infections caused by resistant bacteria can strike
anyone—the young and the old, the healthy and the
chronically ill. Antibiotic resistance is a particularly
serious problem for patients whose immune systems
are compromised, such as people with HIV/AIDS and
patients in critical care units.
• About 2 million people acquire bacterial infections in
U.S. hospitals each year, and 90,000 die as a result.
About 70 percent of those infections are resistant to at
least one drug. The trends toward increasing numbers
of infection and increasing drug resistance show no
sign of abating. 
• Resistant pathogens lead to higher health care costs
because they often require more expensive drugs and
extended hospital stays. The total cost to U.S. society is
nearly $5 billion annually.
• The pipeline of new antibiotics is drying up. Major
pharmaceutical companies are losing interest in the
antibiotics market because these drugs simply are not
as profitable as drugs that treat chronic (long-term)
conditions and lifestyle issues.
• Drug R&D is expensive, risky, and time-consuming. An
aggressive R&D program initiated today would likely
require 10 or more years and an investment of $800
million to $1.7 billion to bring a new drug to market.
• Resistant bacterial infections are not only a public
health problem; they have national and global security
implications as well. 
• The Institute of Medicine and federal officials 
have identified antibiotic resistance and the dearth 





IDSA has investigated the decline in new antibiotic R&D for
more than a year, interviewing stakeholders from all
sectors. Society leaders have met with officials from the
Food and Drug Administration (FDA), the National Institute
of Allergy and Infectious Diseases (NIAID), the Centers for
Disease Control and Prevention (CDC), congressional
members and staff, executives from leading
pharmaceutical and biotechnology companies,
representatives from public-private partnerships that are
focused on infectious diseases-related product
development, patients, and other stakeholders. Each
stakeholder has an important role in furthering future
antibiotic discovery and development and limiting the
impact of antibiotic resistance. However, based upon past
successes, the pharmaceutical and biotechnology industries
are clearly best situated to take the lead in developing the
new antibiotics needed to treat bacterial diseases. As such,
industry action must become the central focus of an
innovative federal public health effort designed to
stimulate antibiotic R&D.  
IDSA’s investigation has revealed that the incentives most
likely to spur R&D within major pharmaceutical companies
include those that provide financial benefits prior to a
drug’s approval (e.g., tax credits for R&D), commence at
the time of approval (e.g., wild-card patent extension),
reduce the costs of clinical trials (e.g., FDA flexibility
concerning the evidence necessary to demonstrate safety
and efficacy; NIAID-sponsored research to develop rapid
diagnostics tests, etc.), and reduce companies’ risks (e.g.,
liability protections). R&D at smaller biotechnology
companies also could be stimulated through statutory and
administrative changes. Finally, new funding for critical
federal public health programs, and public and private
research efforts, would help to ensure progress as well as
limit the public health impact of antibiotic resistance.  
Following is a list of specific potential legislative solutions,
administrative recommendations, and funding requests: 
Potential Legislative Solutions 
To Fuel Innovation
Congress and the Administration must work together to
enact statutory incentives that stimulate the discovery and
development of new antibiotics to treat drug-resistant and
other dangerous infections. Critical priority incentives that
will have the greatest impact are indicated. 
Commission to Prioritize 
Antimicrobial Discovery  
Establish and empower an independent Commission to
Prioritize Antimicrobial Discovery to decide which infectious
pathogens to target using these legislative R&D incentives
and administrative solutions:
Supplemental intellectual property protections:
• “Wild-card patent extension.”
A company that develops and
receives approval for a priority antibiotic could extend
the market exclusivity period of another FDA-approved
drug as long as the company commits to invest a
portion of the profits derived during the extension
period back into antibiotic R&D. 
• Restoration of all patent time lost during FDA's review
of priority antibiotics 
• Extended market exclusivity similar to what has 
been successfully implemented for pediatric and
orphan drugs 
Other potential statutory incentives: 
• Tax incentives for R&D of
priority antibiotics
• Measured liability protections
• Additional statutory flexibility at FDA regarding
approval of antibiotics, as needed 
• Antitrust exemptions for certain company
communications





Establish similar statutory incentives to spur R&D for
rapid diagnostic tests for targeted pathogens, which
will help to reduce the cost of clinical trials   
Potential statutory incentives of interest to small
biopharmaceutical companies: 
• Waive FDA supplemental application user fees for
priority antibiotics  
• Tax credits specifically targeting this segment of the
industry  
• Small business grants
In addition to enacting statutory incentives to spur
antibiotic R&D, Congress should work with the
Administration to implement administrative
recommendations at FDA and NIAID. 
Food and Drug Administration
Recommendations
FDA is a pivotal and constructive partner in the process of
antibiotic development. In order to effectively implement
FDA’s plan, Innovation or Stagnation: Challenge and
Opportunity on the Critical Path to New Medical Products,
modifications to existing policy, procedures, and guidelines
are necessary. Each of the following recommendations is a
critical priority:
• Accelerate the publication of updated guidelines for
antibiotic clinical trials to provide needed clarity, and
revisit existing guidelines as appropriate to ensure their
relevance 
• Encourage imaginative clinical trial designs that lead to
a better understanding of drug efficacy against
resistant bacterial pathogens
• Provide a clear definition of acceptable surrogate
markers as end points for clinical trials of bacterial
infections
• Explore and, when appropriate, encourage the use of
animal models of infection, in vitro technologies, and
valid microbiologic surrogate markers to reduce the
number of efficacy studies required for each additional
indication while maintaining safe and effective drug
dose regimens
• Explore with NIAID all opportunities to streamline






In 2002, out of 89 new







July 1997. A 7-year-old girl from urban
Minnesota was admitted to a hospital with an
infected right hip joint. Doctors drained the
infected joint and treated the girl with the
antibiotic cefazolin. On the third day of her
hospital stay, tests showed the girl was
infected with methicillin-resistant
Staphylococcus aureus (MRSA), and the
doctors changed her antibiotic to vancomycin,
but it was too late: The infection had already
invaded too deeply into her lungs. The girl
suffered respiratory failure that day and was
placed on a ventilator. After five weeks in the
hospital, she died from a lung hemorrhage.
This girl was previously healthy with no
recent hospitalizations.
CRITICAL PRIORITIES
National Institute of Allergy 
and Infectious Diseases
Recommendations
NIAID could play a central role in the R&D process. To do
so, NIAID should implement the following recommendations.
Each is a critical priority:
• Aggressively encourage translational (bench to
bedside) research as described in NIH’s Roadmap for
Medical Research
• Remove roadblocks to antibiotic R&D that may exist in
NIAID’s structure and guidelines, including any
unnecessary restrictions affecting companies’
intellectual property rights  
• Increase the number and size of grants that support
discovery of new drugs that treat targeted pathogens
• Develop and expand collaborations with industry and
the infectious diseases research community
• Sufficiently fund and rapidly launch NIAID’s newly
established Drug Discovery and Mechanisms of
Antimicrobial Resistance Study Section
• Engage outside experts in research planning and
ensure more transparent decision-making 
• Explore with FDA all opportunities to streamline
antibiotic drug development  
• Encourage research on topics directly related to
conduct of clinical trials  
• Sponsor research into new rapid diagnostic tests for
bacterial infections that, when available, could reduce
the cost of clinical trials 
• Encourage research on antibiotic use and resistance
development  
• Fund placebo-controlled trials to evaluate the necessity
of antibiotic therapy for selected diseases 
New Funding Needed
The increasing threat of drug resistance, concomitant with
decreasing antibiotic R&D, requires a dramatic increase in
public funding for CDC, FDA, NIAID, and public-private
research efforts. At a minimum, Congress and the
Administration must work together to invest new
resources (i.e., not shift funds from other public health
efforts) into the following critical program areas:
• Double CDC's antimicrobial resistance program
funding to $50 million in 2005 and continue to
increase it by $25 million increments until 2009 to a
total of $150 million
• Increase FDA’s funding by $25 million to support
implementation of the Critical Path plan (which would
help decrease the cost of antibiotic development), the
development of new antibiotic guidelines, and to
speed antibiotic reviews
• Significantly increase NIAID’s translational and
antibiotic resistance research efforts  
• Support synergistic public/private partnerships that
focus on infectious diseases medicines
Conclusion
Without innovative public policy and additional financial
support, fewer and fewer antibiotics will be available to
treat the increasing number of drug-resistant and
dangerous microbes that threaten Americans and the
global community. The proposals advanced in this
document are intended to ensure a sustainable supply of
safe and effective antibiotics to protect the public’s health. 





physicians are alarmed by
the prospect that effective
antibiotics may not be
available to treat seriously ill
patients in the near future.
There simply aren’t enough
new drugs in the
pharmaceutical pipeline to
keep pace with drug-
resistant bacterial infections,
so-called ‘superbugs.’”
Joseph R. Dalovisio, MD
IDSA President
As Antibiotic Discovery Stagnates ... 
A Public Health Crisis Brews
BAD BUGS, NO DRUGS
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9RESISTANCE ON THE RISE
Antibiotics* have saved millions of lives and eased the
suffering of patients of all ages for more than 60 years.
These “wonder drugs” deserve much of the credit for
the dramatic increase in life expectancy in the United
States and around the world in the 20th century. They
prevent amputations and blindness, advance our ability
to perform surgery, enable new cancer treatments to be
used, and protect the lives of our military men and
women. A famous infectious disease expert once noted
that the discovery of penicillin in the early 1940s gave
more curative power to a lone provider than the
collective talent of all the physicians in New York City at
that time. Unfortunately, it is inevitable that, over time,
bacteria develop resistance to existing antibiotics, making
infections more difficult to treat. 
Antibiotic resistance is not a new phenomenon. National
surveillance data and independent studies show that drug-
resistant, disease-causing bacteria have multiplied and
spread at alarming rates in recent decades. A diverse range
of patients is affected. The Institute of Medicine (IOM),
Centers for Disease Control and Prevention (CDC),
National Institutes of Health (NIH), and the Food and Drug
Administration (FDA) warn that drug-resistant bacteria are
a serious public health threat, especially considering that
there are few novel drugs in the pipeline to combat them.
Infections that were once easily curable with antibiotics are
becoming difficult, even impossible, to treat, and an
increasing number of people are suffering severe illness—
or dying—as a result. This year, nearly 2 million people in
the United States will acquire bacterial infections while in
the hospital, and about 90,000 of them will die, according
to CDC estimates. More than 70 percent of the bacteria
that cause these infections will be resistant to at least one
of the drugs commonly used to fight them. (See Table 1.)
In a growing and frightening number of cases, these
bacteria are resistant to many approved drugs, and
patients have to be treated with new, investigational
compounds or older, toxic alternatives. For many patients,
there simply are no drugs that work.
The resistance problem “has probably been smoldering for
years, but recently it’s almost like a switch got triggered,”
medical professor Stuart H. Cohen, MD, of the University of
California, Davis, recently told the Wall Street Journal.
“Antibiotic resistance is increasing too quickly and in too
many organisms,” said Harvard Medical School pediatric
infectious disease specialist Jonathan Finkelstein, MD, in
the same article. 








Table 1: Estimated Cases of Hospital-
Acquired Infections Caused by
Selected Resistant Bacteria in the
United States in 2002
Source: Centers for Disease Control and Prevention,
Division of Healthcare Quality Promotion
These preliminary estimates were extrapolated by CDC
staff from data collected from hospitals that participate
in the National Nosocomial Infections Surveillance
System. NNIS hospitals are disproportionately large,
urban, and affiliated with medical schools and are more
likely to have more seriously ill patients. As such, these
estimates should be interpreted cautiously.
CNS=Coagulase-negative staphylococci
*Antibiotics are a type of antimicrobial, a broad term used to
describe any agent that inhibits the growth of microorganisms,
including bacteria, viruses, fungi, yeast, protozoa, and parasites.
Antibiotics target bacteria—the “bad bugs” addressed in this
paper. Bacteria are by far the most common cause of infectious
diseases-related deaths in the United States. 
According to IOM and FDA, only two new classes of
antibiotics have been developed in the past 30 years, and
resistance to one class emerged even before FDA approved
the drug. (See Table 2.)
Furthermore, some strains of resistant bacteria are no
longer confined to hospitals and are occurring in otherwise
healthy individuals in communities across the United States
and other countries. 
As resistant bacteria multiply, so does the burden they
place on our health care system. The economic cost has
reached billions of dollars annually in the United States,
according to estimates from IOM and the former
Congressional Office of Technology Assessment. The
human cost in terms of pain, grief, and suffering,
however, is incalculable. 
Fast-Moving Targets
To understand how quickly disease-causing bacteria can
develop resistance to antibiotics, take the example of
Staphylococcus aureus (staph), a common cause of hospital
infections that can spread to the heart, bones, lungs, and
bloodstream with fatal results. Penicillin, introduced in the
early 1940s, once kept staph bacteria at bay. However,
penicillin-resistant staph bacteria were identified as early as
1942. By the late 1960s, more than 80 percent of staph
bacteria were penicillin-resistant. Methicillin was introduced
in 1961 to combat resistant staph bacteria, but reports of
methicillin-resistant Staphylococcus aureus (MRSA) rapidly
followed. In 1974, 2 percent of the staph bacteria found in
U.S. hospitals were methicillin-resistant. By 2002, that figure
had jumped to 57.1 percent, according to CDC data. (See
Chart 1 and Table 3.)
Staph infections have acquired resistance to many other
drugs in addition to penicillin and methicillin. In fact,
according to CDC, about half of the identified MRSA
strains in U.S. hospitals are resistant to all but a few
antibiotics. Causing even greater alarm, staph bacteria
partially resistant to vancomycin, a drug of last resort in
the treatment of several resistant infections, were
discovered in patients in the late 1990s. Two cases of fully
vancomycin-resistant Staphylococcus aureus (VRSA) were
reported in 2002 and a third in 2004. 
MRSA is no longer a problem confined to hospitals. One
ongoing study of children with community-acquired staph
infections at the University of Texas has found nearly 70
percent infected with MRSA. In a 2002 outbreak, 235
MRSA infections were reported among military recruits at
a training facility in the southeastern United States. In
addition, a total of 12,000 cases of community-acquired
MRSA were found in three correctional facilities (Georgia,
California, and Texas) between 2001 and 2003. 
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Table 2: History of Antibiotic
Discovery and Approval
Source: Food and Drug Administration (modified)
Presented by John H. Powers, MD, at April 15-16, 2004
“Antimicrobial Drug Development Workshop,”
co-sponsored by FDA, IDSA, and the International
Society of Anti-Infective Pharmacology.


















Other resistant bacterial infections also are raising
significant public health concerns:
• In 1998, IOM reported an alarming rise in the
incidence of infections due to a bacterium called
enterococcus, which causes wound infections,
infections in blood, the urinary tract and heart, and
life-threatening infections acquired in hospitals.
Vancomycin has been a core treatment for
enterococci. The percentage of enterococci resistant to
vancomycin (VRE) has been increasing dramatically
since the late 1980s, according to CDC. In 2002, more
than 27 percent of tested enterococci samples from
intensive care units were resistant to vancomycin. (See
Chart 1 and Table 3.)
• The percentage of Pseudomonas aeruginosa bacteria
resistant to either ciprofloxacin or ofloxacin, two
common antibiotics of the fluoroquinolone class
(FQRP), has increased dramatically from the late 1980s
to the present. Recent CDC data show that in 2002,
nearly 33 percent of tested samples from intensive
care units were resistant to fluoroquinolones. P.
aeruginosa causes infections of the urinary tract, lungs,
and wounds and other infections commonly found in


















Chart 1: Resistant Strains Spread Rapidly
Source: Centers for Disease Control and Prevention
This chart shows the increase in rates of resistance for three bacteria that are of concern to public health officials:
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and fluoroquinolone-resistant
Pseudomonas aeruginosa (FQRP). These data were collected from hospital intensive care units that participate in the






3rd-gen. Ceph./E. coli 6.3
3rd-gen. Ceph./K. pneumoniae 14.0
Imipenem/P. aeruginosa 22.3
3rd-gen. Ceph./P. aeruginosa 30.2
3rd-gen. Ceph./Enterobacter spp. 32.2
Penicillin/S. pneumoniae 11.3
Table 3: Percent of Drug Resistance in 
Hospital-Acquired Infections in 2002
Source: CDC National Nosocomial Infections Surveillance
System, August 2003 for all, except penicillin resistant
Streptococcus pneumoniae, which is the Active Bacterial
Core Surveillance of the Emerging Infections Network.
This table provides a snapshot of selected drug-resistant
pathogens associated with hospital infections in intensive
care unit patients during 2002. CNS=Coagulase-negative
staphylococci; 3rd Ceph=resistance to 3rd generation
cephalosporins (either ceftriaxone, cefotaxime, or
ceftazidime); Quinolone=resistance to either ciprofloxacin
or ofloxacin.
• Streptococcus pneumoniae is the most feared
bacterium that causes pneumonia. S. pneumoniae
strains that are resistant to penicillin and other drugs
are emerging rapidly in the United States. Up to 40
percent of infections caused by this bacterium are
resistant to at least one drug, and 15 percent are
resistant to three or more drugs, the CDC reports.
Aside from 100,000 cases of pneumonia each year,
this bacterium causes childhood ear infections (6
million per year), meningitis (3,300 per year), and
sinusitis (thousands of cases).  
• Multidrug-resistant Acinetobacter, a type of bacteria
that has caused stubborn wound infections in U.S.
soldiers and civilians stationed in Iraq, has been
increasingly reported worldwide. Pneumonia due to
Acinetobacter infections is now considered one of the
most difficult hospital-acquired infections to control
and treat, according to a recent study in Clinical
Infectious Diseases (CID). An international surveillance
study, also reported in CID, tested hundreds of
Acinetobacter samples and found various levels of
resistance to 15 drugs. Some Acinetobacter strains are
resistant to virtually every available drug with the
exception of one toxic antibiotic that causes
substantial side effects.
• Salmonellosis, a common
foodborne infection that
causes diarrhea, can cause
serious illness and death.
Nationally, the incidence of
Salmonella bacteria resistant
to cephalosporins, an
antibiotic commonly used to
treat severe salmonellosis, rose
nearly fivefold (from 0.5
percent to 2.4 percent)
between 1998 and 2001,
according to a study published
in the Journal of Infectious
Diseases. In Massachusetts
during the same time period,
the prevalence of drug-
resistant Salmonella rose from
0 percent to 53 percent.
• Tuberculosis (TB) is becoming increasingly difficult to
treat. The World Health Organization estimates that 
up to 50 million people worldwide may be infected
with drug-resistant strains of TB. Treatment for
resistant TB strains can take up to 24 months, as
opposed to the six months generally required to 
treat non-resistant strains.
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Many athletes have developed
methicillin-resistant Staphylococcus
aureus (MRSA), which can infect
the heart, bones, lungs, and
bloodstream.
Since 2000, CDC has reported a new
phenomenon—community-acquired outbreaks
of MRSA among athletes, including college
football players in Pennsylvania, wrestlers in
Indiana, and a fencing club in Colorado. Public
health officials believe that physical contact
and the sharing of clothing or equipment
probably leads to the spread of infection in
these otherwise healthy people. In September
of 2003, this issue was brought to national
attention when MRSA broke
out in Florida among the
Miami Dolphins, sending
two players to the hospital
for treatment.
The Human Toll
Statistics cannot convey the human toll that resistant
organisms take on their victims. Throughout this paper are
stories of previously healthy people who became seriously
ill or died as a result of drug-resistant infections. These
examples, reported by the CDC, the media, and infectious
diseases physicians, show that resistant infection can strike
anyone, at any time. They serve as examples of what an
increasing number of Americans could face as a result of
the impending public health crisis. 
The Economic Burden
Drug-resistant bacteria impose an economic burden on the
United States on the order of billions of dollars annually,
according to several authoritative analyses. Drug-resistant
infections are significantly more expensive to treat than
non-resistant infections because of longer hospitalizations,
extra physician visits, the higher cost of alternative
antibiotics, more post-hospital care, lost work days, and
deaths. For example, resistant TB strains are as much as
100 times more expensive to treat than non-resistant
strains, according to Lee B. Reichman, MD, MPH, director
of the New Jersey Medical School National Tuberculosis
Center. MRSA infections cost an average of $31,400 per
case to treat compared to $27,700 per case for non-
resistant infections, according to a study cited in the IOM
report Antimicrobial Resistance: Issues and Options (1998).
The same IOM report estimated that the total cost to U.S.
society of antimicrobial resistance was at least $4 billion to
$5 billion annually. A 1995 cost analysis by the former
Congressional Office of Technology Assessment (OTA)
provided similar dollar estimates when factors such as the
costs of lost work days and costs for post-hospital care are
considered. OTA went further to say that “these costs can
be expected to increase rapidly as the numbers of
antibiotic resistant bacteria increase.”
A multi-pronged approach is essential to limit the impact
of antibiotic resistance on patients and public health. Good
antibiotic stewardship, infection control and prevention
efforts, increased surveillance, and limits on agricultural
uses of antibiotics are extremely important. But a more
pressing concern is that, as the number of resistant
pathogens continues to grow, the pipeline of antibiotics





Antibiotic resistance is a
serious problem for people
with compromised immune systems, including
patients in hospital critical care units and the 40
million people living with HIV/AIDS in the United
States and globally. Their weakened immune systems
make these patients particularly vulnerable to drug-
resistant and other bacterial infections. A recent study
published in Clinical Infectious Diseases has shown
that the very patients most vulnerable to the
devastating impact of resistant infections—those with
compromised immune systems—also are more likely
than other patients to be infected with resistant
pathogens. Furthermore, in many areas of the world,
patients infected with HIV are more likely to die as a
result of bacterial infections, such as tuberculosis,
than of the underlying HIV infection. A wider array of
antibiotics that treat bacterial infections—particularly
drug-resistant strains—could offer significant hope to
people with compromised immune systems. 
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In spite of the pressing need for new drugs to treat
resistant infections, there simply are not enough new
antibiotics in the pharmaceutical pipeline to keep pace.
Major pharmaceutical companies with the R&D “muscle”
to make progress are losing interest in the antibiotics
market, even as they increase their overall R&D budgets.
Of greatest concern is the dearth of resources being
invested in drug discovery.  
The trend started more than 10 years ago. In 1990, half of
the large pharmaceutical companies in the United States
and Japan reported that they had halted or significantly
decreased their antibiotic discovery efforts. That same year,
several companies attempted to get back into the market,
spurred on by worsening problems with MRSA and a VRE
outbreak. But the enthusiasm was short-lived. In 2000,
Roche announced that it was spinning off its anti-infective
discovery division. In 2002, Bristol-Myers Squibb Company,
Abbott Laboratories, Eli Lilly and Company, and Wyeth all
halted or substantially reduced their anti-infective discovery
efforts, and Aventis announced plans to spin off its anti-
infectives division. Procter & Gamble also appears to be
withdrawing from new antibiotic R&D. Other companies
appear to have decreased the number of employees
assigned to antibiotic discovery and development. 
An article in the January-February 2004 issue of Health
Affairs described the impact of these reductions on the
ability of pharmaceutical companies to develop new drugs
to target antibiotic resistance: “Today there are few
champions for the study of infectious diseases
mechanisms, and few within the industry are able to
interpret the epidemiological data in a way that translates
into business decisions.” 
Companies’ efforts to downsize antibiotic R&D activities
have had a notable impact on the number of antibiotics
moving through the pipeline.
A recent analysis published in Clinical Infectious Diseases
found only five new antibiotics in the R&D pipeline out of
more than 506 drugs in development.* The authors
evaluated the websites or 2002 annual reports of 15 
major pharmaceutical companies with a track record in
antibiotic development and seven major biotechnology
companies.** Their analysis revealed four new antibiotics
being developed by pharmaceutical companies, and only
one antibiotic being developed by a biotech company. By
comparison, the analysis found that the pharmaceutical
companies were developing 67 new drugs for cancer, 
THE PIPELINE OF NEW ANTIBIOTICS IS DRYING UP
A growing number of drug











grew Acinetobacter that was resistant to all
antibiotics except colistin, a drug rarely used
because it is very toxic. He died.
*“Development” in this context refers to phases 2 and 3 of
human testing—the later stages of the R&D process. 
**Pharmaceutical companies examined were Merck & Co.,
Johnson & Johnson, Pfizer, GlaxoSmithKline, Bristol-Myers
Squibb, Aventis, Pharmacia, Novartis, F. Hoffman-La Roche,
AstraZeneca, Abbott Laboratories, Wyeth, Eli Lilly & Company,
Schering-Plough, and Bayer. Biotech companies were Amgen,
Genentech, Applera, Genzyme, Serono, Chiron, and Biogen.
The authors’ list of new drugs in the pipeline also included
telithromycin, which was subsequently approved by FDA.
33 for inflammation/pain, 34 for metabolic/endocrine
disorders, and 32 for pulmonary disease. The biotech
companies were developing 24 drugs for inflammation/
immunomodulators, 14 drugs for metabolic/endocrine
disorders, and 13 for cancer.
The end result of the decline in antibiotic discovery
research is that FDA is approving few new antibiotics.
Since 1998, only 10 new antibiotics have been approved,
two of which are truly novel—i.e., defined as having a
new target of action, with no cross-resistance with other
antibiotics. In 2002, among 89 new medicines emerging
on the market, none was an antibiotic. 
IOM’s 2003 report on microbial threats reinforces the
point, noting that although at first glance the situation
with respect to antibiotics currently in clinical
development looks encouraging, not one new class of
antibiotics is in late-stage development. “Rather these
‘new’ antibiotics belong to existing classes, including
macrolides and quinolones, that have been used to treat
humans for years,” IOM said. 
Infectious disease experts are particularly concerned about
the dearth of new “narrow-spectrum” agents—that is,
drugs that fight a specific infectious organism. Many of the
antibiotics in development today are “broad-spectrum”—
meaning they are intended to work against a wide range














Table 4: New Antibacterial Agents
Approved Since 1998
Source: Spellberg et al., Clinical Infectious Diseases, 
May 1, 2004 (modified)
Source: Spellberg et al., Clinical Infectious Diseases, 
May 1, 2004 (modified)











1983-1987   1988-1992   1993-1997   1998-2002   2003-2004
Total # New Antibacterial Agents (5 year intervals)
Only about five new
antibiotics are in the drug
pipeline, out of more than
506 agents in development.
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Medical Need Versus 
Market Realities
There is a growing disconnect between the medical need
perceived by those who practice infectious diseases
medicine and the market as assessed by the
pharmaceutical industry. Infectious diseases physicians see
a significant need for new antibiotics to treat a growing
number of bacterial infections from which their patients
suffer—but antibiotic R&D does not add up from a
business perspective. The costs outweigh the benefits to a
company’s bottom line.
The pharmaceutical industry, like all other publicly traded
industries, must deliver for its shareholders in order to
justify their continued investment. The unique nature of
antibiotics makes securing investments challenging.
Because antibiotics work so well and so fast, they produce
a weak return on investment for manufacturers.
Antibiotics are commonly prescribed for seven to 14 days.
Even for the most serious of infections, these drugs are
rarely needed for more than four to six weeks.  
Understandably, pharmaceutical and biotechnology
companies and their investors are drawn to develop
products that provide greater returns on investments. The
favored drugs include those that patients take for life, like
insulin for diabetes, statins for elevated cholesterol, and
drugs that treat hypertension and arthritis. Although these
drugs do address significant medical needs, other drugs—
like those used to treat impotence, baldness, and other
lifestyle issues—have little to no medical benefit at all but
are likely to reap huge profits.  
Experts in industry, government, and academia understand
the problem and have acknowledged it for years:
• “Product development in areas crucial to public health
goals, such as antibiotics, has slowed significantly
during the past decade.” (U.S. Food and Drug
Administration. Innovation/Stagnation: Challenge and
Opportunity on the Critical Path to New Medical
Products. March 2004.)
• “To describe drug research in trendy terms: chronic
disease medications are in; anti-infectives are out.”
When it comes to annual sales potential, antibiotics
don’t measure up. An industry representative speaking
at a scientific conference noted that a musculoskeletal
drug is worth about $1.150 billion, a neuroscience
treatment is rated at $720 million, and a medicine for
resistant Gram-positive cocci is worth only $100






companies are exiting the field,
what about smaller
biopharmaceutical companies?
Indeed, several smaller companies are focusing on
the development of antibiotic compounds (e.g.,
Cubist Pharmaceuticals, Basilea, Paratek, Vicuron
Pharmaceuticals, and Oscient). However, a
substantial number of other small companies simply
are pursuing development of drugs that have been
licensed from the major companies—i.e., most are
not involved in basic discovery research. While some
smaller companies are funding antibiotic discovery
programs, it remains to be seen whether they can be
successful in the absence of the financial support
and expertise available at larger companies. In order
to advance new classes of antibiotics from discovery
to development, they may need the financial
support of larger companies or other backers to fund
late-stage clinical trials and commercialization. For
the economic reasons described in this paper, it is
not apparent that such support will be forthcoming. 
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• “As a consumer, you want a drug [that] you don’t
have to take very long and works very well. But that
isn’t the most profitable type of drug. … [I]n some
cases the economics and the public health imperative
do not match up.” (Mark Goldberger, acting deputy
director of FDA’s Center for Drug Evaluation and
Research, quoted in Service, RF. Orphan drugs of the
future? Science. March 19, 2004, Vol. 303, 1798.)
• U.S. demographics shifting toward an increasingly
older population will lure even more investors and
companies to the chronic diseases market. As generics
compete with existing products, companies face
additional pressure to develop new blockbusters,
which account for most of their revenue. (Health Care
Industry Market Update: Pharmaceuticals, Centers for
Medicare and Medicaid Service. January 10, 2003.)
Limiting Resistance—and
Profitability, Too
Antibiotic resistance—and public health measures to
combat resistance—also pose unique challenges to
securing investment in antibiotic R&D. Resistance limits
the effectiveness of antibiotics over time and therefore
decreases a drug’s long-term profitability. Antibiotics
and other antimicrobials are the only drugs where
extensive use leads to loss of benefit. 
In addition, infectious diseases physicians and other
public health experts often hold new antibiotics in
reserve, hoping to avoid fostering the rapid emergence
of resistant bacteria and saving them for when they are
most needed. This unusual practice is unique to anti-
infective drugs. From a public health perspective, the
strategy is sensible. However, in pharmaceutical industry
terms, this practice translates into a “slow commercial
uptake” that limits the potential market for new
antibiotics. Drug company representatives have said that
physicians’ efforts to preserve antibiotics for the
treatment of resistant infections serve as a disincentive
to antibiotic discovery and development.
Technical Hurdles
In addition to the lack of effective market incentives,
antibiotic R&D is hampered by technical challenges as well.
As IOM’s microbial threats report noted, “the discovery of
new antibiotics is not as easy as was once believed.” 
Until the early 1990s, pharmaceutical companies tended to
develop new infectious diseases drugs by randomly
screening natural products to identify those demonstrating
antimicrobial activity. New technologies in use since then,
such as combinational chemistry, X-ray crystallography,
high throughput screening, and molecular modeling, have
not been as successful in identifying new antibiotics as
might have been hoped. 
Infectious disease doctors often hold new antibiotics in
reserve because of concerns about resistance.
August 2003. A 7-year-old Texas boy came
down with a fever of nearly 103 degrees and
complained of severe pain in his leg. He was
taken to Hermann Children’s Hospital in
Houston, where doctors discovered that a
virulent, drug-resistant staph infection was
causing a potentially fatal blood clot in the
boy’s leg. Fortunately, in this case, surgery
was life-saving.
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Moreover, industry representatives speaking about these
challenges at a recent scientific meeting said that genomic
data have “failed to deliver the expected flood of novel
targets.” 
Assuming one has a novel target of action within the
bacterium, there is still the challenge of finding a chemical
entity that can reach the target site and inhibit growth,
without being too highly toxic to patients. “The technical
hurdles, coupled with competition for resources within
pharmaceutical companies from other significant medical
needs with larger market opportunities, have led to
reduced investment in or, in the case of most companies,
elimination of antibiotic drug discovery programs,”
concluded IOM.
Additional Hurdles for Clinical
Trials of New Antibiotics
In addition to market and technical challenges, industry
representatives cite scientific and regulatory hurdles as
impediments to antibiotic approvals. 
Because antibiotics are used to treat various types of
infection (e.g., pneumonia, urinary tract infection, skin and
soft tissue infection), the drug approval process requires
clinical trials for each of these indications (one trial or often
more per indication), with enrollment of large numbers of
patients to ensure an understanding of a drug’s safety and
effectiveness against specific bacterial pathogens.
Finding enough patients to enroll in clinical trials of new
drugs to treat resistant pathogens is no easy task. By
contrast, when enrolling patients in a clinical trial to test a
new cancer drug, researchers know from the start whether
a specific patient has the specific type of cancer they are
targeting. With antibiotic clinical trials, that is not
necessarily the case. For many resistant pathogens, there
are no rapid diagnostic tests available to help researchers
to identify patients who would be eligible for their studies.  
As one industry consultant explained, in order to test a
drug that is intended to treat resistant strains, “You have
to wait for epidemics to break out in hospital wards, and
you can’t predict when that will happen. It may take five
years to complete a clinical study.” 
One company’s experience in trying to develop a new drug
to treat vancomycin-resistant enterococci (VRE) illustrates
some of the challenges. Researchers used entry criteria
that were developed in consensus with FDA and academia.
With 54 research sites open for two years, only three
patients enrolled in the study—it was closed for insufficient
enrollment. When a second study was launched, only 45
subjects enrolled over a period of 18 months. This does
not mean that there are few VRE infections; indeed,
according to CDC, there are estimated to be 26,000
hospital-acquired cases each year in the United States. (See
Table 1.)  The problem is in the ability to anticipate their





infection first spent seven weeks in the
hospital, two of those weeks in intensive care,
and then underwent 12 surgeries over the
next two years to excise the infection and
repair the damage it inflicted on his thigh
bone. After two years of operations, body
casts, wheelchairs, and crutches, this boy is
finally able to walk and run again, although
with a limp because his previously infected
leg is now shorter than the other.
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Updated FDA guidance documents defining the
investigational approaches for each type of infection, some
of which are currently in review, will bring needed clarity
to drug development teams within industry. Such guidance
would provide a better understanding about the type of
safety and efficacy data that FDA could find to be
scientifically compelling and acceptable when evaluating
new antibiotic applications.
Lengthy, Costly, and 
Risky Process
As with any other drug, antibiotic R&D is a lengthy, costly,
and risky process.  
According to a September 2003 review by the Tufts
Center for the Study of Drug Development, the median
time from the beginning of clinical testing through FDA
review for new antibiotics and similar drugs was just over
six years (55.8 months in the clinical phase; 18.6 months in
the review phase).* Preclinical identification and testing of
potential candidate drugs may add several more years to
the process.
During the pre-approval phases of drug discovery and
development, a product’s patent clock is ticking away.
Most patents are filed during the pre-clinical phase, which
means that the effective patent life of a new compound
once it is brought to market is less (sometimes substantially
so) than the 20 years provided by law. Although current
law allows for restoration of some patent time lost during
FDA’s period of review, not all lost time is restored. 
The 2003 IOM report acknowledged this challenge, noting
that “the development of an antibiotic is an expensive and
risky process; no guarantee can be made that the
antibiotic will remain effective and the investment will be
regained before the patent period has ended.” As for the
cost, according to a recent FDA report, bringing a new
drug to market can cost $800 million to $1.7 billion.  
The pharmaceutical industry’s risks are high. According to
the Pharmaceutical Research and Manufacturers of
America, only five in 5,000 compounds that enter
preclinical testing make it to human testing, and only one
of these five is approved. If a product is not going to
produce strong profits, then other products with greater
market potential will get the “green light” for the next
phase of development.
*The study looked at small molecule anti-infectives approved
between 1982 and 2001.
Pharmaceutical Charity Helps, 
But Is Not the Solution
The pharmaceutical industry participates in
many areas of public health and provides
many good works pro bono. Some examples
include Merck & Co.’s efforts related to River
Blindness; efforts by Bristol-Myers Squibb,
Pfizer, and other drug companies related to
global AIDS; and GlaxoSmithKline’s malaria
and AstraZeneca’s TB drug discovery
initiatives. Nevertheless, industry cannot alter
its fundamental business strategy in any way
that would place its bottom line at risk.
Policymakers and the public should have no
illusions that future pharmaceutical charity
will be sufficient to address the existing 
and emerging pathogens that threaten 
public health. 
Because antibiotics work so
well and so fast, they produce
a weak return on investment
for manufacturers. 
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Much has been written about antibiotic resistance and the
decline in R&D. Many groups have supported
strengthening the U.S. and international governments’
response to this growing public health crisis, including
IOM, the World Health Organization, the Congressional
Office of Technology Assessment, the American Society for
Microbiology, and the Alliance for the Prudent Use of
Antibiotics. 
To date, the U.S. government’s action has been
inadequate to address the brewing crisis, but the
Administration and Congress recently have announced
several proposals, which, if successfully and fully
implemented, could make a difference. 
• NIH’s Roadmap for Medical Research
NIH’s Roadmap, issued in September 2003, outlines a
series of initiatives to “speed the movement of research
discoveries from the bench to the bedside.”  After
decades of investment in basic biomedical research, the
Roadmap is intended to widen NIH’s mission to include
translational research—i.e., translating basic discoveries
from concept into clinical evaluation, focusing on
specific diseases or therapies. 
• FDA’s Innovation/Stagnation:
Challenge and Opportunity on the
Critical Path to New Medical Products
In March 2004, FDA issued its Critical Path report to
complement the NIH Roadmap initiative. In FDA’s view
“applied sciences have not kept pace with the
tremendous advances in basic sciences.” The Critical
Path plan is FDA’s attempt to encourage the creation of
new tools to get fundamentally better answers about
how the safety and effectiveness of new drugs can be
demonstrated, in faster time frames, with more
certainty, and at lower costs. FDA’s report has been
called “timely and significant” and “courageous” by
THE FEDERAL GOVERNMENT’S RESPONSE
National Security and Antibiotic Resistance 
Antibiotic resistance not only threatens public health, but may have national and global security
implications as well. Virtually all of the antibiotic-resistant pathogens that exist naturally today can be bio-
engineered through forced mutation or cloning. In addition, genetic manipulation of existing pathogens
could render them resistant to currently available antibiotics. A better understanding of the mechanisms
related to drug resistance and tools that could be derived from such research may help U.S. public health
officials as they monitor and respond to any future bioterrorism episodes that involve genetically
engineered resistant pathogens. Moreover, antibiotic resistance may limit the effectiveness of antibiotics
during future bioterrorism events, outbreaks, and other emergencies. 
Members of Congress are beginning to see the connection and to understand our vulnerability. In their
reports on Project Bioshield in 2003, both the House Government Reform Committee and the Energy and
Commerce Committee linked natural conditions, including antimicrobial resistance and dangerous viruses,
to national security concerns. The Energy and Commerce Report stated “advancing the discovery of new
antimicrobial drugs to treat resistant organisms … may well pay dividends for both national security and
public health.”
[See also the report, Beyond Anthrax: Confronting the Biological Weapons Threat, issued May 4, 2004, by
the Democrats of the House Select Committee on Homeland Security simultaneously with the introduction
of the Rapid Pathogen Identification to Delivery of Cures Act (H.R. 4258).]
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industry leaders who have praised the report for
“recognizing the serious problems that are preventing
new, innovative drugs and biologics from getting to the
patients who need them.” 
• Project Bioshield
Following the 2001 anthrax attacks, the Administration
and congressional leaders moved rapidly to introduce
the Project Bioshield Act.* The legislation is intended to
spur R&D of new drugs, vaccines, and diagnostics for
use against potential bioterrorism agents by establishing
a guaranteed market for these products with the federal
government serving as purchaser. Project Bioshield
focuses on the six category A bioterrorism agents of
greatest concern (smallpox, anthrax, botulism, tularemia,
viral hemorrhagic fevers, and plague). 
The legislation does not include incentives to spur R&D
of new antibiotics to treat drug-resistant infections that
threaten public health, despite IDSA’s pleas that they be
included. 
• Public Health Service Action Plan to
Combat Antimicrobial Resistance
In January 2001, a federal interagency task force
including CDC, FDA, NIH, and other agencies published
the Public Health Service Action Plan to Combat
Antimicrobial Resistance. The action plan is a
comprehensive strategy that includes efforts to reverse
the stagnation in antibiotic R&D. Other key action items
target antimicrobial resistance surveillance, prevention
and control, and research. Due to limited
appropriations, the Administration’s implementation of
the plan thus far has been slow, not well coordinated,
and incomplete.
• General Accounting Office Study
In May 2003, Senators Judd Gregg (R-NH) and Jack
Reed (D-RI) asked the General Accounting Office (GAO)
to study the antimicrobial availability problem. The
senators stated: 
“With the threat of bioterrorism, the growing number
of microorganisms resistant to drug therapy, the
reemergence of previously deadly infectious diseases,
such as tuberculosis, and the emergence of new
infectious diseases in the United States, such as severe
acute respiratory syndrome and West Nile virus, there is
an urgent need for new antimicrobials.”
A year later, GAO has yet to begin the study, and their
analysis of the many challenges to antibiotic R&D may 
be years away. ... The time for studying the problem 
is over.
January 1999. A 13-
year-old girl from
rural Minnesota was
brought to a local hospital with fever and respiratory
distress. She was coughing up blood. A chest X-ray
revealed fluid in the lungs. The girl was treated with
the antibiotics ceftriaxone and nafcillin. Within five
hours of arriving at the hospital, the girl’s blood
pressure dropped, and she was transferred to a
pediatric hospital, intubated, and treated with
vancomycin and cefotaxime. Despite intensive
medical care, the girl’s health deteriorated, and she
died on the seventh hospital day from multiple organ
failures and excessive fluid and swelling in the brain.
An autopsy and tests revealed that MRSA had
destroyed her left lung. The girl had no chronic
medical conditions and no recent hospitalizations. 
*Although not enacted at the time this paper went to press, the
Act likely will have been enacted by its publication date.
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The federal government must take decisive action now.
Primarily, policymakers must focus on adopting incentives
to stimulate investment in this area of discovery by
pharmaceutical and biotechnology companies. Any
antibiotic R&D plan that does not include industry action at
its core will yield hollow promises. Government-sponsored
research and refinement of existing regulations, policies,
and guidance can help to address the overall problem of
antibiotic resistance, fill in some of the gaps in research,
and reduce the cost of antibiotic discovery and
development. But industry must take the lead to ensure
success. Industry decision-making is not perfect from a
public health perspective, but the focus on financial
incentives has made industry successful in the past, and
new incentives can lead to future successes.
The past two decades of antibiotic development clearly
have demonstrated that we no longer can rely on existing
market forces to keep companies engaged in this area of
drug discovery and development. Should additional
companies’ antibiotic R&D infrastructures be dismantled, it
will take years to establish new programs—or this
expertise could simply be lost forever. Moreover, given the
10-year time gap that it takes for new antibiotics to move
from concept to market, time for action is running out.  
Creative thinking and innovative policy will solve both the
antibiotic R&D and antibiotic resistance problems. IDSA has
explored with industry, government officials, academics,
patient representatives, and congressional staff the long-
term value of many potential solutions. Our investigation
has revealed that the incentives most likely to spur R&D
within major pharmaceutical companies include those that
provide financial benefits prior to a drug’s approval (e.g.,
tax credits for R&D), commence at the time of approval
(e.g., wild-card patent extension), reduce the costs of
clinical trials (e.g., FDA flexibility concerning the evidence
necessary to demonstrate safety and efficacy; National
Institute of Allergy and Infectious Diseases [NIAID]
sponsored research to foster the development of rapid
diagnostics tests, etc.); and reduce companies’ risks (e.g.,
liability protections). R&D at smaller companies also could
be stimulated through statutory and administrative
changes. Finally, new funding could help to ensure a
better understanding about biological mechanisms related
to antibiotic resistance, limit the public health impact of
antibiotic resistance, and spur public-private R&D efforts.  
IDSA does not claim to possess all of the answers, but a
combination of the solutions listed in the next section will
help. Policymakers should use these recommendations to
shape a framework for governmental action. 
INNOVATIVE FEDERAL POLICY AND
IMMEDIATE ACTION ARE NEEDED
Resistant infections
can lead to longer
hospital stays.
April 2004. A 52-year-old Maryland man,
previously healthy, was hospitalized
complaining of cough, fever, and shortness of
breath. His sputum culture grew MRSA. A
chest X-ray showed pneumonia involving
almost all segments of the lung. He was
treated aggressively with antibiotics,
transferred to the intensive care unit, and
placed on a ventilator but died on the second
hospital day.
23
Legislative action is necessary to stem the tide of
pharmaceutical company departures from antibiotic R&D and
to stimulate the involvement of non-active companies. Critical
priorities that will have the greatest impact are indicated.
Commission to Prioritize
Antimicrobial Discovery
To begin to address the “bad bugs, no drugs” problem,
Congress should establish and empower an independent
Commission to Prioritize Antimicrobial Discovery (CPAD).
CPAD’s specific focus would be to identify the targeted
pathogens that are (or are likely to become) a significant
threat to public health due to drug resistance and other
factors. The statutory R&D incentives that follow would
apply to drugs that treat these pathogens. CPAD’s
decision-making would be based on an analysis of risks as
well as benefits to public health.
An expert independent commission is needed to address the
public health and R&D issues unique to antimicrobial R&D.
Similar entities in other areas of medicine include the National
Vaccine Advisory Committee and the National Cancer
Advisory Board.
CPAD would make recommendations directly to the Secretary
of Health and Human Services (HHS) and would be comprised
of experts from the infectious diseases medical and research
communities, representatives from relevant government
agencies (CDC, FDA, NIH), and representatives from industry
and relevant patient advocacy groups.  
Companies would register with HHS to become eligible 
for the incentives. Once HHS certified a company as eligible, it
could receive tax credits (R&D, capital formation, etc.). When
a company successfully developed a product that met HHS
predetermined specifications, it would become eligible for
other incentives (intellectual property, liability, etc.).
Proposed Statutory Incentives
Congress must enact a robust set of statutory incentives to
stimulate private sector investment and innovation. Unless
such incentives are established, Americans will be at even
greater risk from infectious disease threats in the future.  
The Project Bioshield Act and pending legislation, such as the
Biological, Chemical, and Radiological Weapons
Countermeasures Research Act (S. 666), introduced by
Senators Lieberman and Hatch in 2003, provide good starting
points for congressional discussions about what incentives are
appropriate. Like Project Bioshield, S. 666 includes progressive
ideas to spur R&D for bioterrorism countermeasures. S. 666
goes further, however, providing tax credits, special
intellectual property incentives, and antitrust and
indemnification provisions. 
Existing law offers other models to consider. The Best
Pharmaceuticals for Children Act, for example, provides an
additional six months of market exclusivity for new or already-
marketed drugs and priority review status for pediatric
supplements to a drug application, if the holder of an
approved application undertakes studies of these drugs in
children. Under the Orphan Drug Act,* qualifying drugs
receive seven years of market exclusivity protection against
generics and innovator drugs, tax incentives (up to 50 percent
for clinical research), and research grants. 
Following is a list of potential statutory incentives for
Congress to consider:  
RECOMMENDATIONS FOR CONGRESS
*Orphan diseases or conditions must affect fewer than 200,000
individuals in the United States or provide no reasonable expectation
that the sales of the drug will recover the costs of development.
CRITICAL PRIORITY
24
1. Supplemental intellectual property
protections for companies that invest
in R&D for priority antibiotics 
• Establishment of a “wild-card patent extension”
linked to R&D for antibiotics to
treat targeted pathogens
The original concept of a wild-card patent extension is
provided in S. 666. Under this proposal, a company that
receives approval for a new antibiotic, or a new indication
for an existing antibiotic, that treats a targeted pathogen
would be permitted to extend the market exclusivity period
for another of the company’s FDA-approved drugs. S. 666
supports a patent extension of two years.
The wild-card incentive may not be acceptable to all
policymakers. For that reason, Congress should explore the
feasibility of modifying the wild-card concept to require
that the company commit a substantive portion (10
percent-20 percent) of the profits derived from the patent
extension to additional targeted antibiotic R&D. This
incentive is unlikely to help small biopharmaceutical
companies, but would be a significant lure to major
pharmaceutical firms.
• Restoration of all patent time lost during FDA’s
review of applications for antibiotics that treat
targeted pathogens
FDA’s review time for new antibiotic applications can vary,
but the mean time is as long as 18 months. Although some
of the patent time lost during FDA’s review may be
restored under current law, the specter of losing any patent
time can have dramatic implications for companies’
decision-making. S.666 permits a company to select either
this incentive or the wild-card patent extension incentive,
but not both. Because the profit potential of most
antibiotics is not very high and is likely to decline as the
patent runs out, this is unlikely to be a very strong incentive
in most cases.
• Extension of market exclusivity for antibiotics 
that treat targeted pathogens similar to what has 
been successfully implemented for pediatric and
orphan drugs
Extended periods of market exclusivity can be an incentive
to the original sponsor of a drug, as generic copies of the
drug may not be approved or marketed during this time.
Lengths of market exclusivity used or proposed in the past
include six months under the Best Pharmaceuticals for
Children Act (BPCA), seven years under the Orphan Drug
Act, and 10 years under S. 666. Several pharmaceutical
companies have indicated that an additional six months of
market exclusivity would not provide a sufficient draw for
them to invest in the development of new antibiotics or to
seek a new indication for an existing antibiotic. For that
reason, new legislation should include the longer periods of
exclusivity as available under the Orphan Drug Act or as
proposed in S. 666.
The fundamental principle behind the passage of BPCA and
the Orphan Drug Act is that the government has a public
health interest in spurring the discovery of new treatments
to assist vulnerable populations. This same principle should
prompt Congress to address the problem of drug-resistant
infections.
Because the profit potential of most antibiotics is not high
and is likely to decline over time, this profit is unlikely to be
a very strong incentive in most cases.
2. Other potential statutory incentives
to spur antibiotic R&D 
• Provide tax incentives (as provided in S. 666). The
company seeking to fund research would be eligible to
elect among the following tax incentives:
– Claim tax credits for R&D of
antibiotics that treat targeted pathogens 
CRITICAL PRIORITY
RECOMMENDATIONS FOR CONGRESS (CONTINUED)
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– Allow R&D limited partnerships to conduct research on
drugs to treat targeted pathogens. The partnerships
would pass through all business deductions and credits to
the partners.
– Issue a special class of stock for the entity to conduct the
research. The investors would be entitled to a 
zero capital gains tax rate on any gains realized on 
the stock.
– Receive a special tax credit for research conducted at a
non-profit and academic research institution
• Provide FDA with additional statutory flexibility to
approve antibiotics that treat targeted pathogens as
opposed to types of infection (e.g., resistant 
S. aureus vs. pneumonia) and encourage the agency
to use that authority 
• Create a guaranteed market with the federal
government as purchaser and sufficient
appropriations to stimulate R&D for antibiotics that
treat targeted pathogens (as provided for biodefense in
Project Bioshield and S. 666)  
The “bad bugs, no drugs” problem highlights the need for
an open and flowing pipeline of antibiotics to treat patients
on a daily basis in hospitals and communities across the
United States. A guaranteed market that prompts
stockpiling of drugs is unlikely to have much applicability in
this regard.
3. Establish similar statutory incentives
(as listed previously) to spur R&D for
rapid diagnostic tests to identify
targeted pathogens, which will help
to reduce the cost of clinical trials  
Policymakers should consider applying the incentives outlined
above as potential solutions to encourage R&D for rapid
diagnostic tests. New rapid diagnostics would greatly reduce
the cost and time needed to conduct clinical trials for new
antibiotics. For many resistant pathogens, there currently are
no rapid diagnostic tests available to assist in identifying
eligible patients for clinical trials. Cutting costs and time will
serve as incentives for greater investment in and more speedy
approval of targeted antibiotics. In addition, new rapid
diagnostics will permit physicians to diagnose specific
bacterial infections in their patients. This will enable
physicians to prescribe the most appropriate antibiotics,
which will slow the evolution of new resistance.
4. Potential statutory incentives of
interest to small biopharmaceutical
companies that have far less up-front
capital to invest in R&D for antibiotics
that treat targeted pathogens
• Provide tax incentives to form capital from investors
and retained earnings for biopharmaceutical
companies that cannot use tax credits, because they
have no tax liability, or permit the small company to
save or sell its credits (as provided in S. 666)
• Significantly increase the number and amount of
Small Business Innovation Research (SBIR) grants that
NIH can provide for these antibiotics
• Waive user fees for supplemental new drug
applications submitted to FDA for the treatment of
targeted pathogens
Currently, companies can submit supplemental
applications for new indications of drugs that have
already been approved by FDA—for example, if an
existing drug is found to be effective in treating a
different bacterial infection or the same infection located
in a different area of the body. Under current law, the
user fee is waived for the original new drug application
that an eligible “small company” submits to FDA for
review. However, the company is charged a user fee for
supplemental applications submitted for each new
indication even if the new indication will treat an
organism that threatens public health.
RECOMMENDATIONS FOR CONGRESS (CONTINUED)
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5. Liability protections afforded to
companies that receive FDA approval
for antibiotics that treat targeted
pathogens (as
provided in S. 666)
For obvious reasons, the pharmaceutical company
representatives with whom IDSA met each saw government
indemnification, similar to what has been afforded
childhood vaccines, as a powerful incentive to develop new
antibiotics. IDSA’s recommendation is limited to antibiotics
as they are being used to treat pathogens targeted by the
Commission to Promote Antimicrobial Discovery.
6. Limited antitrust exemptions for
companies that seek to work
together to expedite research 
on targeted antibiotics 
(as provided in S. 666)
Congress must act now to encourage pharmaceutical and
biotech companies to invest in the antibiotics market.
February 2004. A 34-year-old Maryland woman
had the flu and went to an emergency room
where a chest X-ray showed pneumonia.
Laboratory studies confirmed it was due to
MRSA. She developed shock and required a
ventilator and tracheostomy to support
breathing. As a complication of shock, both legs
were amputated. She remained in the hospital
for more than two months.
CRITICAL PRIORITY
RECOMMENDATIONS FOR CONGRESS (CONTINUED)
Next Steps for Congress
Hearings should be scheduled as soon as possible to highlight
the human consequences of the “bad bugs, no drugs”
problem and to determine which combination of incentives are
most appropriate. The Senate and House leadership should
work together in a bipartisan manner to enact sufficient
statutory incentives to stimulate new antibiotic R&D. Congress
should work cooperatively with the Administration to
encourage greater antibiotic R&D and to limit the public health
impact of antibiotic resistance.
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The Food and Drug Administration’s (FDA) high standards for
evaluating antibiotics’ safety and efficacy must be maintained.
However, avenues must be explored to better address the
unique nature of antibiotic discovery and stimulate industry-
sponsored antibiotic R&D. As FDA implements its new Critical
Path plan, the agency should implement the following
recommendations. Each of the recommendations should be
considered a critical priority:
• Publish updated guidelines for clinical trials of anti-
infectives. Industry is understandably hesitant to initiate
new clinical trials in areas where the standards for safety
and efficacy are unclear. FDA should issue, as soon as
possible, guidelines for resistant pathogens, bacterial
meningitis, acute bacterial sinusitis, acute bacterial otitis
media, and acute exacerbation of chronic bronchitis. These
guidelines have been in revision or development for some
time. FDA also should move quickly to identify additional
areas of uncertainty in antibiotic drug development and
develop or update guidelines in those areas as well. Review
of these guidance documents at appropriate intervals also
would be extremely useful in ensuring their continued
relevance and accuracy. 
• Encourage imaginative clinical trial designs that lead
to a better understanding of drug efficacy against
resistant pathogens. For example, clinical trial data on
resistant pathogens are time-consuming and costly to
accrue. FDA could define ways in which an antibiotic’s
efficacy against drug-sensitive types of bacteria could be
used to extrapolate efficacy against drug-resistant strains.  
• Provide a clear definition of acceptable surrogate
markers as endpoints for clinical trials of bacterial
infections. In other words, FDA needs to define new ways
to determine an antibiotic’s effectiveness, such as clearing
bacteria from blood or other body sites (e.g., hip and knee
implants) or resolving fever. This concept has been accepted
for antiviral agents, but has had limited application to
bacterial infections. 
• Explore, and when appropriate encourage, the use of
animal models of infection, in vitro technologies (e.g.,
test tube), and valid microbiologic surrogate markers
(e.g., clearance of bacteremia) to reduce the number
of efficacy studies required for each additional
indication. These data are easier and less costly to obtain
than full results of safety and efficacy testing in human
subjects, and therefore, when appropriate, could result in a
more timely and efficient approval process. Of course, safe
and effective drug dose regimens must be maintained. 
• Explore with NIAID all opportunities to streamline
antibiotic drug development. (See examples outlined
under NIAID recommendations.) 
• Grant accelerated approval status for antibiotics that
treat targeted pathogens. This regulatory pathway allows
FDA to grant approval prior to completion of full human
testing, based upon a demonstration of efficacy using
surrogate endpoints with a commitment for post-approval
human testing to confirm the effect on disease outcomes.
Moving beyond the current scenario, FDA could give
provisional approval for antibiotics that treat targeted
pathogens followed by a post-approval study of the drug
by a select group of investigators certified to treat patients
with the drug. The certified investigators would collect
additional efficacy data needed to lead to a full approval,
while providing patients with earlier access to the drug.
Health care payers would offset the costs of the clinical
trials, which may prompt companies to pursue candidate




NIH has shown leadership in developing the Roadmap
initiative. The true test is still to come as the plan is
implemented. The National Institute of Allergy and Infectious
Diseases (NIAID) has primary responsibility for implementing
the Roadmap in the infectious diseases arena. To achieve
success, NIAID should implement the following
recommendations. Each of these recommendations should be
considered a critical priority:
• Move aggressively to expand the translational (bench
to bedside) research concepts contained in the
Roadmap to strengthen antibiotic R&D, remove
roadblocks that may exist in NIAID’s structure and
guidelines, and accelerate antibiotic resistance
research activities  
• Increase the number and size of grants to small
businesses, academic institutions, and non-profit
organizations that focus on R&D of antibiotics to treat
targeted pathogens  
• Seek greater opportunities to work with
pharmaceutical and biotechnology companies to
advance antibiotic R&D, and ensure that NIAID staff
who oversee technology-transfer efforts understand
industry’s motivations and goals  
• Engage more aggressively the infectious diseases
research community in research planning efforts and
create a more transparent decision-making process 
• Sufficiently fund and rapidly implement NIAID’s
newly launched Drug Discovery and Mechanisms of
Antimicrobial Resistance Study Section
• Encourage research on topics directly related to the
implementation of clinical trials (e.g., surrogate
endpoints of response to therapy, animal models, and
analytical methods)  
• Sponsor research into new rapid diagnostic tests for
bacterial infections that, when available, could reduce
the cost of clinical trials
• Re-examine NIH’s 1999 research tool guidelines and
modify or waive the guidelines where necessary.
NIH’s guidelines have been criticized for unnecessarily
restricting companies’ intellectual property rights and
revenue generation where research tools have been
developed in conjunction with federally funded research.
Critics believe the guidelines should be modified to breathe
new life into research tool development, particularly to
help fight emerging infectious pathogens. Research tools
include cell lines, drug delivery technologies, laboratory
animals, clones and cloning tools, databases, and other
technologies.   
• Develop a fellowship curriculum designed for clinician
investigators to provide expertise in clinical trials of
new antibiotics. FDA and the National Cancer Institute
(NCI) announced an analogous program for anti-cancer
drugs in 2003. 
• Explore joint programs with FDA to streamline
antibiotic drug development similar to programs
initiated by NCI and FDA in 2003. The NCI/FDA
programs are intended to inform and harmonize all phases
of cancer drug discovery, development, and regulatory
review. 
• Encourage research on antibiotic use patterns and
their impact on resistance, specifically the impact of
use restrictions on newly approved antibiotics  
• Fund placebo controlled trials to determine if certain
diseases require antibiotic therapy (e.g., acute otitis
media, acute exacerbation of chronic bronchitis, and
acute bacteria sinusitis). There is reasonable concern that
antibiotics frequently are prescribed to treat diseases that
are not caused by bacteria (e.g., are viral in origin). This
inappropriate use of antibiotics promotes antibiotic
resistance with no benefit to patients. Definitive placebo-





Public and private efforts that target the growing problem of
drug resistance and lack of antibiotic R&D are drastically
under-funded. An infusion of new resources (i.e., not shifting
funds from other public health efforts) in several critical
program areas will go a long way toward assuring Americans
that they will soon be protected from dangerous and drug-
resistant pathogens.  
• Double CDC’s antimicrobial resistance program to $50
million in 2005 and continue to increase it by $25
million increments until 2009 to a total of 
$150 million 
CDC is the primary coordinator of much of the Public
Health Service Action Plan to Combat Antimicrobial
Resistance. Increasing CDC’s funding will enable the agency
to expand its surveillance of clinical and prescribing data
that are associated with drug-resistant infections, which
would assist the Commission to Prioritize Antimicrobial
Discovery (referenced above), CDC, and other public health
agencies in setting priorities. Funding also is needed to
educate physicians and parents about the need to protect
the long-term effectiveness of antibiotics as well as to
strengthen infection control activities across the United
States. Finally, broadening the number of CDC’s extramural
grants targeting applied research at academic-based centers
would harness the brainpower of our nation’s researchers
and assist the agency in developing practical and successful
antimicrobial resistance prevention and control strategies.
• Increase by $25 million funding for FDA’s programs
that support antibiotic development and reduce the
costs of clinical trials
New funding will enable the anti-infective review group
within FDA’s Center for Drug Evaluation and Review to
begin to implement the Critical Path plan, including funding
research efforts envisioned under the plan and creating
guidelines that clarify for industry the standards FDA will
apply to antibiotic R&D. New funding also would
strengthen the anti-infective review group’s ability to
evaluate antibiotics for the treatment of targeted
pathogens, by permitting them to contract with companies
that provide national, real-time microbiological data related
to relevant antibiotics and all clinically relevant strains of
bacteria. This information is not available through
government sources. New funding also would enhance the
Center for Devices and Radiological Health’s ability to
support the review of rapid diagnostics to detect resistant
microorganisms.
• Significantly increase NIAID’s critical translational and
antibiotic resistance research efforts  
IDSA and other organizations have called for a 10 percent
across-the-board funding increase for NIH in 2005. Such
funding is necessary to allow NIAID to move aggressively to
implement the Roadmap initiative in the area of antibiotic




February 1999. A 12-
month-old boy from
rural North Dakota was




airway. He had a
temperature of slightly more than 105 degrees.
Tests and X-rays revealed an infection in his right
lung. Doctors transferred the boy to the intensive-
care unit, inserted a chest tube, and treated him
with the antibiotics vancomycin and cefuroxime.
The next day the boy developed severe respiratory
distress and falling blood pressure, and he died.
The boy had not been hospitalized since birth and
had no known medical problems. However, his 2-
year-old sister had been treated for a culture-
confirmed MRSA infection three weeks earlier. 
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• Support Synergistic Public/Private Solutions 
A growing number of international public-private
partnerships are focusing on the discovery of medicines to
treat infectious diseases in the United States and globally.
Initiatives like the International AIDS Vaccine Initiative
(formed in 1996), the Medicines for Malaria Venture
(1999), and the Global Alliance for TB Drug Development
(2000) offer promising opportunities to advance product
R&D in areas that have languished in the past. Public-
private partnerships have adopted business models that
exploit the venture capital approach to investment in new
product R&D. Such initiatives receive the bulk of funding
from the public and philanthropic sectors. They involve for-
profit partners by seeking in-kind contributions from
industry. The commitment of U.S. public dollars for these
and similar initiatives would take advantage of the 
entrepreneurial spirit possessed by many researchers and
humanitarians. 
In addition to funding public-private partnerships,
policymakers should seriously consider ways to prompt
companies to inventory their shelves for promising drug
candidates that could be donated to the partnerships for
development. Such candidates exist, and companies
recently have shown some interest in donating them. This 
is not a current priority for companies, however, because
the resources required would have to be diverted from
other efforts.
Emerging and Re-Emerging Infections
Robust research and development programs are
needed to respond successfully to existing infectious
diseases as well as new threats on the horizon.
More than three dozen new infectious diseases have been identified since the 1970s that have impacted
the United States and more vulnerable countries. The list includes HIV/AIDS, severe acute respiratory
syndrome (SARS), Lyme disease, hepatitis C, a new form of cholera, waterborne disease due to
Cryptosporidium, foodborne disease caused by E. coli 0157:H7, and a plethora of neglected diseases that
primarily affect patients in the developing world. 
Some of these diseases have no treatment except for supportive care. For diseases that do have effective
treatments, complacency can stifle new research and allow us to be caught off guard when current
treatments become less effective due to resistance. This has been the case with tuberculosis (TB). It has
been 30 years since a new class of antibiotic was approved to treat TB despite the fact that it is the
second most common microbial cause of death in the world. Doctors also are concerned about the rapid
rate at which other bacterial infections, such as gonorrhea and syphilis, are becoming resistant to drugs.
Finally, for diseases such as TB, AIDS, and malaria, which have notoriously complex and sometimes toxic
treatment regimens, there is a substantial need for new drugs that are not only more effective but easier
to deliver to the patient so that greater drug adherence and, ultimately, successful care and treatment
will be achieved. 
NEW FUNDING NEEDED (CONTINUED)
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The time for talk has passed—it’s time to act. The “bad
bugs, no drugs” problem is growing more severe, and
patients are suffering. Government-sponsored research
and refinement of existing regulations, policies, and
guidance can help to address the overall problem of
antibiotic resistance, fill in some of the gaps in drug
development, and help reduce the cost of drug discovery
and development. However, industry action must remain
policymakers’ central focus. Incentives that encourage
pharmaceutical companies to remain active in this area of
discovery or stimulate additional investment by inactive
pharmaceutical and biotechnology companies must be a
critical part of any solution. 
New drugs are desperately needed to treat serious as well
as common infections (e.g., blood, heart, and urinary tract
infections; pneumonia; childhood middle-ear infections;
boils; food poisoning; gonorrhea; sore throat, etc.). The
bacteria that cause these infections are becoming
increasingly resistant to the antibiotics that for years have
been considered standard of care, and the list of resistant
pathogens keeps growing. It is not possible to predict
when an epidemic of drug-resistant bacteria will occur—
but we do know it will happen. 
Congress and the Administration have a window of
opportunity to act now—before a catastrophe occurs—to
spur both R&D of antibiotics to treat dangerous and drug-
resistant infections and to promote a better understanding
of antibiotic resistance and its implications for both public
health and national and global security. Time is running
out. Even if all of the incentives outlined in this paper 
were implemented today, it likely would take 10 or more
years for companies to move safe and effective new drugs
to market.
Federal officials have worked tirelessly over the past few
years to help improve U.S. defenses against, and
treatments for, bioterrorism agents. Although this work is
needed and appropriate, it also is necessary to keep risks in
perspective. Drug-resistant bacterial infections kill tens of
thousands of Americans every year and a growing number
of individuals are succumbing to community-acquired
infections. An epidemic may harm millions. Unless
Congress and the Administration move with urgency to
address these infections now, there is a very good chance
that U.S. patients will suffer greatly in the future.
CONCLUSION
January 1998. A 16-month-old girl from rural
North Dakota was taken to a local hospital
with a temperature of over 105 degrees. She
was suffering from seizures and was in shock.
Doctors treated her with the antibiotic
ceftriaxone, but the girl died within two
hours of heart and lung failure. An autopsy
and tests revealed that MRSA had spread to
her brain, heart, liver, and kidneys. One
month earlier, the patient had been treated
with amoxicillin for otitis media (an ear
infection). Neither the girl nor her family
members had been hospitalized during the
previous year. 
Drug-resistant infections are more difficult to treat.
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The Infectious Diseases Society of America (IDSA) appreciates the opportunity to 
provide this statement before the U.S. Food and Drug Administration’s (FDA) Part 15 
panel on the critically important issue of antimicrobial resistance.  
IDSA represents more than 8,000 infectious diseases physicians and scientists devoted to 
patient care, education, research, prevention, and public health.  Our members care for 
patients of all ages with serious and life-threatening infections, including meningitis, 
pneumonia, tuberculosis, antimicrobial drug-resistant infections, and those with cancer or 
transplants who have life-threatening infections caused by unusual microorganisms, 
HIV/AIDS, and other emerging infections. 
Antimicrobial resistance is a serious patient safety and burgeoning public health problem.  
The resistant infections about which Infectious Diseases specialists and other physicians 
are most concerned at this time are caused by bacteria.  For this reason, our statement will 
primarily focus on antibacterial resistance.  IDSA’s statement includes a discussion of the 
antibacterial resistance problem and why Infectious Diseases and other physicians are 
concerned, the critical need for new products to detect, treat and prevent resistant 
infections as well as 12 priority recommendations that require FDA’s immediate 
consideration.
Antibacterial-Resistant Infections:  Why IDSA Is Concerned 
Bacterial infections affect hundreds of thousands of Americans and cause tens of 
thousands of deaths each year, perhaps more.  Resistant infections are painful, difficult to 
treat, and cost many billions of dollars to the U.S. health care system annually.  These 
“bad bugs” have become a silent epidemic in communities and hospitals across the 
United States as well as around the world.  And yet, an astoundingly diminutive amount 
of federal resources are being committed to address this staggering problem.  In fiscal 
year (FY) 2006, FDA spent only $24 million on its collective antimicrobial resistance 
activities, the Centers for Disease Control and Prevention (CDC) spent only $17.2 
million, and the National Institutes of Health (NIH) spent only $220 million ($194.5 
million of which was spent at the National Institutes of Allergy and Infectious Diseases 
(NIAID)—4.4% of NIAID’s total budget.  $90 million of NIAID’s antimicrobial 
resistance research budget was dedicated to antibacterial resistance research—2.1% of 
NIAID’s total budget).
The bacteria of greatest concern include multi-drug-resistant Staphylococcus aureus 
(MRSA), resistant Escherichia coli (E. coli), Acinetobacter baumannii (which is 
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threatening soldiers returning from Iraq and Afghanistan), resistant Klebsiella species 
(which appear to have originated in or near Brooklyn and now are spreading across the 
East Coast and into the Midwest), extensively drug-resistant tuberculosis (XDR-TB), 
Clostridium difficile, Enterococcus faecium, Enterobacter species, and resistant 
Pseudomonas aeruginosa. There are many others. 
Although primarily affecting ill people in hospitals, a growing number of the victims of 
drug-resistant bacteria, such as MRSA, are people in the community and outside 
hospitals, including healthy athletes and children.  A recent study in the Journal of the 
American Medical Association (October 17, 2007) demonstrates that more than 94,000 
people are infected and nearly 19,000 die annually from MRSA alone around the country 
– more deaths than those caused by emphysema, HIV/AIDS, Parkinson’s disease and 
homicide.  New national surveillance data from the CDC demonstrate that an incredible 
80% of E. faecium associated with device-related healthcare-associated infections (HAIs) 
were resistant to vancomycin. More broadly, these new data demonstrate high rates of 
antimicrobial resistance in the gram-negative pathogens associated with device-related 
HAIs.  Disturbingly, analysis of national data indicated that twenty-six to thirty-seven 
percent of A. baumannii were carbapenem-resistant, as was ten percent of  
K. pneumoniae.  Thirty percent of P. aeruginosa were resistant to fluoroquinolones. 
Antibacterial Drug Portfolio:  Why IDSA Is Concerned 
Of serious concern, Infectious Diseases physicians are alarmed by the prospect that 
effective antibacterial drugs may not be available to treat seriously ill patients in the near 
future.  Since their discovery, antibacterial drugs have dramatically reduced the morbidity 
and mortality associated with bacterial diseases, saving millions of lives and easing 
patients’ suffering.  However, over time, certain classes of drugs are losing their 
effectiveness to increasingly resistant infections.  Until recently, the pharmaceutical 
industry’s research and development (R&D) efforts counteracted this phenomenon by 
developing new drugs in time to treat bacteria that became resistant to older antibacterial 
drugs.  However, that is no longer the case.  Unfortunately, both the public and private 
sectors appear to have been lulled into a false sense of security based on past successes.
The potential crisis at hand is the result of a marked decrease in industry R&D, 
government inaction, and the increasing prevalence of resistant bacteria.  It takes 8 years 
to develop a new antibacterial drug.  Thus, today we should be planning for our 
pharmaceutical needs of 2012-2015.  Given the state of the current pipeline, our future 
looks bleak.  To call attention to the resistance problem and the diminishing pipeline, in 
2004, IDSA launched its “Bad Bugs, No Drugs” advocacy campaign by issuing a 
landmark report and several subsequent articles to highlight the brewing patient safety 
and public health crisis. (www.idsociety.org/badbugsnodrugs).
FDA has acknowledged there is problem in the antibacterial drug pipeline.  In the 
agency’s March 2004 Critical Path report “Innovation/Stagnation: Challenge and 
Opportunity on the Critical Path to New Medical Products”, the agency reported that 
“product development in areas crucial to public health goals, such as antibiotics, has 
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slowed significantly during the past decade.” However, since 2004, the agency has 
dedicated insufficient time and resources to solve the resistance or pipeline problems.  In 
fact, if anything, the Agency’s recent actions have produced greater cause for worry as 
growing uncertainty about FDA’s anti-infective drug review process mounts.    
It is frustrating to see patients with life-threatening infections and the toll it takes on their 
lives and on their families and friends, or to see children and adults die when we have the 
resources and the tools to reduce the impact of these diseases.  We cannot stop the 
development of antibacterial resistance – bacteria will continue to mutate in response to 
antibacterial drug use.  However, we can slow the pace of the rise in antibacterial 
resistance, if we have the will to act.  
The Path Forward
Antibacterial resistance and the diminishing antibacterial pipeline are complex and multi-
dimensional problems.  Multi-pronged solutions are required to sufficiently limit the 
impact of antibacterial resistance on patients and the public and to spur the development 
of products to address antibacterial resistant infections.  Such efforts include:
 removing disincentives in the antibacterial drug review process by reestablishing 
consistency, predictability and timeliness;  
 providing economic and other incentives to spur the development of new products 
in this area (e.g., antibacterial drugs, relevant diagnostic tests, and vaccines);
 significantly strengthening federal research in new, relevant rapid diagnostics as a 
means to reduce the number of patients needed for antibacterial drug clinical 
trials;  
 creating an antimicrobial resistance strategic research plan that establishes 
priorities and significantly strengthens collaborations between FDA, NIH, CDC, 
the Departments of Agriculture, Veteran Affairs, Defense and the Environmental 
Protection Administration. 
 educating physicians, patients, and parents about the appropriate use of 
antibacterial drugs;  
 developing and applying infection control and immunization policies and 
practices to prevent transmission;  
 improving our collection of data regarding clinical, veterinary and human 
antibacterial use, and other data;
 protecting antibiotics of importance to human health from being used in 
agriculture; 
 improving surveillance efforts to detect and monitor the emergence of resistance; 
and
 developing safer alternatives to antibacterial drug uses in agriculture.
Implementing many of these solutions will require significant attention, resources, and, in 
some cases, substantial political will to overcome special interests in favor of public 
health and patient safety.   
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In 2001, the Administration recognized the gravity of the problem and developed a 
federal “Action Plan to Combat Antimicrobial Resistance,” an effort led by CDC, FDA, 
and NIH.   Unfortunately, very limited progress has been made toward implementing the 
Action Plan’s 13 Top Priority Action Items, let alone the remainder of the 84 action 
items.  Moreover, in 2000, FDA’s own Task Force on Antimicrobial Resistance issued a 
report (http://www.fda.gov/oc/antimicrobial/taskforce2000.html) containing nine (9) 
recommendations which, if implemented, could have helped significantly to address the 
antimicrobial resistance problem.  Unfortunately, the Agency has made little progress 
toward implementing these recommendations since 2000.   
Below are twelve additional recommendations that IDSA believes will go far toward 
addressing the antimicrobial resistance and pipeline problems.  Within these 
recommendations are several critical steps that FDA can take immediately. 
The United States Government, including FDA, can no longer take a business-as-usual 
approach toward addressing the antimicrobial resistance problem.  Following today’s Part 
15 hearing, it is imperative that the agency dedicate sufficient resources to implement the 
Action Plan’s recommendations, FDA’s own recommendations from 2000 as well as the 
additional recommendations that IDSA outlines below.    
IDSA’s Twelve Recommendations For FDA’s Immediate Consideration 
[The following recommendations are not listed by priority ranking.  They are listed 
chronologically as they will be presented by IDSA’s presenters.] 
Recommendation # 1 FDA Should Work Aggressively To Re-Establish Consistency, 
Predictability, and Timeliness In The Antibacterial Drug Review Process.
Significant uncertainty exists within the agency’s antibacterial human drug review 
process, which we fear is shaking the foundation of the nation’s antibacterial 
pharmaceutical industry.  The agency must move quickly to reestablish consistency, 
predictability, and timeliness to this process which IDSA believes requires the attention 
and leadership of the director of the Center for Drug Evaluation and Review as well as an 
infusion of additional staff and resources.  IDSA has heard from many pharmaceutical 
industry representatives that FDA has lost credibility by throwing out existing policies 
without having new policies available to replace the old, rejecting prior agreements with 
companies, and employing endless delays including in the issuance of clinical trial 
guidances.  Time delays are costing millions and threatening bankruptcy for some 
companies.  FDA must move rapidly to restore trust by making public its plan to resolve 
internal disincentives to antibacterial drug discovery and development.  The plan should 
include the agency’s priorities for action. 
Recommendation # 2 FDA Should Strengthen Critical Path And Other Research, 
Establish Research Priorities With NIH, CDC, USDA, and Other Agencies And 
Collaborate More Often With These Agencies On Antibacterial Resistance and Drug 
Pipeline-Supportive Research. 
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In 2000, FDA’s Task Force on Antimicrobial Resistance reported “In hearing about the 
efforts of multiple centers, it also became clear that coordination of antimicrobial 
resistance research, both within FDA and with sister government agencies and academia, 
is currently largely informal.”  In IDSA’s estimation, little has changed to formalize the 
U.S. antimicrobial resistance research agenda and to establish and publicize U.S. 
priorities.  For this reason, in June 2007 IDSA proposed the creation of an antimicrobial 
resistance strategic research plan to strengthen existing epidemiological, interventional, 
clinical, translational and basic research efforts in a letter to Drs. Anthony Fauci, NIAID 
Director, and Julie Gerberding, CDC Director, 
(http://www.idsociety.org/WorkArea/showcontent.aspx?id=4642).  FDA has a critical 
role to play in that effort, and we urge FDA, NIH, CDC, the U.S. Department of 
Agriculture (USDA), and other relevant agencies to move immediately to establish a 
Blue Ribbon Panel to establish U.S. research priorities and create a strategic research 
plan.
Even without such a strategic plan, FDA should act now to support research that can help 
lead to a reduction in the number of patients necessary for antibacterial clinical trials.  
Such research should include validation of endpoints such as quality of life, length of 
stay, duration of fever, time to elimination of pathogen, patient-reported outcomes, etc. as 
well as the development of new, rapid diagnostics.  The agency should seek and 
strengthen collaborations with NIH, CDC, USDA and other agencies on studies that will 
address resistance and support the antibacterial drug pipeline.  Finally, FDA should 
publish a summary of the antimicrobial resistance/pipeline research efforts it currently 
has underway under its Critical Path and other initiatives.
Recommendation # 3 FDA Should Take Immediate Action To Update 
Antibacterial Clinical Susceptibility Concentrations.
Physicians need accurate information on antibacterial clinical susceptibility 
concentrations (“breakpoints”) to use antibacterial drugs wisely.  Patients’ 
safety and lives are on the line.  Given a new requirement included in the FDA 
Amendments Act, it is incumbent upon the agency to establish workable processes for 
expeditiously updating antibacterial breakpoints as well as to publish its methodology for 
setting breakpoints.  FDA staff's recent inventory of antibacterial labels has uncovered 
that out of the more than 100 currently approved antibacterial labels more than 70 contain 
breakpoints that are out-of-date.
Prior to 2006, FDA's Center for Devices and Radiological Health (CDRH) allowed 
susceptibility test device manufacturers to include both FDA-established breakpoints 
listed in package inserts at the time of the drug’s approval as well as the more up-to-date 
breakpoint recommended by the Clinical Laboratory Standards Institute (CLSI) (formerly 
NCCLS).  CLSI, a 501(c)(3) non profit organization, is a recognized standard setting 
body comprised of experts in infectious diseases and clinical microbiology.  CLSI is not 
affiliated with IDSA.  In 2006, FDA began to require that CLSI submit citizen petitions 
to the agency when recommending updated breakpoints.  In IDSA’s estimation, the new 
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process has been a failure as FDA has taken limited definitive action on the five CLSI 
petitions submitted to date. 
The agency should explore several options available to it for updating breakpoints 
including:
 establishing a less-cumbersome process for reviewing and accepting CLSI’s 
recommendations; 
 creating FDA’s own scientific board of external experts comprised of infectious 
diseases clinicians, microbiologists, pharmacologists, and others who understand 
the clinical impact of changes in the interpretations of the MIC.  The board 
could help the agency update breakpoints and/or review and approve 
breakpoints recommended by CLSI or other appropriate entities;   
 contracting out some of the activities needed to update breakpoints through 
organizations such as CLSI.  Infusing some of the agency's patient safety funding 
into CLSI's effort could help to more quickly address out-of-date breakpoints.
Specifically, IDSA urges FDA to: 
 review and update antibacterial drug breakpoints on a regular basis as clinical 
need dictates, but no less frequently than every 5 years 
 return to purchasing from private vendors the critically needed susceptibility data 
used to update breakpoints;
 require pharmaceutical sponsors (both pioneer and generic) to provide any such 
additional data as may be needed to update breakpoints quickly; and
 immediately publish its methodology for setting breakpoints, which previously 
has not been made public.  IDSA members have heard statements from FDA 
officials that such methods are "not written down anywhere".  This is 
unacceptable and only helps to demonstrate the lack of attention and sufficient 
resources the agency has devoted to this critical patient safety responsibility over 
the last several decades.   
Recommendation # 4 FDA, Working With Other Agencies Represented On The 
Interagency Task Force On Antimicrobial Resistance, Should Establish A Public 
Health Antimicrobial Advisory Board Of Outside Experts To Advise The Task Force In 
Its Efforts.
Antimicrobial resistance is a complex, multi-dimensional problem.  Addressing the 
problem will require expertise from the infectious diseases, medical (including hospital 
and community-based physicians), veterinary, public health, research, 
pharmacoeconomic, and international health communities.  The private sector provides 
incredible expertise in each of these fields which would be extremely valuable to the 
Interagency Task Force on Antimicrobial Resistance in setting and maintaining priorities 
and in carryout out its responsibilities.  For this reason, IDSA strongly recommends that 
FDA, NIH and CDC create an advisory board to advise the existing Interagency Task 
Force on Antimicrobial Resistance.  Such an advisory board should meet with Task Force 
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members on a regular (biannual) basis.   For a list of the advisory board’s potential duties 
and responsibilities see H.R. 3697/S. 2313, the “Strategies to Address Antimicrobial 
Resistance Act”.   
Recommendation # 5 FDA Should Reevaluate And Strengthen Regulatory 
Requirements On Data Collection Of Antibacterial Use In Humans.
FDA should reevaluate (including by holding a public workshop) the manner by which it 
collects antibacterial drug human use data from pharmaceutical companies to determine 
if it may be collected in a manner and format that is reliable and comparable and which 
best ensures it is of maximum value to the study of antibacterial resistance development 
(e.g., using defined daily doses, collected by calendar year).  In addition, the agency 
should seek an agreement with IMS Health or another private vendor to obtain 
antibacterial drug human use data in a manner whereby such data may be shared with the 
Interagency Task Force on Antimicrobial Resistance as well as with members of the 
advisory board proposed in Recommendation #4.   Of course, members of the Task Force 
and advisory board will need to sign confidentiality agreements.  
Recommendation # 6 FDA’s Center For Veterinary Medicine Should Move Quickly 
To Issue Its Long-Delayed Draft Regulation And Guidance #146 On Collection Of 
Data On Antibacterial Use In Animals.
FDA’s Center for Veterinary Medicine (CVM) should move forward immediately to 
issue for public comment its draft Guidance #146 and draft regulation developed in 2001 
and 2002, which were intended to redefine the type of antibacterial distribution data that 
animal drug manufacturers must provide to the agency on antibacterial drug use in 
animals.  The draft regulation and guidance have been held up within the agency since 
2002 for unknown reasons.  It is extremely important that animal antibacterial drug use 
data be collected in a manner and format that is reliable and comparable and which best 
ensures it is of maximum value to the study of antibacterial resistance development (e.g., 
collection using "defined daily doses," by species and indication, and based on a calendar 
year model as opposed to the anniversary date of the product’s approval).  The collection 
of such use data will make information currently collected under the National 
Antimicrobial Resistance Monitoring System of greater relevance as it can be used to 
show where there may be correlations between antibacterial use and the development of 
resistance.  This likely will be one of those instances where the Administration will need 
to muster substantial political will to overcome special interests in favor of public health 
and patient safety.
Recommendation # 7 FDA/CVM Should Update Guidance #152 To Include 
Missing Criteria Concerning The Relative Importance Of Antibacterials In Human 
Medicine.
FDA’s CVM should hold a public workshop to bring together experts in infectious 
diseases human and veterinary medicine as well as other key stakeholders to reassess the 
criteria currently contained in CVM’s Guidance #152 with regard to their potential 
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impact on resistance patterns in human drugs.  Guidance #152 is the framework 
document used for the approval of antibacterial drugs for use in animals.  In particular, 
the agency should reconsider the criteria used to categorize antibacterial drugs as 
“critically important” and “highly important” to human health and whether the scope of 
such criteria should be broadened beyond enteric pathogens.  Additionally, the agency 
immediately should change the classification of cefepime to “critically important" to be 
consistent with the World Health Organization’s classification of this drug.  Cefepime is 
the only 4th generation cephalosporin in use in the United States in humans, and IDSA 
and other expert organizations have emphasized the threat posed both to cefepime and to 
3rd generation cephalosporins by the prospect of 4th generation cephalosporin use in 
livestock.
Recommendation # 8 FDA Should Move Forward Immediately To Implement Its 
Own Recommendations On Antimicrobial Resistance.
In December 2000, FDA’s Task Force on Antimicrobial Resistance issued a report 
(http://www.fda.gov/oc/antimicrobial/taskforce2000.html) containing priority 
recommendations the agency was to implement to address the antimicrobial resistance 
and pipeline problems.  Few of these recommendations have been implemented to date.  
Such inaction can only be interpreted as demonstrating the Agency’s past lack of 
commitment to a brewing crisis that Infectious Diseases physicians believe should be a 
significant priority of the U.S. Government.  IDSA hopes that along with the Agency’s 
desire to hold today’s Part 15 hearing, we are witnessing a turning point in the Agency’s 
thinking and a demonstration of it’s desire to tackle these critical patient safety and public 
health problems.  To confirm this, the Agency should act immediately to dedicate the 
necessary resources necessary to implement its own Task Force’s recommendations as 
well as the additional recommendations that IDSA is proposing today.
Recommendation # 9 FDA Should Require That Antibacterial Impact Statements 
And Management Plans Intended To Predict And Limit Resistance Development Be 
Included In Human Drug Applications.
FDA should require antibacterial drug sponsors (both pioneer and generic) to submit as 
part of their drug applications a resistance impact statement that attempts to predict how 
approval and use of such antibacterial drug may impact upon the development of 
resistance.  Pioneer and generic sponsors of human drugs also should be required to 
submit antibacterial use management plans intended to be used to limit the development 
of resistance associated with the drug’s use.  Such impact statements and management 
plans should be made public so that researchers may use each to study and strengthen our 
understanding of the science of predicting resistance development as well as how to 
prevent and control its development.  Neither the impact statement nor management plan 
should be used for enforcement purposes.    
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Recommendation #10 FDA Should Commission A Study Through The Tufts Center 
On The Study Of Drug Development (Or Another Appropriate Entity) To Obtain 
Expert Recommendations As To Which Incentives Are Necessary To Strengthen The 
Antibacterial Drug, And Relevant Diagnostics And Vaccine Pipelines.
New products (antibacterial drugs, vaccines, diagnostic tests) are critically needed to treat 
and prevent serious and life-threatening antibacterial resistant infections as well as to 
rapidly detect the organism causing that infection.  New rapid diagnostic tests will be 
particularly useful in helping to reduce the numbers of patients needed to demonstrate the 
safety and effectiveness of antibacterial drugs in clinical trials.   
Tax credits for R&D, extensions on periods of market exclusivity, strengthening of 
intellectual property rights, priority FDA review vouchers, grants, prizes and other 
incentives have all been offered as potential incentives.  IDSA does not have all of the 
answers as to which combination of incentives will ultimately be successful.   
Within the federal Interagency Task Force’s Action Plan to Combat Antimicrobial 
Resistance issued to 2001, FDA was designated to take the lead on implementing two of 
the thirteen “Top Priority Action Items.”  These include: 
“Top Priority Action Item — Create an Interagency AR Product Development Working 
Group to identify and publicize priority public health needs in human and animal 
medicine for new AR products (e.g., innovative drugs, targeted spectrum antibiotics, 
point-of-care diagnostics, vaccines and other biologics, anti-infective medical devices, 
and disinfectants).” 
“Top Priority Action Item — Identify ways (e.g., financial and/or other incentives or 
investments) to promote the development and/or appropriate use of priority AR products, 
such as novel compounds and approaches, for human and veterinary medicine for which 
market incentives are inadequate.”
To date, FDA has done nothing to address either Top Priority Action Item.
Arguably, neither FDA nor any federal agency is well-placed to examine and make 
recommendations about the type of incentives that will promote antibacterial drug 
development.  However, the Tufts Center for the Study of Drug Development commonly 
studies pharmaceutical pipelines and the pharmacoeconomic and non-economic factors 
that spur drug development.  For this reason, IDSA strongly urges FDA to commission a 
study through the Tufts Center (or some other similar entity, if one exists) seeking a 
report on strengths and weaknesses in the antibacterial and related diagnostics and 
vaccine R&D pipelines with a particular emphasis on products needed to treat, detect, 
and prevent serious and life-threatening infections.  The study also should provide 
recommendations as to what combination of incentives, considering each phase of 
product development, will work to spur greater R&D of such products among the 
biotechnology, pharmaceutical, vaccine, and diagnostics industries as well as within 
academic settings.  
10
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Recommendation #11 FDA Should Immediately Clarify Its Policies Under The 
Orphan Drug Act Relating To Serious and Life-Threatening Infectious Diseases 
Associated With Antibacterial Resistant Organism.
FDA should immediately clarify how it calculates prevalence of cases under the Orphan 
Drug Act related to serious and life-threatening infectious diseases associated with 
antibacterial resistant organisms.  Agency officials have provided contradictory messages 
on this point, which has had a negative impact on IDSA's ability to advocate for the 
adoption of new statutory incentives to spur R&D on products that will protect patient 
safety and public health.
Recommendation #12 FDA Should Effectively Communicate Its Professional 
Judgment As To The Funding It Needs To Sufficiently Address The Antimicrobial 
Resistance Problem.
The Department of Health and Human Services (HHS), including FDA, NIH, and CDC 
need to effectively communicate the resources the department and agencies need to 
address antimicrobial resistance.  Last year, two members of Congress [Reps. Jim 
Matheson (D-UT) and James McGovern (D-MA)] asked Secretary Leavitt during an 
HHS’ budget hearing for FDA’s, NIH’s, and CDC’s professional judgments concerning 
the amount of funding each agency needs to implement their respective responsibilities 
under the federal Action Plan to Combat Antimicrobial Resistance.  It is unclear whether 
FDA ever submitted its professional judgment request to HHS.  However, it is clear that 
HHS did not submit any professional judgments to the Congressmen.   
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Foreword 
The introduction of antibacterial agents (commonly referred to as antibiotics) led to a revolution in the 
management of bacterial infections. Today, emerging and increasing resistance to antibiotics has become a threat 
to public health in Europe and globally. Only 70 years after their introduction, we are now facing the possibility of 
a future without effective antibiotics for several types of bacteria that cause infections in humans.  
In 2001, the European Commission presented its ‘Community Strategy against Antimicrobial Resistance’. It 
proposed 15 actions in the areas of surveillance, prevention, international cooperation and research and 
development of new antibacterial agents. Later in the same year, European Union (EU) Health Ministers adopted a 
Council Recommendation on the prudent use of antimicrobial agents in human medicine1.
While surveillance of resistance, infection control measures and strategies to prevent the occurrence of infections 
are central to combating antibacterial resistance trends, patients still get infected and there is a particular lack of 
antibacterial agents to treat infections caused by bacteria that are resistant to many of the available treatments 
(i.e. multidrug-resistant bacteria). 
In 2004, a report from the World Health Organization on ‘Priority Medicines for Europe and the World’2 identified 
infections caused by resistant bacteria as the number one disease requiring priority medicines based on the 
potential public health impact if effective new antibiotics were not developed. The report suggested that Europe 
should play a global leadership role in this area.  
In 2007, the European Centre for Disease Prevention and Control (ECDC), the European Medicines Agency (EMEA) 
and the international network Action on Antibiotic Resistance (ReAct) entered into a discussion on the need to 
produce a report that reviewed and documented the gap between infections caused by multidrug-resistant 
bacteria in the EU and the development of new antibiotics to treat them. An ECDC/EMEA Joint Working Group was 
established in 2008 to prepare this report. 
The objective of this report is to give an account of facts and figures that would allow reasonable predictions of 
the gap between bacterial resistance in the EU and the likely availability of new treatments that would be effective 
against multidrug-resistant bacteria in the near future. As such, this technical report is made available to the 
European Commission, and particularly to DG SANCO, DG ENTR and DG RTD, for consideration. The report will 
also serve as a basis for discussions at the expert conference on ‘Innovative Incentives for Effective Antibacterials’ 
scheduled for 17 September 2009, as part of the Swedish EU Presidency. 
We note with satisfaction the timely availability of the final report endorsed by the main scientific Committees in 
the two agencies and would like to thank the working group for its achievement.  
Zsuzsanna Jakab, ECDC Director Thomas Lönngren, EMEA Executive Director 
1 Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC). 
Available from: http://antibiotic.ecdc.europa.eu/PDFs/l_03420020205en00130016.pdf
2 http://whqlibdoc.who.int/HQ/2004/WHO_EDM_PAR_2004.7.pdf




There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new 
antibiotics to tackle the problem. 
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious 
infections in humans and reaches 25% or more in several EU Member States. 
• Resistance is increasing in the EU among certain Gram-negative bacteria such as recently observed for 
Escherichia coli.
• Each year, about 25 000 patients die in the EU from an infection with the selected multidrug-resistant 
bacteria.
• Infections due to these selected multidrug-resistant bacteria in the EU result in extra healthcare costs and 
productivity losses of at least EUR 1.5 billion each year.  
• Fifteen systemically administered antibacterial agents with a new mechanism of action or directed against a 
new bacterial target were identified as being under development with a potential to meet the challenge of 
multidrug resistance. Most of these were in early phases of development and were primarily developed 
against bacteria for which treatment options are already available. 
• There is a particular lack of new agents with new targets or mechanisms of action against multidrug-
resistant Gram-negative bacteria. Two such agents with new or possibly new targets and documented 
activity were identified, both in early phases of development. 
• A European and global strategy to address this gap is urgently needed. 
In 2007, the European Centre for Disease Prevention and Control (ECDC), the European Medicines Agency (EMEA) 
and the international network Action on Antibiotic Resistance (ReAct) entered into a discussion on the need to 
document the gap between the frequency of multidrug-resistant bacterial infections in the EU and the 
development of new antibiotics. As a result, an ECDC/EMEA Joint Working Group was established in 2008 to give 
an account of facts and figures that would allow reasonable predictions of the extent of the gap in the coming 
years.
The following antibiotic-resistant bacteria were selected because they frequently are responsible for bloodstream 
infections and because the associated antibiotic resistance trait is, in most cases, a marker for multiple resistance 
to antibiotics: 
• Staphylococcus aureus, methicillin resistance (MRSA); 
• S. aureus, vancomycin intermediate resistance and vancomycin resistance (VISA/VRSA); 
• Enterococcus spp. (e.g. Enterococcus faecium), vancomycin resistance (VRE);  
• Streptococcus pneumoniae, penicillin resistance (PRSP); 
• Enterobacteriaceae (e.g. Escherichia coli, Klebsiella pneumoniae), third-generation cephalosporin 
resistance;
• Enterobacteriaceae (e.g. K. pneumoniae), carbapenem resistance; and 
• Non-fermentative Gram-negative bacteria (e.g. Pseudomonas aeruginosa), carbapenem resistance.
Trends and burden of infections due to multidrug-resistant 
bacteria in the EU
Data on these selected antibiotic-resistant bacteria in invasive infections (mainly bloodstream infections) were 
available from the European Antimicrobial Resistance Surveillance System (EARSS) for EU Member States, Iceland 
and Norway for each year during the period 2002–2007.  
The trends in the proportion of antibiotic-resistant isolates among blood isolates of the selected bacteria frequently 
responsible for bloodstream infections in Europe are shown in Figure E1.
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Figure E1. Population-weighted, average proportion of resistant isolates among blood isolates of 
bacteria frequently responsible for bloodstream infections, EU Member States, Iceland and Norway, 
2002–2007. 




















































































































Third-gen. cephalosporin-resistant E. coli
Third-gen. ceph.-resistant K. pneumoniae** 
Carbapenem-resistant P. aeruginosa**
* S. pneumoniae: excluding Greece, which did not report data on this bacterium to EARSS. 
** K. pneumoniae and P. aeruginosa: excluding Belgium and Slovakia, which did not report data on these bacteria to EARSS. 
In 2007, the average proportion of Staphylococcus aureus blood isolates that showed resistance to methicillin 
(% MRSA) was the highest proportion of antibiotic-resistant isolates among the selected bacteria frequently 
responsible for bloodstream infections in the European Union. However, this proportion has been decreasing in 
recent years (Figure E1). This is due to decreasing MRSA trends in several Member States, likely due to action 
plans at national level as documented for France, Slovenia and United Kingdom. The average proportion of MRSA 
has reached a level close to that of the selected antibiotic-resistant Gram-negative bacteria.  
The proportion of S. aureus blood isolates that showed intermediate resistance to vancomycin (VISA) was very 
low (less than 0.1%) in EU Member States, Iceland and Norway. No vancomycin-resistant S. aureus isolates were 
reported to EARSS in 2007 (data not presented on Figure E1). 
In contrast, the average proportion of Escherichia coli – the most common Gram-negative bacteria responsible for 
infections in humans – blood isolates showing resistance to third-generation cephalosporins has been rising 
steadily.
At the same time, there is no sign of decreasing resistance to third-generation cephalosporins in Klebsiella
pneumoniae or to carbapenems in Pseudomonas aeruginosa (Figure E1).  
In 2007, the proportion of K. pneumoniae blood isolates from EU Member States, Iceland and Norway that 
showed resistance to carbapenems was, in general, very low (median=0%) with the exception of Greece, where it 
reached 42% (data not presented on Figure E1). 
The human and economic burden of antibiotic-resistant bacteria could only be estimated for the following five 
antibiotic-resistant bacteria: MRSA, vancomycin-resistant Enterococcus faecium, third-generation cephalosporin-
resistant E. coli and K. pneumoniae and carbapenem-resistant P. aeruginosa.
The study confirmed that MRSA was the most common, single, multidrug-resistant bacterium in the European 
Union. However, the sum of cases of common, antibiotic-resistant Gram-positive bacteria (mostly MRSA and 
vancomycin-resistant Enterococcus faecium) was comparable to that of common, antibiotic-resistant Gram-
negative bacteria (third-generation cephalosporin-resistant E. coli and K. pneumoniae, and carbapenem-resistant P.
aeruginosa).
Overall, it was estimated that in 2007 approximately 25 000 patients died from an infection due to any of the 
selected five antibiotic-resistant bacteria in the European Union, Iceland and Norway. In addition, infections due to 
any of the selected antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days and extra 
in-hospital costs of more than EUR 900 million. 
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Subsequently, an estimate was made of loss of productivity due to these infections. Based on 2007 data, 
outpatient care costs were estimated at about EUR 10 million and productivity losses due to absence from work of 
infected patients were estimated at more than EUR 150 million, each year. Productivity losses due to patients who 
died from their infection were estimated at about EUR 450 million each year. Overall, societal costs of infections 
due to the selected antibiotic-resistant bacteria were estimated at about EUR 1.5 billion each year. 
There are many reasons (e.g. limited range of included bacteria, outpatient infections not being considered, 
average cost of hospital care which does not take into account special patient care such as intensive care) to 
support a conclusion that these figures correspond to an underestimate of the human and economic burden of 
infections due to antibiotic-resistant bacteria.  
Research and development pipeline of antibacterial agents  
In order to assess the state of the antibacterial drug development pipeline, two commercial databases (Adis 
Insight R&D and Pharmaprojects) were queried for antibacterial agents in clinical development worldwide. It was 
decided not to perform an in-depth exploration of agents that had not yet reached clinical trials due to the high 
attrition rate during preclinical testing and the scarcity of data available for review. 
Whenever possible, agents identified by the search were assessed for their antibacterial activity against the 
selected bacteria based on actual data available in the databases or in the literature. In the absence of actual in
vitro data, reviewers also took into account reasonable assumptions of the activity of some agents based on the 
properties of similar agents (i.e. of the same class or with a common mechanism of action) in order to construct a 
‘best-case scenario’.
Additionally, for each agent, reviewers were requested to indicate whether it was of a new class or belonged to an 
existing class of antibiotics and to indicate whether it: 
• acted on the same target and in the same way as that of at least one previously licensed antibacterial 
agent;
• acted through a known mechanism of action on a new target; or  
• acted through a new mechanism of action. 
The main results from this analysis were as follows: 
• Of 167 agents identified by the searches, there were 90 antibacterial agents with in vitro activity in a best-
case scenario (based on actual data or assumed based on class properties of mechanism of action) against 
at least one organism in the panel of bacteria selected for their public health importance. 
• Of these 90 agents, 24 were new presentations of licensed antibacterial agents and 66 were new active 
substances.
• Of the 66 new active agents, only 27 were assessed as having either a new target or a new mechanism of 
action, thus potentially offering a benefit over existing antibiotics. 
• Of these 27 agents, there were 15 that could be systemically administered. 
• Of the 15 agents with systemic administration, eight were judged to have activity against at least one of 
the selected Gram-negative bacteria.  
• Of the eight with activity against Gram-negative bacteria, four had activity based on actual data and four 
had assumed activity based on known class properties or mechanisms of action. 
• Of the four with activity against Gram-negative bacteria based on actual data, two acted on new or possibly 
new targets and none via new mechanisms of action. 
Figure E2 shows the information on these 15 antibacterial agents. Notably, only five of these agents had 
progressed to clinical trials to confirm clinical efficacy (Phase 3 or later of clinical development). 
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Figure E2. New systemic antibacterial agents with a new target or new mechanism of action and in
vitro activity based on actual data (dark colour bars) or assumed in vitro activity based on class 
properties or mechanisms of action (light colour bars) against the selected bacteria (best-case 
scenario), by phase of development (n=15).  









































Note: In vitro activity based on actual data is depicted at the bottom of each column in darker colour. Assumed in vitro activity 
based on class properties or mechanisms of action (where applicable) is depicted in a lighter colour at the top of each column.
* Two carbapenems have been omitted from Figure E2b since they are no more active than earlier carbapenems against Gram-
negative bacteria. The relative novelty of these agents was based on a better profile of activity against antibiotic-resistant Gram-
positive bacteria and are therefore included in Figure E2a. 
The burden of bacterial resistance in the EU is already substantial and is likely to increase. Based on current data, 
it is expected that particular problems will arise in the coming years due to resistance among Gram-negative 
bacteria.
At the same time, there are very few antibacterial agents with new mechanisms of action under development to 
meet the challenge of multidrug resistance. There is a particular lack of new agents to treat infections due to 
multidrug-resistant Gram-negative bacteria. 
This report has identified a gap between the burden of infections due to multidrug-resistant bacteria and the 
development of new antibacterial agents to tackle the problem. A European and global strategy to address the gap 
is urgently needed. Measures that spur drug development need to be put in place. 
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1 Introduction 
1.1 Multidrug resistant bacteria: an increasing concern
1.1.1 What is antibacterial resistance?  
Antibacterial agents inhibit the growth of bacteria and may rapidly kill them by disrupting one or more of their 
essential cellular functions. For example, depending on the type of antibacterial agent, the mechanism of activity 
may result in: 
• inhibition of the production of proteins or cell wall materials; 
• inhibition of DNA replication; 
• disruption of cell membrane activities that maintain chemical balance. 
Bacteria are usually grouped according to various attributes such as the structure of their outer coverings and 
their metabolic functions. The primary classification of bacteria is based on their staining properties, which, for 
almost all types of bacteria, divides them into Gram-positive or Gram-negative groups. Those called Gram-positive 
have a cell membrane plus a thick layer of cell wall material (peptidoglycan) lying outside the membrane. In 
contrast, Gram-negative bacteria have a cell membrane, a relatively thin layer of peptidoglycan and then an outer 
membrane. These major structural differences result in different patterns of susceptibility to antibacterial agents 
because the outer coverings of the bacteria affect access to the sites where they exert their activity. Therefore, 
each group of bacteria is usually susceptible to the actions of only a limited range of antibacterial agents and show 
inherent (i.e. normal) resistance to the actions of others.  
Moreover, bacteria have the ability to acquire resistance to one or more antibacterial agents to which they would 
normally be susceptible. Acquired resistance can arise by mutations that can occur during replication or by gaining 
genes encoding a mechanism of resistance from other bacteria [1]. The ease with which resistance can be 
acquired varies between bacterial types. Unfortunately, some of the types of bacteria that are normally not 
susceptible to many antibacterial agents are also easily able to acquire resistance to others. The result is multidrug 
resistance. In extreme cases, bacteria can show resistance to most or all of the agents that would commonly be 
used to treat them. 
In addition, each acquired mechanism of resistance may render the bacterium resistant to many or all antibacterial 
agents of the same type (class) and sometimes confers resistance to agents from many classes. This is called 
cross-resistance. The genes encoding some mechanisms of resistance are sometimes linked in such a way that 
they are transferred all together between organisms. This is often referred to as co-resistance. 
Each time an antibacterial agent is used to treat an infection, there is a risk that the agent will select, in the 
population of infecting bacteria, for bacteria that are resistant to it, thus causing unresolved infection in the 
patient who was treated. The agent will also select for resistant bacteria in the patient’s commensal flora, thus 
resulting in colonisation by resistant bacteria, which may subsequently be responsible for another infection at the 
same or another body site. In both cases, these resistant bacteria will have the possibility to spread to other 
patients, especially within hospitals. Thus, increasing rates of resistance to an antibacterial agent and to all other 
agents that are rendered inactive by common mechanisms of resistance is an inevitable consequence of its use. In 
the last 10–20 years, multidrug resistance has emerged in many frequently encountered pathogenic bacteria. In 
extreme cases, these bacteria are not susceptible to any licensed antibacterial agent or are susceptible only to 
those that are more toxic to the patient than the more commonly used drugs. 
1.1.2 What are the consequences of resistance and multidrug 
resistance? 
Multidrug-resistant bacteria represent a major threat to the success of almost all branches of medical practice. 
Some patients are especially vulnerable to acquiring multidrug-resistant bacterial infections as a consequence of 
treatments for underlying illnesses, such as organ transplant patients, haemodialysis patients and those with 
various types of cancer [2-7].  
Bacterial resistance potentially complicates the management of every infection, no matter how mild it may be at 
the time of first presentation. For example, bladder infections in young women should be very easy to treat with 
commonly used antibacterial agents but the appearance of multidrug resistance among organisms often 
associated with these infections means that physicians have to resort to other agents that may not be so well 
tolerated and may even have to be given intravenously when usually oral agents are efficient. 
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Physicians in the EU are increasingly faced with infections for which antibacterial treatment options are very 
limited. However, the overall burden of infections caused by multidrug-resistant bacteria is not well documented in 
the EU. There is a lack of data on the morbidity and mortality attributable to antibacterial resistance, including the 
economic impact on individuals as well as on healthcare systems and societies.  
Multidrug resistance among bacteria is a global problem and organisms are easily carried across international 
boundaries. All regions of the world [8] are already experiencing the effects of multidrug resistance on clinical 
practise. Therefore, stimulating the development of new antibiotics has far-reaching potential benefits. 
1.1.3 Antibacterial resistance and the response from the 
pharmaceutical industry 
The launch of every antibiotic has been and will be followed by resistance in the targeted bacteria. Therefore, 
there is a constant need to develop new agents to keep up with the acquisition of resistance among pathogenic 
bacteria.
For approximately four decades (from the 1940s up to the 1970s) the pharmaceutical industry provided a steady 
flow of new antibiotics, including several with new mechanisms of action that circumvented the problems caused 
by bacterial resistance to earlier agents. Since then, only three systemically-administered antibiotics (quinupristin-
dalfopristin, linezolid and daptomycin), including two from new classes (oxazolidinones and lipopeptides,) have 
been marketed in the EU to treat infections caused by multidrug-resistant Gram-positive bacteria. The other 
systemically-administered antibiotics that have reached the EU market during this period belong to existing classes 
of antibiotics and are not efficacious against the majority of organisms already resistant to other agents in the 
same class. 
Figure 1. Discovery of new classes of antibiotics.  














Source: [4, 9-10] 
* Penicillins were the first beta-lactams. Other frequently used agents of the beta-lactam class include cephalosporins and 
carbapenems, developed in the 1960s and 1980s, respectively. 
Meanwhile, multidrug resistance among Gram-negative bacteria has been increasing relentlessly. International and 
local surveillance networks such as the European Antimicrobial Resistance Surveillance System (EARSS)3, as well 
as numerous reports in the literature [11-13] provide evidence that the frequency of infections caused by 
multidrug-resistant Gram-negative bacteria is escalating in many countries. In some Gram-negative bacteria, 
acquired resistance to three or more classes of antibiotics that are commonly used to treat infections is often 
reported [14]. Therefore, there is particular concern regarding the paucity of new agents with activity against 
Gram-negative bacteria that have reached the market in the last decade. Those that have been marketed do not 
show efficacy against Gram-negative bacteria with resistance to most or all beta-lactam drugs. 
                                                                 
3 http://www.rivm.nl/earss/result/Monitoring_reports/
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1.2 Time to react 
The growing gap between the increasing frequency of infections caused by multidrug-resistant bacteria and the 
decline in research and development of new antibiotics is now threatening to take us back to the pre-antibiotic era. 
Strategies to curtail the spread of multidrug-resistant bacteria have met with limited success. While effective 
implementation of these strategies may reduce the rate of increase in infections caused by multidrug-resistant 
bacteria, a reversal of the existing problems cannot be expected. The continued development of effective 
antibiotics must be considered as a ‘common good’ [15-16]. An analysis of the antibacterial agents currently under 
development in view of current resistance patterns and trends is a starting point for discussing incentives for the 
development of urgently needed new treatments. 
1.3 The response from ECDC and EMEA 
One of the aims of the EMEA Road Map 2010 is to foster research and innovation in the pharmaceutical industry 
across the European Union. In this context, an ‘EMEA/CHMP think-tank group on innovative drug development’ 
was set up in 2006. The purpose was to offer stakeholders the possibility to present and discuss informally their 
views on evolving strategies in drug development. The report from the think-tank4 describes the technical and 
scientific highlights of all these consultations, incorporates reflections and draws recommendations from the think-
tank group. In this process, the paucity of new antibacterial agents, which has been the subject of several reports, 
including the Antibiotic Innovation Study5 from the international network Action on Antibiotic Resistance (ReAct) in 
2005, attracted considerable attention. During this EMEA/CHMP think-tank discussion with industry and academia, 
the idea of an analysis of the gap between the frequency of infections caused by multidrug-resistant bacteria in 
the EU and the development of new antibiotics was raised.
ECDC was established in 2005 with the mission to identify, assess and communicate current and emerging threats 
to human health posed by infectious diseases. In its first Annual Epidemiological Report, published in 20076, ECDC 
identified antimicrobial resistance as one of the most serious public health problems, globally and in Europe. 
Antimicrobial resistance, together with healthcare-associated infections, was consequently selected as one of the 
priority work areas in the ECDC Strategic Multi-annual Programme 2007–20137 with the objective of significantly 
contributing to the scientific knowledge base on antimicrobial resistance and its health consequences, its 
underlying determinants, the methods for its prevention and control, and the design characteristics that enhance 
effectiveness and efficiency of its prevention and control programmes. 
In 2007, ECDC, EMEA and ReAct entered into a discussion on the need to provide a comprehensive technical 
report to the European Commission on the pipeline of antibacterial medicinal products in development. In 
particular, to describe the frequency, trends and burden of disease associated with multidrug-resistant bacteria in 
the European Union and to assess the pipeline of new agents in development that might have clinically useful 
activity against them. Production of a joint report was included as a priority project for 2008 and 2009 in the 
ECDC’s programme on antimicrobial resistance and healthcare-associated infections and for EMEA. The 
assessment of the pipeline of antibacterial drug development was performed in co-operation with ReAct and was 
conducted under a memorandum of understanding between Duke University, EMEA and ReAct. 
An ECDC-EMEA joint working group was established in 2008 with a mandate to produce the joint report. The 
mandate, composition, meetings, roles and responsibilities of the joint working group are presented in Annex A 
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2 Trends and burden of infections due to 
multidrug-resistant bacteria in the EU 
Most relevant findings: 
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious 
infections in humans and reaches 25% or more in several EU Member States. 
• Resistance is increasing in the EU among certain Gram-negative bacteria such as recently observed for 
Escherichia coli.
• Each year, about 25 000 patients die in the EU from an infection with the selected multidrug-resistant 
bacteria.
• Infections due to these selected multidrug-resistant bacteria in the EU result in extra healthcare costs and 
productivity losses of at least EUR 1.5 billion each year. 
2.1 Introduction 
Antibiotic resistance is not by itself a disease entity. It encompasses many types of infections, bacteria and 
antibiotic resistance traits. Although the global nature of the problem is known, the lack of overview of the size 
and the consequences of multidrug-resistant bacteria means that this public health threat is not fully appreciated 
and often ignored by policymakers and the public.  
Data on antibiotic resistance in various bacteria are available from many countries [17], but summarising the 
situation for the whole European Union in a simple manner remains a challenge. Additionally, there are studies 
showing that infections due to antibiotic-resistant bacteria result in higher mortality and extra hospital costs 
[18,19]. However, there currently is no estimate of the burden imposed by multidrug-resistant bacteria on the EU. 
The purpose of this study was to give an overview of the trends of antibiotic resistance in bacteria frequently 
responsible for infections in humans, as well as estimating the human and economic burden associated with 
multidrug-resistant bacteria, in the EU, Iceland and Norway. 
2.2 Materials and methods 
2.2.1 Selection of bacteria  
The study focused on bacteria most frequently isolated from blood cultures in Europe [20]. For each bacterium, 
the resistance traits, which in most cases are markers of multiple resistance to antibiotics, were listed (Table 1). 
Although they are frequently isolated from blood cultures, coagulase-negative staphylococci, beta-haemolytic and 
viridans streptococci, Enterobacter spp. and Acinetobacter spp. were excluded from the study because reliable 
resistance data were not available. 
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Table 1. Bacteria frequently responsible for bloodstream infections and resistances used as markers 
for resistance to multiple antibiotics.  
Bacteriaa Resistance used as a marker of multiple resistance to antibiotics 
Gram-positive bacteria 
Staphylococcus aureus Methicillin resistance (MRSA) 
Vancomycin-intermediate resistance and resistance (VISA/VRSA) 
Enterococcus spp. (e.g., Enterococcus 
faecium)
Vancomycin resistance (VRE) 
Streptococcus pneumoniae Penicillin resistanceb
Gram-negative bacteria  
Enterobacteriaceae 
Escherichia coli Third-generation cephalosporin resistancec,d
Carbapenem resistancee
Klebsiella spp. Third-generation cephalosporin resistancec,d
Carbapenem resistancee
Non-fermentative Gram-negative bacteria
Pseudomonas aeruginosa Carbapenem resistancee
a Coagulase-negative staphylococci, beta-haemolytic and viridans streptococci, Enterobacter spp. and Acinetobacter spp. are 
among the list of the 10 bacteria most frequently isolated from blood cultures [20], but were excluded from the study because 
reliable resistance data are not available for these bacteria. 
b Most fully penicillin-resistant Streptococcus pneumoniae isolates are resistant to both penicillin and macrolides.  
c Resistance to cefotaxime or ceftriaxone or ceftazidime (as in the European Antimicrobial Resistance Surveillance System, 
EARSS).
d Mostly extended-spectrum beta-lactamase (ESBL)-producing isolates. 
e Resistance to imipenem or meropenem (as in EARSS). 
2.2.2 Data source 
The European Antimicrobial Resistance Surveillance System (EARSS) is the preferred source of data for multidrug-
resistant bacteria in Europe because it includes ongoing surveillance data on antibiotic resistance in bacteria 
responsible for invasive infections (mostly bloodstream infections) such as Staphylococcus aureus, Escherichia coli,
Enterococcus faecium, Streptococcus pneumoniae, Klebsiella pneumoniae and Pseudomonas aeruginosa causing 
invasive infections.  
EARSS is a network of national antimicrobial resistance surveillance systems in European countries coordinated by 
the Dutch National Institute of Public Health and the Environment (RIVM). EARSS collects comparable and 
validated antibacterial susceptibility data for public health action. In 2007, routine data for major indicator bacteria 
were submitted by more than 900 laboratories serving more than 1 400 hospitals in 31 countries [17].  
2.2.3 Assessment of the situation in 2007 and of trends of selected 
antibiotic-resistant bacteria 
Data on the proportion of isolates resistant to antibiotics among selected bacteria responsible for invasive 
infections (mainly bloodstream infections) in each EU Member State, Iceland and Norway and each year during the 
period 2002–2007 were extracted from the EARSS interactive database8. This proportion represents the 
percentage of bloodstream infection cases in which, based on in vitro laboratory data, the antibiotic (or antibiotic 
group) would be inactive to treat an infection due to this bacteria. 
                                                                 
8 http://www.rivm.nl/earss/database/
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Such data were available for methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate and -
resistant S. aureus (VISA/VRSA), vancomycin-resistant Enterococcus faecium, penicillin-resistant Streptococcus 
pneumoniae and third-generation cephalosporin-resistant Escherichia coli, carbapenem-resistant E. coli for the 
period 2002–2007, and for third-generation cephalosporin-resistant Klebsiella pneumoniae, carbapenem-resistant 
K. pneumoniae and carbapenem-resistant Pseudomonas aeruginosa for the period 2005–2007. 
Mid-year population data for each EU Member State, Iceland and Norway and each year during the period 2002–
2007 were obtained from Eurostat9.
To give an overview of the situation for each selected antibiotic-resistant bacteria, data were presented on maps, 
as well as plotted on graphs where each square represented one country. The trends in the proportion of resistant 
isolates in each country for the period 2005–2007 were assessed by the Chi-square test for trend (Epi Info™ 
Version 3.3.2, Statcalc). 
Additionally, for each year in the study period 2002–2007 and for each bacteria and antibiotic included in the 
survey, a population-weighted average proportion (percentage) of resistant isolates was calculated. These data 
were plotted on two graphs. When data were not available for a particular year, data for the closest available year 
were used. Data were not available for the whole study period for S. pneumoniae in Greece and for K.
pneumoniae and P. aeruginosa in Belgium and Slovakia. 
2.2.4 Assessment of the human burden of infections caused by the 
selected antibiotic-resistant bacteria in 2007 
For estimating the burden of antibiotic-resistant bacteria, data were only available on the following five antibiotic-
resistant bacteria: MRSA, vancomycin-resistant Enterococcus faecium, third-generation cephalosporin-resistant 
Escherichia coli and Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa.
Number of infections  
Data on the number of isolates resistant to antibiotics among bacteria responsible for invasive infections (mainly 
bloodstream infections) in each EU Member State, Iceland and Norway in 2007 were extracted from the EARSS 
interactive database10.
Data on the estimated population covered by EARSS for each type of bacteria were obtained directly from country 
representatives in the EARSS network. For each country, the number of invasive infections (mainly bloodstream 
infections) due to the selected antibiotic-resistant bacteria was estimated from this reported population coverage. 
Data for Belgium and Slovakia on K. pneumoniae and P. aeruginosa were not available. They were replaced by 
values based on the median incidence of invasive infections due to these bacteria multiplied – for Belgium with the 
percentage of resistance in 2005–2007 from national surveillance of nosocomial septicaemia11, and for Slovakia 
with the average percentage of resistance for the EU, Iceland and Norway.  
The number of infections due to the selected antibiotic-resistant bacteria (with the exception of vancomycin-
resistant E. faecium and penicillin-resistant S. pneumoniae) from the three other main body sites (respiratory tract, 
skin and soft tissue and urine), was estimated by applying correction factors corresponding to the relative 
distribution of infections from these body sites compared to bloodstream, as reported in published literature [21-
22].
For third-generation cephalosporin-resistant E. coli, the same relative distributions as for third-generation 
cephalosporin-resistant K. pneumoniae were used [22]. For vancomycin-resistant E. faecium, the three other main 
body sites considered were: abdomen (abdominal infections), skin and soft tissue (wounds) and urine [23]. For 
penicillin-resistant S. pneumoniae, the only other body site considered was respiratory tract [24]. Parameters used 
to estimate the number of infections are shown in Annex B1. 
The total number of infections due to the selected antibiotic-resistant bacteria was obtained by adding the number 
of invasive infections (mainly bloodstream) and of infections from the three other main body sites (respiratory 
tract, skin and soft tissue and urine). 
Number of extra deaths due to these infections
Attributable mortality corresponds to the percentage of deaths that are attributable to infection with an antibiotic-
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bacteria when all other possible causes of deaths have been controlled for. It was calculated with the formula: 
attributable mortality = ((relative risk -1)/relative risk)  crude mortality. For each selected antibiotic-resistant 
bacteria, data for calculating attributable mortality of bloodstream infections were obtained from published studies 
[19,22-23,25-26]. Such data were not available for penicillin-resistant S. pneumoniae. When only attributable 
mortality of bloodstream infections was available from published studies, attributable mortality was estimated by 
applying correction factors corresponding to the relative mortality of nosocomial infections from these body sites 
compared to nosocomial bloodstream infection [27]. Parameters used to estimate the number of extra deaths are 
shown in Annex B1. 
The number of extra deaths due to the selected antibiotic-resistant bacteria was estimated by applying 
attributable mortality to each of the estimates of the number of infections described above. 
Number of extra hospital days due to these infections 
Extra days spent in a hospital are a direct, short-term effect of infections due to antibiotic-resistant bacteria. For 
each selected antibiotic-resistant bacteria, the extra length of hospital stay for each infection was estimated as the 
difference between the average length of hospital stay in patients infected with an antibiotic-resistant isolate of a 
given bacteria to the average length of hospital stay in patients infected with an antibiotic-susceptible isolate of 
the same bacteria, as reported in published studies selected because they controlled for other factors affecting 
length of hospital stay such age, sex, comorbidities, severity of underlying diseases, antibiotic therapy and 
appropriateness of antibiotic therapy [18,23,25,28-29]. For carbapenem-resistant P. aeruginosa, the extra length 
of hospital stay for bloodstream infections was used for all infections [25]. Such data were not available for 
penicillin-resistant S. pneumoniae. Parameters used to estimate the number of extra hospital days are shown in 
Annex B1. 
The number of extra hospital days due to the selected antibiotic-resistant bacteria was estimated by applying the 
extra length of hospital stay to each of the estimates of the number of infections described above. 
2.2.5 Assessment of the economic burden of infections caused by the 
selected antibiotic-resistant bacteria in 2007 
Principles of cost calculations 
Cost-of illness analyses involve the identification, measurement and valuing of resources related to an illness.  
The principal features of this study were: 
• Time frame: Year (2007) 
• Perspective:  Societal 
• Methodology: Standard prevalence-based 
• Approach:  Bottom-up 
An annual time frame was considered whereby all costs within the most recent year for which data were available 
were measured. The reference year was 2007, the most recent year for which EARSS data were available. The 
most recently reported year was used for those few instances where 2007 data were not available.  
A societal perspective was adopted considering direct and indirect healthcare costs, as well as productivity losses 
from absence from work due to illness or premature death. 
A prevalence-based study was performed to estimate annual costs. In such studies, costs are measured during 
one period, usually a year, regardless of the date of onset of illness.  
A bottom-up approach was used because only aggregated data on the number of infections due to the selected 
antibiotic-resistant bacteria were available. This approach estimates costs by multiplying the number of cases of 
an illness by the unit cost of treatment of this illness.
Publications and websites from international organisations, national ministries, bodies and statistical institutes, as 
well as published literature, were consulted for epidemiological and healthcare utilisation data. If no data were 
found for a specific country, extrapolations were performed from data from similar countries based on gross 
domestic product, population and geographical location. 
Hospital inpatient care and outpatient care were included in cost calculations for healthcare services. Activities 
aiming at the prevention of patient-to-patient transmission of antibiotic-resistant bacteria such as the search-and-
destroy approach for MRSA that is actually being performed in some EU countries, e.g. the Netherlands, but is not 
routine in all EU Member States, were not included. 
Non-health service costs include productivity losses, informal care costs, patient travel costs and out-of-pocket 
expenses. Little data is available on informal care, patient travel and out-of-pocket expenses. As a consequence, 
only productivity losses from absence from work due to illness or premature death were estimated.
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Hospital inpatient care costs 
Total hospital inpatient care costs were estimated by multiplying the number of extra hospital days, as calculated 
above, by an average cost for a hospital day in the EU in 2007 of EUR 366. The average cost of a hospital day was 
obtained from the European Commission [30] and converted to 2007 prices using the health component of the 
harmonised index of consumer prices (HICP)12.
Outpatient care costs 
In this study, outpatient care corresponded to one consultation with a general practitioner after hospital discharge. 
An estimate of the cost of this consultation was obtained from published literature [31]. These data were not 
available for Bulgaria and Romania, Iceland and Norway, for which costs of similar countries were used. All costs 
were converted to 2007 prices using the health component of the harmonised index of consumer prices (HICP)13.
Productivity losses 
Productivity losses include the foregone earnings from absence from work due to illness or premature death. 
For each country, productivity losses due to absence from work were estimated by multiplying the number of days 
being absent from work due to infection with an antibiotic-resistant bacteria by the daily earnings and employment 
rates in 2007, assuming that the number of days being absent from work was equal to the number of extra 
hospital days due to the infection. A friction period, i.e. the period until another worker from the pool of 
unemployed has fully replaced the worker who is absent due to illness, was not taken into account because 
absence from work due to infection is generally not long enough for a worker to be replaced. 
Productivity losses from premature deaths from infection due to antibiotic-resistant bacteria correspond to the 
likely earnings that patients who died would otherwise have received from paid employment. For each country, 
they were estimated by calculating age-specific products of the following: 
• estimated number of extra deaths attributable to antibiotic-resistant bacteria in 2007;  
• population distribution in 2007, by age; 
• probability of dying, by age; 
• number of remaining work years at time of death, by age;  
• average annual gross earning in 2007; and  
• employment rate in 200714.
Because these productivity losses will be incurred in the future, earnings were discounted using a 3.5% annual 
rate to obtain present values [32]. Additionally, since the age distribution of patients with an infection due to 
antibiotic-resistant bacteria is different from that of the general population and skewed towards older age, a 
correction factor of 0.37 was applied, based on the percentage of individuals aged less than 65 years in the 
general population and among patients with a healthcare-associated infection as reported in a national prevalence 
survey15.
Total productivity losses were obtained by adding productivity losses for each selected type of antibiotic-resistant 
bacteria and for each country. 
2.3 Results 
2.3.1 Antibiotic resistance situation in 2007 and trends
The population-weighted, average proportions (percentages) of resistant isolates among the selected bacteria are 
presented in Figure 2. This is an attempt to summarise the general antibiotic resistance situation in the EU, 
Iceland and Norway. However, for each selected antibiotic-resistant bacteria, there were large variations between 
countries from less than 1% to more than 50% resistant isolates in many instances. These maps, as well as 
graphs presenting the distribution of country data, are presented in Figures 3 and 4. 
Methicillin-resistant Staphylococcus aureus (MRSA) 
Overall, the average proportion of MRSA in the EU, Iceland and Norway was high (22%), although it has been 
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Iceland, Norway and Sweden to more than 25% in 10 countries (Figure 3a). Between 2005 and 2007, the 
proportion of MRSA significantly decreased in eight EU Member States (Figure 3a). These decreasing trends are 
likely due to increased prevention and control at national level, as documented for France, Slovenia and United 
Kingdom [33-35].  
Vancomycin-intermediate and vancomycin-resistant S. aureus (VISA/VRSA) 
The proportion of S. aureus isolates that showed intermediate resistance to vancomycin (VISA) was very low in 
the EU, Iceland and Norway. Overall, it represented less than 0.1% of S. aureus bloodstream isolates reported to 
EARSS by these countries, corresponding to only four confirmed isolates, reported by France (n=1), Ireland (n=1) 
and the Netherlands (n=2). No vancomycin-resistant S. aureus isolates was reported to EARSS in 2007. 
Vancomycin-resistant Enterococcus faecium
The average proportion of Enterococcus faecium isolates that showed resistance to vancomycin was below 8% in 
the EU, Iceland and Norway (Figure 2a). There was a large intercountry variation, from less than 1% in 14 
countries to more than 25% in Ireland, Greece and Portugal, with very few significant variations over the period 
2005–2007 (Figure 3b). 
Penicillin-resistant Streptococcus pneumoniae
The average proportion of S. pneumoniae isolates in the EU, Iceland and Norway, that showed full resistance to 
penicillin was 4% in 2007 (Figure 2a). Intercountry variation showed a much narrower range than for other 
bacteria, with most countries reporting a proportion below 10% (Figure 3c). Only a few countries showed an 
increasing or decreasing trend over the period 2005–2007 (Figure 3c).
Third-generation cephalosporin-resistant Escherichia coli
The average proportion of third-generation cephalosporin-resistant isolates among Escherichia coli – the most 
common Gram-negative bacterium responsible for infections in humans – is rising steadily in the EU, Iceland and 
Norway and reached 8% in 2007 (Figure 2b). Indeed, 13 countries showed a significant increase in this proportion 
during the period 2005–2007 (Figure 4a). There was a large intercountry variation in the proportion reported in 
2007, from 1–5% in 12 countries to more than 25% in Romania (Figure 4a).
Third-generation cephalosporin-resistant Klebsiella pneumoniae
The average proportion of third-generation cephalosporin-resistant isolates among K. pneumoniae in the EU, 
Iceland and Norway remained high (19%) in 2007 (Figure 2b). There was a large intercountry variation, from less 
than 5% in Estonia, Finland, Iceland, Norway and Sweden to more than 25% in 11 countries, but only a few 
countries showed increasing or decreasing trends over the period 2005–2007 (Figure 4b).
Carbapenem-resistant K. pneumoniae
Carbapenem resistance was still absent from K. pneumoniae isolates from blood cultures in most EU Member 
States in 2007 and only six countries reported such isolates. Five of these countries reported only a few isolates: 
Cyprus (n=1; 3%), France (n=1; <1%), Germany (n=3; 2%), Italy (n=4; 1%) and United Kingdom (n=1; <1%). 
Greece was a notable exception with 410 reported carbapenem-resistant K. pneumoniae isolates, which 
corresponded to 42% of reported K. pneumoniae isolates. The situation in Greece has been attributed to the 
spread of a hyperepidemic, carbapenemase-producing clone, as well as the spread of the blaVIM-1 resistance gene 
cassette and ecological pressure due to antibiotic use [13,36]. 
Carbapenem-resistant Pseudomonas aeruginosa
The average proportion of carbapenem-resistant isolates among P. aeruginosa in the EU, Iceland and Norway 
remained high (18%) in 2007 (Figure 2b). There was a large intercountry variation, from less than 5% in Denmark, 
Iceland and the Netherlands to more than 25% in the Czech Republic, Greece, Italy and Lithuania, but only a few 
countries showed increasing or decreasing trends over the period 2005–2007 (Figure 4c). 
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Figure 2. Population-weighted, average proportion of resistant isolates among blood isolates of 
bacteria frequently responsible for bloodstream infections, EU Member States, Iceland and Norway, 
2002–2007. 




















































































































Third-gen. cephalosporin-resistant E. coli
Third-gen. ceph.-resistant K. pneumoniae** 
Carbapenem-resistant P. aeruginosa**
* S. pneumoniae: excluding Greece, which did not report data on this bacterium to EARSS. 
** K. pneumoniae and P. aeruginosa: excluding Belgium and Slovakia, which did not report data on these bacteria to EARSS. 
Figure 3. Proportion of resistant isolates among blood isolates of Gram-positive bacteria frequently 
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b. Vancomycin-resistant Enterococcus faecium
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Figure 4. Proportion of resistant isolates among blood isolates of Gram-negative bacteria frequently 
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2.3.2 Human burden of antibiotic resistance 
The estimated human burden of infections due to the selected antibiotic-resistant bacteria is presented in Table 2.  
The study confirmed that MRSA was, in 2007, the most common, single, multidrug-resistant bacterium in the EU 
as per the estimated number of cases of infection due to this bacterium. However, the sum of cases of antibiotic-
resistant Gram-positive bacteria (mostly MRSA and vancomycin-resistant Enterococcus faecium) was comparable 
to that of antibiotic-resistant Gram-negative bacteria (third-generation cephalosporin-resistant E. coli and K.
pneumoniae, and carbapenem-resistant P. aeruginosa).
Overall, it was estimated that in 2007 approximately 25 000 patients died from an infection due to any of the 
selected frequent antibiotic-resistant bacteria in the EU, Iceland and Norway. Notably, about two thirds of these 
deaths were caused by infections due to Gram-negative bacteria. In addition, infections due to any of the selected 
antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days.  
2.3.3 Economic burden of antibiotic resistance 
The estimated economic burden of infections due to the selected antibiotic-resistant bacteria is presented in Table 
3.
Based on the number of extra hospital days, extra in-hospital costs in 2007 were estimated at more than EUR 900 
million in the EU, Iceland and Norway.  
Based on 2007 data, outpatient care costs were estimated at about EUR 10 million and productivity losses due to 
absence from work of infected patients were estimated at more than EUR 150 million, each year. Productivity 
losses due to patients who died from their infection were estimated at about EUR 450 million each year. Overall, 
societal costs of infections due to the selected antibiotic-resistant bacteria were estimated at about EUR 1.5 billion 
each year. 
There are many reasons to suggest that these figures correspond to an underestimate of the human and 
economic burden of infections due to the selected antibiotic-resistant bacteria. These reasons are developed in the 
discussion section of this chapter. 
The bacterial challenge: time to react TECHNICAL REPORT
14
Table 2. Estimated yearly human burden of infections due to the selected antibiotic-resistant 
bacteria and percentage of this burden due to bloodstream infections, EU Member States, Iceland 
and Norway, 2007. 
Antibiotic-resistant bacteriaa















Antibiotic-resistant Gram-positive bacteria 
Methicillin-resistant Staphylococcus aureus (MRSA) 171 200 (12%) 5 400 (37%) 1 050 000 (16%) 
Vancomycin-resistant Enterococcus faecium 18 100   (9%) 1 500 (28%) 111 000 (22%) 
Penicillin-resistant Streptococcus pneumoniaec 3 500 (27%)  –f –
Sub-total 192 800 (12%) 6 900 (35%) 1 161 000 (16%) 
Antibiotic-resistant Gram-negative bacteria 
Third-generation cephalosporin-resistant Escherichia colid 32 500 (27%) 5 100 (52%) 358 000 (27%) 
Third-generation cephalosporin-resistant Klebsiella 
pneumoniae 18 900 (27%)   2 900 (52%) 208 000 (27%) 
Carbapenem-resistant Pseudomonas aeruginosae 141 900   (3%) 10 200 (7%) 809 000   (3%) 
Sub-total 193 300   (9%) 18 200 (27%) 1 375 000 (13%) 
Total 386 100 (11%) 25 100 (29%) 2 536 000 (14%) 
aData on antimicrobial resistance for Klebsiella sp. other than K. pneumoniae, Enterobacter spp. and Acinetobacter spp. were not 
available from EARSS. Although coagulase-negative staphylococci as well as beta-haemolytic and viridans streptococci are 
among the 10 most common bacteria isolated from blood cultures [20], they were excluded from the study because reliable 
resistance data are not available for these bacteria. 
bBloodstream infections, lower respiratory tract infections, skin and soft tissue infections and urinary tract infections. 
cMost fully penicillin-resistant Streptococcus pneumoniae isolates are resistant to both penicillin and macrolides. 
dResistant to cefotaxime or ceftriaxone or ceftazidime. 
eResistant to imipenem or meropenem. 
f -, could not be calculated 
Table 3. Estimated yearly economic burden of infections (four main typesa) due to the selected 






costs (EUR ) 
Extra
outpatient 
costsc (EUR ) 
Productivity 
losses due to 
absence from 
work (EUR ) 
Productivity 
losses due to 
patients who 
died from their 










503 100 000 4 500 000 59 300 000 300 300 000 867 200 000 
Total 927 800 000 10 000 000 150 400 000 445 900 000 1 534 100 000 
aBloodstream infections, lower respiratory tract infections, skin and soft tissue infections and urinary tract infections. 
bGram-positive bacteria: methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium. Data 
for penicillin-resistant Streptococcus pneumoniae were not available. Gram-negative bacteria: third-generation cephalosporin-
resistant Escherichia coli and Klebsiella pneumoniae (i.e., resistant to cefotaxime or ceftriaxone or ceftazidime) and carbapenem-
resistant Pseudomonas aeruginosa (i.e., resistant to imipenem or meropenem). 
Data on antimicrobial resistance for Klebsiella sp. other than K. pneumoniae, Enterobacter spp. and Acinetobacter spp. were not 
available from EARSS. Although coagulase-negative staphylococci as well as beta-haemolytic and viridans streptococci are 
among the 10 most common bacteria isolated from blood cultures [20], they were excluded from the study because reliable 
resistance data are not available for these bacteria. 
cVisit to general practitioner. 
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2.4 Discussion 
This is the first study that provides an overview of overall trends in antibiotic resistance, as well as estimates of 
the human and economic burden of infections due to antibiotic-resistant bacteria in the EU, Iceland and Norway. 
For the study, certain antibiotic-resistant bacteria were selected because they represent markers for resistance to 
multiple antibiotics. Multidrug-resistant bacteria represent a challenge for therapy since the number of antibiotics 
that remain active and can be used for treatment is limited. 
The study showed that the average proportion of MRSA among S. aureus from bloodstream infections, although 
on average high, has levelled out and even decreased in several countries; a phenomenon that has already been 
reported by EARSS [17]. Since, in EARSS, the proportion of MRSA is correlated with the incidence of MRSA 
bloodstream infections [17], this suggests that the incidence of MRSA bloodstream infections is currently 
decreasing in these countries. Despite this trend, the study also indicated that MRSA was the most common single 
multidrug-resistant bacterium in the EU, Iceland and Norway. Other common antibiotic-resistant Gram-positive 
bacteria contributed to a much smaller fraction of the burden of antibiotic-resistant bacteria, although there were 
variations between countries. 
The study also showed that the average proportion of antibiotic-resistant Gram-negative bacteria was high or 
increasing in the case of third-generation cephalosporin-resistant E. coli. These findings corroborate those of 
independent analyses from EARSS and other reports in the literature showing that infections caused by multidrug-
resistant Gram-negative bacteria are becoming increasingly frequent in Europe [11-13,17,37]. Considering this 
current trend, it is likely that the human and economic burden caused by antibiotic-resistant Gram-negative 
bacteria will outweigh that of antibiotic-resistant Gram-positive bacteria such as MRSA and will represent a major 
challenge to appropriate therapy, prevention and control in the foreseeable future. 
The number of deaths attributable to infections due to the selected antibiotic-resistant bacteria in the EU, Iceland 
and Norway was estimated at approximately 25 000 each year; two-thirds being due to Gram-negative bacteria. 
As a comparison, each year in the EU, about 48 000 persons are killed in a road accident16, about 37 000 patients 
die as a direct consequence of a hospital-acquired infection and an additional 111 000 die as an indirect 
consequence of the hospital-acquired infection [38].  
For the United States, the Centers for Disease Control and Prevention made similar estimates of about 99 000 
deaths associated with a healthcare-associated infection [39] and 12 000 deaths associated with either MRSA, VRE 
or Clostridium difficile each year [40]. Although they are within the same range, data from the EU and the United 
States are not immediately comparable since different bacteria were included (e.g. Clostridium difficile was not 
included in the EU study) and US data include cases where antibiotic-resistant bacteria directly and indirectly 
contributed to patient death whereas this EU study only considered directly attributable deaths.
This study has several limitations. Although EARSS provides the most comprehensive database on antibiotic 
resistance in Europe, the system itself has some limitations. EARSS does not centrally test bacterial isolates. 
Efforts are made by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and EU Member 
States to standardise antimicrobial susceptibility testing in Europe. EARSS organises regular external quality 
assessment exercises to foster improvement of antimicrobial susceptibility testing in laboratories that participate in 
EARSS. Nevertheless, EARSS relies on data as reported by Member States according to the EARSS protocol. For 
some Member States, population coverage is low and EARSS data are not yet geographically representative of the 
country. Updated data on the estimated population covered by EARSS for each type of bacteria were obtained 
directly from country representatives in the EARSS network. These data, however, often represent a broad 
estimate (‘best estimate’) of population coverage by the EARSS network in each country. Data were missing for 
only a few countries in the EARSS database. For this study, missing data were replaced by data from the closest 
available year or by an estimate based on an EU median or average. The number of antibiotic-resistant bacteria 
included in this study was limited to those bacteria included in EARSS. In particular, EARSS does not perform 
surveillance of extensively drug-resistant or pandrug-resistant bacteria, i.e. bacteria that are almost totally or 
totally resistant to antibiotics, which are currently emerging in the EU [14]. Finally, many parameters used in the 
study were extracted from published literature and may not exactly reflect the value of these parameters in each 
EU Member State, Iceland and Norway in 2007. 
The costs of infections due to the selected antibiotic-resistant bacteria for the EU, Iceland and Norway were 
estimated at about EUR 1.5 billion each year, with more than EUR 900 million corresponding to hospital costs. 
Because these costs are based on many assumptions, a nomogram is provided in Annex B1, which allows to 
calculate yearly in-hospital costs using other values for the total number of infections, the average extra length of 
16 http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home
The bacterial challenge: time to react TECHNICAL REPORT
16
hospital stay per infection and the average cost per hospital day, thus providing a means of testing the sensitivity 
of the estimates in this study. 
In the US, the US Office of Technology Assessment estimated the hospital costs for five major groups of hospital-
acquired infections due to antibiotic-resistant bacteria at USD 1.3 billion (in 1992 dollars) [41]. More recently, 
Spellberg et al. [42] estimated the societal costs of infections due to one single type of antibiotic-resistant bacteria, 
i.e. multidrug-resistant P. aeruginosa, at USD 2.7 billion each year in the US. However, cost comparisons with the 
US should be made with caution since healthcare is more costly in the US than in the EU [43]. 
Despite the limitations described earlier, there are many reasons to believe that the human and economic burden 
of antimicrobial resistance for the EU from this study corresponds to an underestimate. Firstly, population 
coverage data obtained directly from country representatives in the EARSS network may be overestimated 
because, in many countries, catchment populations of participating hospitals frequently overlap, which leads to 
underestimating the total number of infections from these population coverage data. Secondly, data on infections 
in outpatients are not reported to EARSS and could not be included. This, in particular, includes bacteria such as 
Neisseria gonorrhoeae, for which resistance to first-line agents is increasing in Europe. Thirdly, although the study 
focused on selected antibiotic-resistant bacteria, there are several other antibiotic-resistant bacteria, e.g. 
multidrug-resistant Enterobacter spp., Acinetobacter spp. and coagulase-negative staphylococci that are often 
responsible for healthcare-associated infection and for which data were not available from EARSS. Fourthly, the 
study only considered the four main body sites of infection (bloodstream, lower respiratory tract, skin and soft 
tissue and urinary tract), thus slightly underestimating the number of infections for each of the selected antibiotic-
resistant bacteria.
In addition, there are several reasons, other than the above stated underestimation of the number of infections, to 
believe that the results of the economic burden analysis correspond to an underestimate. Many patients with an 
infection due to antibiotic-resistant bacteria require intensive care and incur substantially higher hospital costs, 
since the cost of a day in an intensive care unit is more than twice that of the average cost for a hospital day 
considered in this study [44]. Infections due to antibiotic-resistant bacteria generally require antibiotics that are 
more costly than for infections with susceptible bacteria, and these antibiotic costs were not considered. Moreover, 
in the absence of rapid point-of-care diagnostic tests for multidrug-resistant bacteria, these costly antibiotics are 
also used empirically to treat many patients with a suspected infection with a multidrug-resistant type of bacteria. 
These costs were not included. Indirect costs after discharge from the hospital – such as informal care, patient 
travel and out-of-pocket expenses – were not considered. The costs related to possible disabilities following the 
infection were also not considered. Finally, the costs of infection control and prevention strategies, such as the 
search-and-destroy approach for MRSA, were not considered.  
In conclusion, and despite its limitations, this study showed that overall, antibiotic resistance in the EU, Iceland 
and Norway is high, sometimes increasing, and its human and economic consequences are serious. Considering 
current trends, it is likely that the burden of antibiotic-resistant bacteria will soon shift towards an increasing 
prevalence of antibiotic-resistant Gram-negative bacteria such as third-generation cephalosporin-resistant 
Enterobacteriaceae and carbapenem-resistant non-fermentative Gram-negative bacteria.  
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3 Analysis of the research and development 
pipeline of antibacterial agents 
Most relevant findings 
• Fifteen systemically administered antibacterial agents with a new mechanism of action or directed against a 
new bacterial target were identified as being under development with a potential to meet the challenge of 
multidrug resistance. Most of these were in early phases of development and were primarily developed 
against bacteria for which treatment options are already available. 
• There is a particular lack of new agents with new targets or mechanisms of action against multidrug-
resistant Gram-negative bacteria. Two such agents with new or possibly new targets and documented 
activity were identified, both in early phases of development.
3.1 Introduction 
Recent reports suggest that drug development will not adequately address the problems posed by the increasing 
frequency of antibiotic resistance among common bacterial pathogens [4,45-46]. In contrast, there are other 
reports that paint a more optimistic picture of the future availability of new antibacterial agents [47-48]. 
Hence, the aim of this study was to document and characterise the activity of those antibacterial agents that had 
entered clinical development as accurately and as comprehensively as possible based on information in the public 
domain. The focus was on antibacterial agents with potential to be clinically active against at least one of the 
selected panel of antibiotic-resistant bacteria of public health interest. Special emphasis was placed on agents 
being developed for systemic administration that also appeared to have a new bacterial target and/or a new 
mechanism of action.  
3.2 Methods 
3.2.1 Selection of bacteria  
In accordance with the trends and burden analysis (see Chapter 2), the same panel of antibiotic-resistant bacteria 
was selected for the pipeline analysis: 
• Methicillin-resistant Staphylococcus aureus (MRSA) 
• Vancomycin-intermediate and vancomycin-resistant S. aureus (VISA/VRSA)  
• Vancomycin-resistant Enterococcus spp. (VRE)  
• Penicillin-resistant Streptococcus pneumoniae (PRSP) 
• Third-generation cephalosporin-resistant Enterobacteriaceae (ENB)
• Carbapenem-resistant Enterobacteriaceae
• Carbapenem-resistant non-fermentative Gram-negative bacteria
3.2.2 Pipeline database search 
In a joint undertaking between EMEA (London, United Kingdom) and the Strategic Policy Unit of ReAct at Duke 
University (Durham, North Carolina, United States), a pipeline search was carried out on 14 March 2008. 
Selection of databases 
Three commercial databases were identified for the analysis of the R&D pipeline: Pharmaprojects (T&F Informa 
UK Limited, London, UK), Adis Insight R&D (Wolters Kluwer Health, Amsterdam, NL) and BioPharm Insight 
(Infinata, Norwood, MA-USA). A pilot sensitivity analysis was performed, following a two-step approach, which 
compared Pharmaprojects with Adis Insight R&D and Pharmaprojects with BioPharm Insight. The first step 
consisted of a search for antibacterial agents that had reached phase II of clinical development for any given 
indication. The second step consisted in evaluating the results obtained in a search for antibacterial compounds in 
phases I-III of development. The combination of Pharmaprojects with Adis Insight R&D was chosen based on the 
higher yield provided by this search (see results). The criteria of inclusion into these databases are described in 
Annex B2. 
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Search strategy
The database searches followed the Anatomical Therapeutic Chemical (ATC) classification systems of either 
Pharmaprojects or EphMRA (European Pharmaceutical Market Research Association) for Adis Insight R&D. Both 
databases were searched for antibacterial agents that had reached phase I, II or III clinical trials. Due to 
differences in the classification of the databases consulted, the search for antibacterial agents in Adis Insight R&D 
database had to be extended to include topical antibacterial agents. 
The search also included agents for which an application to at least one regulatory agency had already been made. 
Agents with a status of ‘no development reported’ or ‘discontinued’ according to the database definitions were 
excluded. Agents that had reached clinical trials but were reported as suspended (i.e. put on hold rather than 
definitely discontinued) were considered to be still under active development, in accordance with the definition by 
Pharmaprojects (Janet Beal, personal communication) and were therefore included in the search. Details on the 
relevant definitions used by each of the pipeline database companies can be found in Annex B2. 
Pooled dataset 
The results produced by the database searches were matched by compound name, synonyms and originator in 
order to avoid duplicate entries and to highlight any inconsistencies (e.g. misclassifications) in the dataset. If 
differences on the development phase of the agent were found between the databases, the most advanced phase 
reported was included in the analysis. Where compounds were marked as ‘discontinued’ or ‘no development 
reported’ in one of the databases, but not in the other, these were considered as still being under active 
development. Agents reported as ‘suspended’ in one database but under a clinical phase of development on the 
other were included in the pooled dataset as being under clinical development. 
Sensitivity analysis  
To check the completeness of the data, PubMed was searched for literature relevant to the topic, published from 
January 2006 through January 2009, using the following Boolean combinations of Medical Subject Headings 
(MeSH) terms, as well as the search terms previously described by Talbot et al. [7]: (((("Anti-Bacterial 
Agents/therapeutic use"[Mesh] AND "Bacteria/drug effects"[Mesh]) AND "Bacterial Infections/drug 
therapy"[Mesh]) AND "Drug Resistance, Bacterial"[Mesh]) OR ("Anti-Bacterial Agents"[Mesh] AND "Drugs, 
Investigational"[Mesh])) AND "Humans"[Mesh] AND anti-bacterial agents[Substance Name] OR "antimicrobial drug 
development" OR "investigational antimicrobials" OR "novel antimicrobials". Only PubMed-designated reviews 
published in English were examined. Agents identified through this search were then checked for fulfilment of the 
inclusion criteria in the Adis Insight R&D database. 
3.2.3 Assessment strategy 
Scope and inclusion criteria 
The agents identified by the searches were divided into two categories: new active substances or new 
presentations of licensed antibacterial agents, as defined below: 
New active substances – All unlicensed (anywhere in the world, to the knowledge of the working group of this 
report) antibacterial chemical and biological agents with a direct antibacterial effect on at least one of the selected 
bacteria were considered for further analysis. Agents which had a mechanism of action involving only 
immunomodulation, vaccines and monoclonal antibodies were excluded. 
New presentations of licensed antibacterial agents – Unlicensed presentations of approved active agents were 
considered for further analysis if there were data to suggest that the new presentation might be active against at 
least one of the selected bacteria.
Agents in both of the above categories were excluded from the analysis if they were being developed only to treat 
bacteria not included in the target list (e.g. those that were apparently under development only to treat 
tuberculosis, Helicobacter pylori, Chlamydia trachomatis or non-bacterial pathogens such as Plasmodium spp.).
Outcome parameters – best case scenario 
The two outcome parameters considered for the assessment were the spectrum of in vitro activity and novelty of 
the agent using the approaches and definitions given below. Any information available in the databases or found 
in the public domain was taken into account. 
In vitro activity of each agent against the selected bacteria was assigned based on the following approaches: 
• Actual data on in vitro activity were reviewed whenever available. If actual data on in vitro activity were not 
reported for an agent against any of the selected pathogens then assumptions were made regarding likely 
activity based on the properties of the antibiotic class or of the mechanism of action involved. 
• The assessment of in vitro activity disregarded any known potential for cross-resistance and co-resistance. 
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• While in vitro activity alone cannot predict in vivo efficacy, it was decided not to take into account any 
available pharmacokinetic data or PK/PD analyses when scoring the antibacterial activity of agents since 
the amount of data available was very variable.  
• However, if there was already information available on non-clinical or clinical efficacy, these data were 
factored into the assessment. 
• In the case of new agents intended for topical or inhalational administration and new presentations and/or 
routes of administration of licensed antibacterial agents, the assessment took into account the possibility 
that very high local concentrations of drug might occur. In the case of licensed agents, the antibacterial 
spectrum was sometimes considered to be possibly extended beyond that associated with systemic 
administration of the licensed product. 
The assignment of in vitro activity, which took into account available data together with assumptions based on 
class properties or mechanisms of action as well as the route of administration, took the most optimistic view of 
what the new agent might be able to achieve and represents a ‘best case scenario’. 
Novelty was rated according to the following:  
a) Substance that acts on the same target as that of at least one previously licensed antibacterial agent; 
b) Substance with a known mechanism of action that likely acts on a new target. Agents displaying a broader 
range of activity than earlier agents from the same class, implying different target range, were also 
included here, e.g. beta-lactam agents with activity against MRSA were assumed to be able to bind to PBP 
2’ (PBP 2a). In some cases it was acknowledged that activity reported against organisms resistant to earlier 
agents from the same class might not actually represent a different target range but could be due only to 
evasion of resistance mechanisms by the new agent. However, in the absence of information to allow for 
differentiation, these agents have been counted in this category. In addition, beta-lactamases that 
appeared to inhibit enzymes not inhibited by licensed inhibitors were also included in this category; 
c) Substance with a new mechanism of action known or very likely. 
Assessment procedure 
Anti-infective compounds identified by the searches were divided into five batches and each batch was allocated 
to a team of two reviewers, including one from the working group and one external reviewer selected for their 
experience in the field. Reviewers were unaware of the identity of their team counterparts. Each reviewer 
independently assessed their allotted list of agents and assigned to each an antibacterial spectrum of activity and 
a level of novelty using the approaches and definitions detailed above. All assessments were discussed in the 
ECDC/EMEA Joint Working Group in order to resolve any discrepancies between reviewers’ opinions. 
3.3 Results 
3.3.1 Selection of databases based on pilot sensitivity studies 
In the first step of the sensitivity analysis (i.e. based upon antibacterial agents that had reached at least phase II 
of clinical development), combining the results from the Pharmaprojects and Adis Insight R&D databases resulted 
in an increase in the number of identified agents by 10%. In the second step of the sensitivity analysis, the 
addition of information from the BioPharm Insight database into the Pharmaprojects database provided no 
additional information. 
3.3.2 Pooled dataset 
The results from the searches for antibacterial agents, including topical agents, in phases I, II, III and pre-
registration were pooled and matched as described above. In total 167 agents were identified through the 
searches and were examined by the reviewers.  
3.3.3 Sensitivity analysis 
The search for information on antibacterial agents in development yielded 320 PubMed-designated review articles 
of which 29 were considered relevant and were subsequently analysed. The only extra agent that potentially 
fulfilled the study inclusion criteria was the novel efflux-pump inhibitor MP-601,205 [49]. However, this agent does 
not possess any direct antibacterial activity by itself and at the time of the data search, no clinical study involving 
co-administration of this efflux pump inhibitor with an antibacterial agent had commenced. Therefore it was 
excluded from the analysis.
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3.3.4 Overall findings 
After completion of the assessment by the reviewers, 90 out of 167 agents in the pooled dataset were considered 
to fulfil the inclusion criteria for the analysis. Of these 90 agents, 24 were new presentations of licensed 
antibacterial agents and 66 were new active substances (see also flow chart Annex B2). 
3.3.5 New presentations of licensed antibacterial agents 
Of the 24 new presentations of licensed antibacterial agents, 11 were assigned in vitro activity that went beyond 
the known spectrum of activity of the licensed presentation based on optimistic assumptions of what might be 
achieved by using a different route of administration. These 11 agents comprised topical or inhalational 
presentations of ciprofloxacin, tobramycin or amikacin, mainly being developed for P. aeruginosa infection. They 
were assessed as possibly having activity against PRSP based on the higher concentrations that could be achieved 
in the eye or in the respiratory tract. A list of those 11 agents is provided in Annex B2 (List A). 
3.3.6 New active substances 
Of the 66 new active substances, 30 (45%) were in phase I of development, 16 (24%) in phase II, nine (14%) in 
phase III, eight (12%) had been filed with a regulatory agency and three (5%) were reported to have been 
suspended from further development. Twenty-seven (41%) of these 66 compounds were assessed as having 
either a new target or a new mechanism of action, thus displaying some degree of novelty (Figure 5). A list of 
those 39 agents that were assessed as acting on the same target via the same mechanism of action as that of at 
least one previously licensed antibacterial agent is provided in Annex B2 (List B).
Figure 5. Novelty of new antibacterial agents which, in a best-case scenario (in vitro activity based 
on actual data and assumed in vitro activity based on known class properties or mechanisms of 




Same target as other licensed agents
New target likely
New mechanism of action likely
An analysis by route of administration (Figure 6) showed that, at the time of the search, 50 of these 66 agents 
were formulated for systemic administration (34 for oral and 33 for parenteral administration).
Figure 6. Route of administrationa of new antibacterial agents which, in a best-case scenario (in
vitro activity based on actual data and assumed in vitro activity based on known class properties or 
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a Some agents have several possible routes of administration. 
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A list of agents with new mechanism of action or new target and topical administration can be found in Annex B2 
(List C). Agents that have a new mechanism of action or a new target and that can be systemically administered 
are shown in Figure 7. It should be noted that the 15 agents in this figure result from adopting the best-case 
scenario approach described above, i.e. taking into account the agents with actual data available and also those 
with the likelihood of activity based on known class properties or mechanisms of action. 
Figure 7. New systemic antibacterial agents with new target or new mechanism of action and in
vitro activity against selected bacteria based on actual data () or assumed activity based on known 
class properties or mechanisms of action (), by phase of development (n=15, as of 14 March 2008). 




Gram-positive bacteria Gram-negative bacteria Phase of 
developmentMRSA VISA/VRSA PRSP VRE 3
rd Gen Cep. 
R ENB Carb. R ENB
Carb. R NF 
GNB
WAP 8294A2  I
PZ-601*      I
ME 1036*     I
NXL 101     I
Friulimicin B     I
Oritavancin     Filed
Telavancin     Filed
Ceftobiprole medocaril
†    Filed
Ceftaroline fosamil
†    III
Tomopenem
‡       II
hLF1-11      II
Lactoferrin      I
Talactoferrin-alfa      II
Opebacan    III
NXL 104/ceftazidime§    I
 12 9 8 5 3 2 2
 1 3 1 1 4 4 4
Total 13 12 9 6 7 6 6
Abbreviations:  
– 3rd Gen Cep. R ENB: Third-generation cephalosporin-resistant Enterobacteriaceae
– Carb. R ENB: Carbapenem-resistant Enterobacteriaceae
– Carb. R NF GNB: Carbapenem-resistant non-fermentative Gram-negative bacilli 
* Are no more active than earlier carbapenems against Gram-negative bacteria. The relative novelty of these agents was based 
on a better profile of activity against antibiotic-resistant Gram-positive bacteria. 
† Reported MRSA activity suggests a different binding profile to PBPs than currently licensed cephalosporins. 
‡ Reported activity against bacteria resistant to earlier carbapenems might not actually represent a different target range but
could be due only to evasion of resistance mechanisms by the new agent. 
§ Ceftazidime is a licensed cephalosporin. Only the beta-lactamase inhibitor NXL104 displays additional enzyme inhibition 
resulting in a broader range of activity than earlier agents. 
Note: Phase of development refers to the highest phase of development, regardless of indication. 
Table 4 describes the individual characteristics of the antibacterial agents presented in Figure 7. 
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Table 4. New systemic antibacterial agents with new target or new mechanism of action and in vitro 
activity based on actual data or assumed based on known class properties or mechanisms of action 
against the selected bacteria (n=15, as of 14 March 2008). 
Name of agent Mechanism of action (MoA) Degree of novelty Route of administration* 
WAP 8294A2 Membrane integrity antagonist New MoA IV, Top 
PZ-601 Cell wall synthesis inhibitor New target IV 
ME 1036 Cell wall synthesis inhibitor  New target IV 
NXL 101 DNA gyrase inhibitors / 
DNA topoisomerase inhibitor 
New MoA IV, PO 
Friulimicin B Cell wall synthesis inhibitor New MoA IV 
Oritavancin Cell wall synthesis inhibitor 
Membrane integrity antagonist 
New target IV, PO 
Telavancin Cell wall synthesis inhibitor 
Membrane integrity antagonist 
New target IV
Ceftobiprole medocaril Cell wall synthesis inhibitor New target IV 
Ceftaroline fosamil Cell wall synthesis inhibitor New target IV 
Tomopenem Cell wall synthesis inhibitor New target IV 
hLF1-11 Chelating agent / immunomodulation New MoA IV, PO 
Lactoferrin Chelating agent / immunomodulation New MoA IV, PO 
Talactoferrin-alfa† Chelating agent / immunomodulation New MoA PO, Top 
Opebacan† Membrane permeability 
enhancer/immunomodulation 
New MoA IV
NXL104/ ceftazidime Beta-lactamase inhibitor + cell-wall synthesis 
inhibitor 
New target IV
* Information on routes of administration is uncertain in early drug development.  
† Agents with only assumed in vitro activity. 
3.4 Discussion 
This study is believed to be the first systematic review of available commercial databases that compile publicly-
available information on antibacterial agents in clinical development. 
The focus of the study was to give a detailed description of agents with some degree of novelty. These agents 
may have the potential to become useful in the treatment of infections due to the selected multidrug-resistant 
bacteria. They may also have the potential to become useful in the treatment of other bacteria of public health 
importance that were not included in this study such as Neisseria gonorrhoeae or fluoroquinolone-resistant Gram-
negative bacteria. 
A decision was made to take an optimistic approach to the identification of agents potentially active against the 
selected panel of antibiotic-resistant bacteria. For example, the pooled dataset was built taking into consideration 
the most optimistic phase of development reflected in the databases used (i.e. the highest phase of clinical 
development was taken; and reports on clinical development were preferred over those of suspension or 
discontinuation of studies). The possibility of cross- and co-resistance was not taken into account when assessing 
in vitro activities. Also, assumptions were made on in vitro activity based on class properties in the absence of 
data in order to present a best-case scenario. All of these approaches could have lead to the pipeline looking 
‘healthier’ than it actually is. 
Based on this optimistic approach, the main results from the analysis conducted by the ECDC/EMEA Working 
Group were as follows: 
• Of 167 agents identified by the searches, there were 90 antibacterial agents with in vitro activity in a best-
case scenario (based on actual data or assumed based on known class properties or mechanisms of action) 
against at least one organism in the panel of bacteria selected for their public health importance. 
• Of these 90 agents, 24 were new presentations of licensed antibacterial agents and 66 were new active 
substances.
TECHNICAL REPORT The bacterial challenge: time to react
23
• Of the 66 new active agents, 27 were assessed as having either a new target or a new mechanism of 
action, thus potentially offering a benefit over existing antibiotics. 
• Of these 27 agents, there were 15 that could be systemically administered. These 15 agents included 13 
for which actual data indicated in vitro activity against at least one of the selected bacteria, and two 
additional agents for which activity was assumed due to known class properties or mechanisms of action. 
• Of the 15 agents with systemic administration, eight were judged to have activity against at least one of 
the selected Gram-negative bacteria.  
• Of the eight with activity against Gram-negative bacteria, four had activity based on actual data and four 
had assumed activity based on known class properties or mechanisms of action. 
• Of the four with activity against Gram-negative bacteria based on actual data, two acted on new or possibly 
new targets and none via new mechanisms of action. 
The data search was done on 14 March 2008. These results therefore represent the state of the antibacterial drug 
pipeline at the search date. Since this date, development was discontinued for several agents. Other agents 
moved from preclinical to clinical development. 
Overall, these findings corroborate earlier reports [3,45-46] on the lack of antibacterial drug development to tackle 
multidrug resistance. In particular, the results of the current analysis indicate that there is a general lack of agents 
that act on new targets or possess new mechanisms of action. 
The IDSA has also attempted to give a systematic account of what is in the antibacterial pipeline, restricted to 
agents in phase II of clinical development. These reports used the following sources to identify drug candidates: 
the Pharmaceutical Research and Manufacturers Association survey of medicines in development for treatment of 
infectious diseases abstracts from the Interscience Conferences on Antimicrobial Agents and Chemotherapy 2002–
2004; the websites of the 15 major pharmaceutical and the seven largest biotechnology companies identified by 
Spellberg et al. [6] and literature referenced in the PubMed database from January 2003 to December 2007. In 
contrast, this study takes also into account investigational agents in phase I of clinical trials. In addition, the 
databases used in the present analysis state screening all of the sources used by IDSA plus considering additional 
specialised literature as well as having regular direct communication with companies (see Annex B2). 
There are many reasons for the current situation, including difficulties encountered in identifying new bacterial 
targets and the possibility that the majority of targets amenable to antibacterial activity have already been 
identified [50]. It is no surprise then that the majority of the investigational agents identified by the searches were 
directed against the same target and had the same mechanism of action as at least one licensed agent. Almost a 
third of those with activity against the selected panel of bacteria were new presentations of licensed antibacterial 
agents. Only 11 out of the 24 new presentations of licensed agents were thought likely to possess an extended 
spectrum of activity (and only against penicillin-resistant S. pneumoniae) as a result of the new route of 
administration.
It could be argued that there are a number of agents in preclinical development that could improve the gloomy 
picture presented here. However, it was decided not to include an in-depth exploration of the preclinical pipeline 
given the high attrition rate of compounds during this phase of development and also due to the scarcity of data 
available for review. Moreover, it should be noted that the databases used excluded information on agents that 
were, so far, under development only by academic groups. The search criteria contained EphMRA or EphMRA-
derived ATC codes, which are assigned by the database companies and could be subject to variability. Both of 
these limitations were minimised by performing the literature search for reviews on PubMed and by selecting 
broader criteria for the main search as described previously. 
Multidrug-resistant Gram-negative bacteria constitute a major challenge for the future [45]. Therefore, the lack of 
systemically administered agents with activity against Gram-negative bacteria displaying new mechanisms of 
action found in this study is particularly worrisome, and more so when the high attrition rates for agents in early 
stages of clinical development [50] is taken into consideration. In fact, it is unclear if any of these identified agents 
will ever reach the market, and if they do, they may be indicated for use in a very limited range of infections. Even 
if a public health driven approach for R&D of antibacterial agents is commenced in the near future the burden of 
resistance will inevitably increase during the next years. Therefore, a European and global strategy to address this 
serious problem is urgently needed, and measures that spur new antibacterial drug development need to be put in 
place.
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4 Conclusions 
• There is a gap between the burden of infections due to multidrug-resistant bacteria and the development 
of new antibiotics to tackle the problem.  
• Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious 
infections in humans. 
• Resistance is increasing among certain Gram-negative bacteria. 
• Infections caused by multidrug-resistant bacteria are associated with excess morbidity and mortality.
• Infections caused by multidrug-resistant bacteria are associated with substantial extra costs. 
• Very few antibacterial agents with new mechanisms of action are under development to meet the challenge 
of multidrug resistance. 
• There is a particular lack of new agents to treat infections due to multidrug-resistant Gram-negative 
bacteria.
• A European and global strategy to address this gap is urgently needed. 
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Glossary
Antimicrobial agents: medicinal products that kill or stop the growth of living microorganisms and include 
antibacterial agents (more commonly referred to as antibiotics), which are active against bacterial infections. 
Antibacterial (antibiotic) resistance: is the ability of a bacterium to survive and even replicate during a course 
of treatment with a specific antibiotic. Failure to resolve an infection with the first course of antibiotic treatment 
may mean that the infection may spread, may become more severe and may be more difficult to treat with the 
next antibiotic that is tried. 
• Intrinsic resistance: natural resistance of bacteria to certain antibiotics.
• Acquired resistance: normally susceptible bacteria have become resistant as a result of adaptation 
through genetic change.
• Multidrug resistance: corresponds to resistance of a bacterium to multiple antibiotics. 
Attrition rate: the number of antibacterial agents moving out of development over a specific period of time. 
Bacteria are microorganisms and can be divided into categories according to several criteria. One way to classify 
bacteria is based on staining them using a method that divides most bacteria into two groups – Gram-positive
and Gram-negative – according to the properties of their cell walls. 
Bloodstream infection: presence of bacteria in the blood, in quantities that allow isolation from blood samples 
in the laboratory. 
Burden of disease: refers to the overall impact of disabling clinical or public health conditions at the individual 
level, or at the societal level or to the economic costs of diseases. 
Carbapenemase: enzyme produced by some bacteria causing resistance to carbapenems, a class of antibiotics.
Cephalosporins: a class of antibiotics. The class is often divided into generations to indicate incremental 
increase in spectrum of antibacterial activity. Third-generation cephalosporins, for example, have a broad 
spectrum of activity and further increased activity against Gram-negative bacteria as compared to previous 
generations of cephalosporins.
Clinical development of antibacterial agents: see annex B. 
Clinical trial: a research activity that involves the administration of a test regimen to humans to evaluate its 
efficacy and safety. 
Commensal flora: the natural bacteria that live on and in a healthy person.
Comorbidities: the presence of one or more diseases or disorders in addition to a primary disease or disorder. 
Drug (antibiotic) formulation: the composition of a dosage form, including the characteristics of its raw 
materials and the operations required to process it. Examples are oral formulation (by mouth), intravenous 
formulation (by infusion into a vein). 
Extended-spectrum beta-lactamase (ESBL): enzyme produced by Gram-negative bacteria causing resistance 
to most beta-lactams, including most penicillin and cephalosporins. 
Enterobacteriaceae: a family of Gram-negative bacteria. Examples of common Enterobacteriaceae are 
Escherichia coli and Klebsiella pneumoniae.
Gram-positive bacteria: bacteria that are stained purple or violet by Gram staining.  
Gram-negative bacteria: bacteria that cannot retain the purple stain of Gram staining and are stained pink as a 
result of Gram staining. 
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In vitro activity: activity tested outside the living body and in an artificial environment. 
Morbidity: any departure, subjective or objective, from a state of physiological or psychological well-being. 
Mortality rate: an estimate of the portion of a population that dies during a specified period. 
Multidrug resistance: occurs when a bacterium is resistant to the action of many types of antibiotics. This 
severely limits the choice of antibiotics that would be suitable for treatment.
Non-fermentative bacteria: bacteria that do not ferment sugars, which distinguishes them from fermentative 
bacteria.
Nosocomial (hospital-acquired) infection: an infection occurring in a hospital or another healthcare facility, 
when the infection was not present or incubating at time of admission.
Pharmacokinetics: study of the rate of drug action, particularly with respect to the variation of drug 
concentrations in tissues with time, and the absorption, metabolism and excretion of drugs and metabolites (i.e. 
what the body does to the drug).  
Pharmacodynamics: study of the physiological effects of drugs on the body (or on microorganisms within or on 
the body), the mechanisms of drug action and the relationship between drug concentration and effect (i.e. what 
the drug does to the body or microorganisms).
PK/PD: Pharmacokinetics/pharmacodynamics. 
Phases of clinical trials of antibiotics: see annex B. 
Preclinical development of antibiotics: see annex B. 
Priority medicines: those medicines which are needed to meet the priority healthcare needs of the population 
(‘essential medicines’) but which have not yet been developed. In this Report, a ‘priority’ medicine for a priority 
disease is by definition also a significant improvement over already marketed agents. 
Soft tissue: tissues that connect, support, or surround other structures and organs of the body, e.g. tendons, 
ligaments, muscles, fibrous tissue. 
Systemic (or systemically administered) antibiotics: compounds administered parenterally (e.g. 
intravenously) or systemically absorbed after oral administration. 
Systemic infection: an infection in which the pathogen is distributed throughout the body rather than 
concentrated in one area.
Topical antibiotics: antibiotic applied to body surfaces, e.g. to treat skin infections.
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Annex A: Mandate, composition, meetings, 
roles and responsibilities 
Mandate
The ECDC/EMEA Joint Working Group is agreed by the ECDC and the EMEA to oversee, facilitate, follow-up and be 
part of the work aimed at producing a report on the gap between the increasing prevalence of multidrug-resistant 
bacteria and antibacterial drug development aimed at treating such infections. The Scientific Committees of the 
ECDC and the EMEA will finally adopt the Technical Report prior to publication.  
Composition and meetings 
1. Core members of the Joint Working Group 
• Two members appointed by each of the Scientific Committees from ECDC and EMEA, respectively.  
• One representative from the administrative staff of EMEA and ECDC, respectively. 
• Two co-opted independent experts. They will be selected by the working group for their 
clinical/microbiological expertise in the field of interest. 
• The paid consultant employed to run the project. 
2. Observers
• One observer from each of DG Enterprise, DG SANCO, DG Research and ESCMID17.
3. Invitation of additional experts to attend a working group meeting 
• Invitation of additional experts is made on a case-by-case basis according to the expertise required to 
provide advice. The Chairperson, together with the members of the implementation group, will call for 
additional experts to attend working group meetings or other ad hoc technical meetings that may become 
necessary.
• The working group may decide to invite representatives of interested parties (e.g. industry organisations) 
to address and discuss issues of common interest, such as aspects on the drug development pipeline.
Chairperson and Vice-Chairperson
The Chairperson – and in his absence, the Vice-Chairperson – is in charge of the efficient conduct of the business 
of the working group meetings and shall in particular: 
• Plan the work of the working group meetings together with the implementation group and paid consultant. 
• Ensure the fulfilment of the mandate of the working group. 
• Be in charge of the conduct and running of the meetings. 
• Seek confirmation from working group members that no conflict of interest exists in relation with topics 
raised during meetings.    
The Vice-Chairperson will deputise for the Chairperson when the latter is unable to chair either all or part of the 
working group meeting. On such occasions, the Chairperson will seek the agreement of the Vice-Chairperson as 
early as possible, prior to the meeting and the implementation group shall be informed immediately. 
Election of Chairperson and Vice-Chairperson  
Core members of the working group shall elect one of the core members to act as Chairperson and one to act as 
Vice-Chairperson.  
Organisation of meetings  
1. Dates for working group meetings will preliminary be set for 2008 with additional ad hoc meetings to be 
decided as appropriate (see point 7). 
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2. The working group shall meet at the ECDC in Stockholm. Ad hoc meetings may also take place at the EMEA 
in London.  
3. The meetings will be held and minuted in English and sent to EMEA and ECDC Scientific Committees for 
information.
4. The draft agenda for every meeting shall be circulated, together with the relating documents, by the 
implementation group/paid consultant, in consultation with the Chairperson, at least seven calendar days 
before the meeting. 
5. When a member of the working group is unable to participate in a meeting, or part of a meeting, he/she 
must inform the paid consultant/implementation group in advance, in writing. 
6. A minimum of five core members are required to attend the working group meeting or the meeting will 
have to be rescheduled. 
7. The proposal for an ad hoc working group meeting and the conduct and objectives of such meeting shall 
be proposed by the Chairperson in collaboration with the implementation group. The implementation 
group/paid consultant shall inform the working group on the need for an ad hoc meeting as early as 
possible.
Roles and responsibilities of the working group 
In accordance with its mandate to oversee, facilitate, follow-up and advise on the work aimed at producing a 
report on the gap analysis, the working group and its Chairman will regularly be kept updated on the progress of 
the project as set out in this document. 
• The main role of the working group will be to advise the implementation group with regard to: 
 definitions of objectives and main output, i.e. the gap analysis and technical reports; 
 overall strategy; 
 definitions of the individual components of the gap analysis;   
 proposals for improvements to reach the objectives; 
 discussions on the scientific methodology for the individual project;  
 content of the technical reports; and 
 giving support to the implementation group and paid consultant as far as meeting the objectives, 
including the final reports. 
• The members shall provide declarations of interest in the area of antibiotic drug development by filling in 
an agreed form provided by EMEA/ECDC. In addition, members shall declare any conflict of interest as 
appropriate before or during the working group meetings. At the discretion of the Chairman, the member 
may be prevented from active participation on certain specific issues. 
• The members shall commit to active participation of the activities of the group. Should a member fail to 
attend two consecutive meetings, replacement of the member will be considered by any of the appointing 
bodies.
Roles and responsibilities of the implementation group 
Under the authority of the working group, the implementation group shall closely oversee and lead the work of the 
paid consultant responsible for the daily running of the individual projects.  
• Provide technical and scientific lead to the paid consultant. 
• Provide legal and regulatory lead to the paid consultant. 
The composition of the implementation group includes EMEA and ECDC staff representatives, one of the co-opted 
members and the paid consultant. 
Responsibilities of the paid consultant 
The overall projects will be run and monitored by a paid consultant. The responsibilities of the paid consultant 
include the close monitoring of the ongoing projects to ensure timely feedback of the work in accordance with the 
agreed timetable. The paid consultant will be part of the implementation group and will produce: 
1. A regular report on the progress of the different projects, which includes: 
 monthly written updates to the implementation and working groups members; and 
 regular telephone discussions and agreements with members of the implementation group and the 
working group Chairperson. 
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2. In consultation with the Chairperson and the implementation group, the relevant documents to be 
conveyed to the working group, i.e. timely invitations to meetings, provision of agendas, documents and 
presentations, as appropriate. 
3. In liaison with the different study contractors to convey technical and scientific steer to meet the objectives 
of each project and thereby to ensure high quality output from the projects. 
4. The overarching technical report and reports on the subprojects in liaison with the working group members 
and implementation group. 
Observers and contractors 
In addition to the observers mentioned above, the working group may admit additional representatives of 
international organisations, EU scientific committees or political bodies with interests in the issues of antimicrobial 
resistance as observers during working group meetings. 
In addition, contractors of the scientific projects may be invited to discuss and give presentations to the working 
group.
General provisions 
The members of the working group, as well as observers and all experts, shall not disclose any information, which, 
by its nature, must be covered by professional secrecy (i.e. not to divulge any of the materials discussed at the 
meetings until such time that this material becomes published, unless otherwise sanctioned by the working group). 
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Annex B: Additional information on the study 
on the burden of infections due to multidrug-
resistant bacteria and pipeline analysis 
B1 Burden study 
B1.1 Table of parameters used  
Parameter Unit Value Reference 
No. MRSAa from LRTIb / from BSIb Ratio 1.25 [21]
No. MRSA from SSTIb / from BSI Ratio 5.25 [21]
No. MRSA from UTIb / from BSI Ratio 0.75 [21]
Attributable mortality of MRSA BSI % 9.8 [26]
Attributable mortality of MRSA LRTI % 7.0 [26-27]
Attributable mortality of MRSA SSTI % 1.4 [26-27]
Attributable mortality of MRSA UTI % 0.2 [26-27]
Extra length of hospital stay for MRSA BSI Days 8 [29]
Extra length of hospital stay for MRSA LRTI Days 9.4 [29]
Extra length of hospital stay for MRSA SSTI Days 5 [29]
Extra length of hospital stay for MRSA UTI Days 6.1 [28]
No. VREc from wound infection / from BSI Ratio 4.67 [23]
No. VRE from intra-abdominal infection / from BSI Ratio 1.89 [23]
No. VRE from UTI / from BSI Ratio 3.44 [23]
Attributable mortality of VRE BSI % 25 [23]
Attributable mortality of VRE wound infection % 6 [23]
Attributable mortality of VRE intra-abdominal infection % 3 [23]
Attributable mortality of VRE UTI % 9 [23]
Extra length of hospital stay for VRE BSI Days 15 [23]
Extra length of hospital stay for VRE wound infection Days 6.2 [23]
Extra length of hospital stay for VRE intra-abdominal infection Days 2.6 [23]
Extra length of hospital stay for VRE UTI Days 5.4 [23]
No. penicilllin-resistant Streptococcus pneumoniae from respiratory tract 
infection/ from BSI 
Ratio 2.7 [24]
No. third-generation cephalosporin-resistant Klebsiella pneumoniae from LRTI 
/ from BSId
Ratio 1.19 [22]
No. third-generation cephalosporin-resistant K. pneumoniae from SSTI / from 
BSId
Ratio 0.33 [22]
No. third-generation cephalosporin-resistant K. pneumoniae from UTI / from 
BSId
Ratio 1.19 [22]
Attributable mortality of third-generation cephalosporin resistant E. coli and K.
pneumoniae BSI % 30 [19]
Attributable mortality of third-generation cephalosporin resistant E. coli and K.
pneumoniae LRTI % 21 [19, 27]
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Parameter Unit Value Reference 
Attributable mortality of third-generation cephalosporin resistant E. coli and K.
pneumoniae SSTI % 4 [19, 27]
Attributable mortality of third-generation cephalosporin resistant E. coli and K.
pneumoniae UTI % 1 [19, 27]
Extra length of hospital stay for third-generation cephalosporin resistant E.
coli and K. pneumoniae infection Days 11 [18-19] 
No. carbapenem-resistant Pseudomonas aeruginosa from LRTI / from BSI Ratio 16.0 [22]
No. carbapenem-resistant P. aeruginosa from SSTI / from BSI Ratio 4.67 [22]
No. carbapenem-resistant P. aeruginosa from UTI / from BSI Ratio 11.3 [22]
Attributable mortality of carbapenem-resistant P. aeruginosa BSI % 17.7 [25]
Attributable mortality of carbapenem-resistant P. aeruginosa LRTI % 12.7 [25, 27]
Attributable mortality of carbapenem-resistant P. aeruginosa SSTI % 2.6 [25, 27]
Attributable mortality of carbapenem-resistant P. aeruginosa UTI % 0.4 [25, 27]
Extra length of hospital stay for carbapenem-resistant P. aeruginosa BSIe Days 5.7 [25]
aMethicillin-resistant Staphylococcus aureus (MRSA)  
bBSI, bloodstream infection; LRTI, lower respiratory tract infection; SSTI, skin and soft tissue infection (including wounds and
surgical site infections); UTI, urinary tract infection 
cVancomycin-resistant enterococci (VRE) 
dThese ratios were also used for third-generation cephalosporin resistant Escherichia coli.
eThis extra length of hospital stay was also used for LRTI, SSTI and UTI. 
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B1.2 Nomogram  
This nomogram can be used to calculate yearly in-hospital costs attributable to infections due to multidrug-
resistant bacteria with various values for the total number of infections, the average extra length of hospital stay 
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B2 Pipeline analysis 
B2.1 Flow-chart of the pipeline analysis 
167 agents from search
(presented to reviewers)
90 agents met inclusion criteria
24 new presentations
of licensed antibacterial agents
66 new active substances
Novelty
15 agents with new mechanism of 




B2.2 Agents with same target as previously licensed agents. 
List A. New presentations of licensed antibacterial agents with assigned in vitro activity that goes 
beyond the known spectrum of activity of the licensed presentation, based on optimistic 
assumptions of the activity that might be achieved by using a different route of administration 
(n=11, search date 14 March 2008). 
Amikacin inhalation  
Amikacin sustained release  
Ciprofloxacin inhalation  







Ciprofloxacin otic solution 
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List B. Agents that were assessed as acting on the same target via the same mechanism of action as 
that of at least one previously licensed antibacterial agent (n=39, search date 14th March 2008). 
AFN 1252 E 5065 RX 1741 
AR 709 EDP 420 Sulopenem 
BC-3205 Faropenem medoxomil Tebipenem pivoxil 
BC-7013 Finafloxacin WCK 1152
CBR 2092 Iclaprim WCK 771A 
Cetefloxacin MCB 3837 Zabofloxacin 
Cethromycin Rifalazil TD 1792
CS 834 MK 2764 WQ 3034 
TR 701 Nemonoxacin Clinafloxacin 
DC 159a NXL 103 Dalbavancin 
DW 286 Ozenoxacin Trospectomycin 
DX 619 PF 3709270 Besifloxacin 
E 4767 Ranbezolid NPI-32101 
List C. New topical* antibacterial agents with new target or new mechanism of action and in vitro 
activity based on actual data or assumed based on known class properties or mechanisms of action 













* Oral non-systemically absorbed agents have been also counted in this category.  
† In addition, Iseganan can also be given via inhalation. 
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B3. Technical information provided by the pipeline database 
companies
B3.1 Adis Insight R&D (Wolters Kluwer Health) 
Internal processes 
Information Sources 
Proceedings from 150+ major scientific meetings are monitored routinely and pertinent data presented as posters 
and abstracts are included in R&D Insight within 10 days of each meeting. News from media releases is added to 
the database daily from PR Newswire, Business Wire, Canada Newswire, Hugin Online, Japan CNN and direct from 
company websites that do not use these services.  
Additional sources are: 
• Direct contact with pharmaceutical company representatives to verify information. 
• Company reports and regulatory filings are routinely checked for new and updated information. More than 
3 500 companies are monitored. 
• Information from ongoing clinical trials is incorporated from international media releases and more than 20 
clinical trial registries, such as www.clinicaltrials.gov.
• Scientific journals: more than 1 400 journals are monitored routinely for inclusion 
All information sources are evaluated by expert staff for relevance to R&D Insight. All staff are provided with 
comprehensive training by experienced senior editors on the selection of relevant material. 
Inclusion and exclusion criteria 
All information on drugs being developed by pharmaceutical companies and biotechnology companies, either alone 
or in collaboration with non-commercial institutions, is entered into the database for all countries, all therapeutic 
areas and all indications. Information about the following is excluded:  
• Medical devices (unless in combination with a drug). 
• Generic drugs, unless undergoing reformulation and regulation as new drugs, and biosimilars. 
• Drugs launched in all major markets prior to 1995 that do not have new development since launch. 
Company profiles – Inclusion criteria 
Adis R&D Insight contains links to more than 400 company profiles, detailing information about each company’s 
subsidiaries, history, R&D expenditure, licensing agreements, mergers and acquisitions, as well as links to the 
complete R&D pipeline for each company. 
To qualify for the addition of a Company Profile to R&D Insight a company must have: 
• 10 or more active drugs in development; 
• be amongst the top 50 biotechnology companies according to MedAd News (Engel Publishing); 
• be a client of Wolters Kluwer Health with five or more products in development; or 
• made a specific request to have a company profile included. 
Timeliness
• Client queries and requests: response within 24 hours of receipt. 
• Media releases: three-day turnaround.  
• Scientific conference processing: completion 10 working days post conference. 
• Company reports: annual, quarterly and half-yearly reports completed throughout each year as they 
become available; 
• Clinical trial data: incorporated when the data is made available. 
• All relevant scientific data added for completeness in advance of regulatory submission (phase III). 
EPhMRA codes 
These are codes used by the European Pharmaceutical Market Research Association (EPhMRA) classification 
system. These codes mainly classify products according to their indications and use. Therefore, the same 
compound may be found in several classes, depending on the product. For example, Naproxen tablets can be 
classified in M1A (anti-rheumatic), N2B (analgesic) and G2C (if indicated for gynaecological conditions only). The 
main purpose of the EPhMRA classification system is to satisfy the marketing needs of pharmaceutical companies.
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Research The early development of a drug research programme, including lead screening and lead validation. Used when a 
company has identified a small number of candidates and is conducting early research to identify or optimise lead 
compounds for further in vitro and in vivo testing. 
Preclinical The drug is being tested in vitro (cells, test tubes) or in vivo (animals). The developer applies for permission to go 
into clinical testing.  
The procedure for applying for permission will depend on the country. For example, in the USA, an Investigational 
New Drug (IND) application must be granted before clinical trials can begin.  
Phase 0 Purpose: the drug is being tested in first-in-human trials conducted in accordance with US FDA 2006 Guidance on 
Exploratory Investigational New Drug (IND) studies. These studies are designed to speed up development of 
promising drugs by establishing very early on whether the agent behaves in human subjects as was anticipated 
from preclinical studies. Studies will include the administration of single subtherapeutic doses of the study drug to 
a small number of subjects (10–15) to gather preliminary data on the agent’s pharmacokinetics and 
pharmacodynamics. 
Phase I Purpose: to identify adverse events and determine efficacy and initial pharmacokinetics. These trials of a new 
drug or therapy are usually conducted in normal male volunteers. Patients may be evaluated instead of volunteers 
in phase I trials in order to treat immediately life-threatening and serious conditions for which there is no 
comparable or satisfactory alternative therapy available. In addition, expanded access programmes allow patients 
for whom standard therapy is ineffective or contraindicated, and who are ineligible to enter trials, to receive 
investigational drugs in parallel with controlled trials.  
Phase I/II Purpose: to establish the maximum tolerated dose (phase I) and drug tolerability (phase II) in patients. In life 
threatening and serious conditions, the second part may confirm preliminary efficacy. 
Phase II Purpose: to provide a measure of efficacy in addition to short-term tolerability and safety. Phase II studies are 
conducted in patients who have the disease or condition that the drug is intended to treat. Other phase II study 
objectives include determining the minimum dose that is maximally effective, or that is sufficiently effective 
without undue toxicity.  
For the purposes of using R&D Insight, phase II includes phase IIa pilot or feasibility trials, and phase IIb well 
controlled, pivotal trials.  
Phase II/III Purpose: to address within a single trial objective what is normally addressed through separate trials in phases IIb 
and III. The aim of having the seamless phase II/III trial design is so that data can be used more efficiently, 
which may lead to a reduction in the duration of drug development. The trial is designed to assess efficacy and 
safety of the test drug and most are designed with parallel treatment groups rather than crossover. 
Phase III Purpose: to confirm efficacy and monitor adverse reactions from long-term use. In phase III studies, a drug is 
tested under conditions more closely resembling those under which the drug would be used if approved for 
marketing. The goal is to gather additional information about efficacy and tolerability that is needed to evaluate 
the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labelling.  
NB. Approval/disapproval decisions are based on the results of adequate and well-controlled (pivotal) studies. To 
be considered pivotal, a study must meet at least the following four FDA-defined criteria; they must be:  
(1) controlled – using placebo or a standard therapy;  
(2) double-blind – when such a design is practical and ethical;  
(3) randomised;  
(4) of adequate size – study sample size is a common clinical trial design flaw.  
For the purposes of using R&D Insight, phase III includes phase IIIa and phase IIIb trials. Phase IIIb trials 
are usually those undertaken after a regulatory dossier has been submitted.  
Pre-registration All the necessary clinical trials have been completed and the drug is waiting for registration or approval for use by 
a governing body. For example, a New Drug Application (NDA) has been filed with the FDA in the USA.  
Registered The drug has been registered or approved for use in a particular country, or group of countries such as the 
European Union countries. 
Launched The drug has been launched and is now marketed in a particular country, or group of countries. 
Discontinued The company has chosen to stop development. This term is usually qualified by the phase at which development 
was discontinued, for example, discontinued (preclinical). 







If there has been no activity associated with a drug (no commercial information released, no recently published 
studies) for 18 months to two years, the term ‘no development reported’ is assigned. The time frame depends on 
the last phase of the drug. This is the term used until a drug is confirmed as discontinued, withdrawn or 
suspended, or activity is resumed. 
Withdrawn The drug has been withdrawn from the market. This term applies to drugs that have been launched but 
subsequently withdrawn from the market. 
Suspended This term is used when a company has suspended development of a drug, often in order to focus on the 
development of some other drug. Development has not been discontinued. 
Clinical (Phase 
unknown) 
This option is only used when the clinical phase of development is unclear. 
Phase groupings 
Active This group will include all active phases: those which are not discontinued, suspended, withdrawn, or have a no 
development reported status. 
Inactive This group will include all inactive phases: those which are discontinued, suspended, withdrawn, or have a no 
development reported status. 
Clinical This group will include all active, clinical phases from phase 0 to launched. 
Preclinical This group will include active, preclinical and research phases. 
B3.2 Pharmaprojects (T&F Informa UK Ltd.) 
Development status 
The following development stages are used throughout Pharmaprojects: 
Preclinical All stages of preclinical investigation including discovery, research, lead optimisation. 
This is also used where the developmental status is unknown. 
Phase I clinical trial Human pharmacokinetic and volunteer studies. 
Phase II clinical trial Early clinical studies to demonstrate activity in patients. 
Phase III clinical trial Multicentre clinical trials to obtain data for registration. 
Clinical trial In clinical trials, stage unknown 
Pre-registration (also known as pre-approval) Registration documents submitted but not yet approved. 
Registered (also known as approved) Registration obtained but marketing not yet started. 
Launched Product available in at least one market. 
Suspended Development suspended with the possibility of restarting. 
Discontinued Development terminated. 
No development reported No evidence of continuing development reported. 
Withdrawn Withdrawn from marketing. 
How the drug profiles are updated 
As a drug advances and new information becomes available, its profile is amended and updated. Where there is 
controversy surrounding important information, this is verified with the developing company before a profile is 
amended.
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The Pharmaprojects editorial staff are continually reviewing worldwide information on new drug development. In 
addition, a significant amount of new information derives from the work of the editorial team of Pharmaprojects’ 
sister publication Scrip World Pharmaceutical News. 
Much of the Pharmaprojects data comes directly from the companies themselves, with extensive reference to 
company websites, reports and press releases. 
There is continual two-way communication between Pharmaprojects staff and their contacts in the pharmaceutical 
and biotechnology industries; both to gather new data and importantly, to verify information obtained from other 
sources.
Every company with an entry in Pharmaprojects is asked to verify, at least annually, the information relating to its 
development pipeline. 
Pharmaprojects editorial staff attend the major international medical and scientific congresses to gather 
information often entering the public arena for the first time. Editors use these opportunities to question company 
personnel attending the congress to ascertain the companies’ development plans for any products reported. This 
ensures that, as far as possible, all new compounds entered into the database are true development candidates. 
International research literature is scanned for new developments; however, there is less dependence on journals 
since, by definition, research information is ‘old’ by the time it is published. 
Criteria for addition to Pharmaprojects of new drug candidates  
Here, we look at the criteria used to decide when to add a new product entry on to the database – and, just as 
importantly, when not to. 
The aim of Pharmaprojects is to provide the most accurate picture possible of what is really going on in 
pharmaceutical research and development worldwide. A vital part of this is deciding whether or not a preclinical 
compound is a genuine candidate for development as a new drug. Now more than ever, in the days of 
combinatorial chemistry and mass screening, there are thousands more compounds synthesised than are 
development candidates. If we added every compound which we came across onto the database, the 
Pharmaprojects active database would be huge and just as full of inactive compounds as if we did not perform the 
‘No Development Reported’ procedure (see later). So we have to be selective. One of the questions we get asked 
most often is what are the criteria our editors use to decide whether or not to add a new compound to the active 
database. Some databases, particularly those that rely heavily on patent applications as data sources, add on 
many more preclinical drugs than are ever seriously considered as drug development candidates. While it can be 
useful to alert those in the industry to early research areas in which companies have interests, the downside is 
that it can give a badly distorted view of what is really in company’s portfolios. At Pharmaprojects, we make 
strenuous efforts to discover whether or not a drug is a serious candidate for development before adding it on to 
the database to keep ours the most accurate reflection of genuine pipelines. 
So how do we do this? Certain data sources themselves can be regarded as confirmation of active development; 
for example, if a drug appears on the pipeline section of a company’s website. Often companies will contact us 
themselves and provide us with details of new drugs that they wish to see included in their Pharmaprojects 
pipeline, particularly if the drugs are available for licensing. Company press releases or R&D portfolio presentations 
are also reliable sources. It gets more difficult if the first appearance of a compound is not in such a source. In 
such cases where it is not explicitly stated that a compound is in development, we will generally contact the 
company concerned to see if it is a pipeline compound. However, many companies decline to comment on early 
development compounds. It is in these cases that we have to use other criteria to decide whether or not to add 
the compound to the database. 
Although we do use a set series of criteria to evaluate the likelihood of a product being in development, we do not 
use a ‘points’ system or a formula; rather we combine our analysis on a number of fronts with the years of 
experience our editorial team has accrued. However, here are a number of points that they will consider. 
Firstly, the name of the compound will be considered. If it is obviously an INN, it is more likely to be a serious 
development candidate. If it is given a more spurious name, for instance one based on the research institute 
where it was synthesised or discovered, it might be treated with more caution. A lot of information can be 
gathered from a compound’s lab code. For instance, Merck & Co’s research compounds begin with an L- code; 
when they are chosen for development, they are rechristened with an MK- number. The same applies with Abbott 
and A- codes becoming ABT- codes. Thus an editor coming across an MK- or ABT- code would be inclined to treat 
this as a potentially serious development candidate. Also, as most companies label their lab codes sequentially, we 
can get a good idea of the age of a compound, with a higher numbered code more likely to be a new candidate. 
A very important consideration is the published source of the data. Most drugs that we have to decide whether or 
not to include will be those presented at conferences or appearing in journals. The identity of the journal thus has 
TECHNICAL REPORT The bacterial challenge: time to react
41
a bearing. For instance, the Japanese Journal of Antibiotics is a very important source of useful information for us, 
but it also includes reports on many antibiotics that have been newly isolated, but are not serious candidates for 
development as medicines. Thus, we have to be careful. 
One of the ways in which we are aided in our decision is by actually looking at the scientific data provided and, in 
particular, its activity. For instance, in the case of an antibiotic, a good rule of thumb is that reasonable activity is 
indicated by an MIC of less than 1mg/ml. Higher MICs may thus indicate a less active compound that is therefore 
less likely to be taken forward. However, this would be organism-dependent, with a higher MIC for a multidrug-
resistant organism being looked at more seriously. 
We can also apply our judgement on other benefits a new drug has or does not have against existing therapies. 
These may include a better side-effect profile, easier dosing regimen, or a more convenient route of administration. 
A serious development candidate would be expected to have advantages in at least one area. 
Finally, we are more likely to add in a new profile if the drug is in a new therapeutic area for the company 
involved. In other words, we may feel it is more important to alert to the fact that a company has moved into the 
analgesic area with its first compound in that field than we would to inform that a 14th preclinical analgesic had 
been reported by a company. In the latter case, we would probably wish to ascertain from the company whether 
the drug was a serious lead rather than just another in a series that they have synthesised. 
So the combination of good contacts, entry criteria and, above all, editorial experience come together in deciding 
whether a drug mentioned in the literature merits inclusion in Pharmaprojects. These procedures, along with 
others such as the ‘No Development Reported’ programme enable us to provide what we believe is the most 
accurate picture of what is really in development at the world’s pharmaceutical companies. 
Keeping our pipelines accurate using the No Development Reported status 
The challenge for Pharmaprojects is to bring you the most accurate picture of what is really happening in 
pharmaceutical R&D. To do this, we must not only add to the active section of the database all compounds that 
enter development, but we must remove all of those whose development ceases. The latter task is not as easy as 
it might seem. Although the discontinuation of products in more advanced stages of development is often high-
profile news, companies are usually unwilling to make announcements about drug failures at earlier stages. It is 
perfectly normal for many compounds not to make it past the early stages of development, but quite naturally, a 
company is not going to send out a press release every time it drops an early drug candidate. 
At Pharmaprojects, we will only list a drug as discontinued if this has positively been confirmed by the company. 
Therefore, we needed to devise a programme to weed out other drugs whose development is not continuing. This 
involves contacting companies to ask them about drugs that we suspect have been dropped, and having a way to 
deal with such drugs that the companies decline to comment on. This is where the ‘No Development Reported’ 
(NDR) status comes in. 
The first stage of the process is to identify which drugs may have dropped out of development. To do this, we 
look at how long it is since we last obtained new information on a drug. With our extensive contacts at companies, 
our wide-range of published information and our series of stringent checks to keep our data up-to-date, if nothing 
new has been heard on a development project for over a year, we begin to suspect that it has halted. Thus, each 
month, we produce from our internal database a list of compounds that have not been updated for some time, 
typically 14 to 18 months (it varies slightly due to our publishing schedule). We then get in touch with all of the 
companies involved, using our extensive network of contacts built up over 25 years, to enquire about the 
development status of the programmes. In some cases, the companies will confirm that development is ongoing; 
in some, they will confirm that development has been dropped. But in quite a large number of cases, they decline 
to comment at all. 
The reasons why companies decline to respond to our questioning are many. In some cases, it is company policy 
never to comment on early development projects. Some companies do not comment on ‘negatives’, such as lapses 
of development. In a small number of cases, although the compound has been reported as a development 
candidate at a meeting, it may never have been a serious candidate, so the company’s Investor Relations 
department or whichever department deals with our queries may have no information on it. 
We now have to decide what to do with these compounds whose development appears to have stalled. The NDR 
category was created to apply to those compounds that are believed to have been dropped, but for which the 
companies involved have not confirmed discontinuation. Thus these entries can be listed as ‘No Development 
Reported’. They immediately become part of the Ceased data set and do not appear as part of a company’s R&D 
pipeline any more. The passing of a drug to NDR is recorded as a Major Event. In fact, there is a little more 
editorial discretion than the above would suggest. Compounds in phase II and beyond are often investigated 
further before being moved to NDR, as since phase II and III trials can take more than 18 months, there may be 
nothing unusual about the lack of new data reported. Preclinical and phase I drugs are much more likely to be 
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switched to NDR after the first inquiry, but even here, each one is looked at on a case-by-case basis. For instance, 
if the text of an entry reads ‘Company A and Company B have entered into a 3yr agreement to investigate COX-2 
inhibitors’, it does not make much sense to mark up the entry as ceased after only 18 months! 
Of course, if Pharmaprojects subsequently uncovers evidence that a project marked as NDR is indeed proceeding, 
it is brought back into active development and ‘Development Continuing’ is recorded to alert subscribers to this 
fact. Around 91% of records marked up as NDR never return to active development. Of those that do, most do so 
within a year of being marked up as NDR. If a profile has been listed as NDR for a year or more, you can thus be 
97-98% certain that its development has ceased. 
The importance of the ‘No Development Reported’ process in keeping our company R&D pipelines accurate cannot 
be overstated. Without this process, we would be giving a totally distorted view of the company’s development 
programme.
At Pharmaprojects, we are committed to reporting only what is really in development at the pharmaceutical 
companies across the world. This involves much more than just scanning the literature and reporting every 
compound mentioned as a development drug. This is a complex process that involves vetting which compounds 
are added and close liaison with all of the pharmaceutical companies. The ‘No Development Reported’ process is 
just one of the methods that we employ to provide a truer picture of today’s drug R&D. 
November 20, 2009  
 
President Barack Obama   
The White House       
1600 Pennsylvania Avenue NW     
Washington D.C. 20500      
                                                                                      
Dear President Obama and Prime Minister Reinfeldt: 
 
I write on behalf of the Infectious Diseases Society of America (IDSA), a 
medical society comprised of more than 9,000 infectious diseases physicians and 
scientists based in the United States (U.S.) and globally, to applaud your mutual 
decision to establish a Transatlantic Task Force (“Task Force”) to address 
antimicrobial resistance, an urgent and growing problem that threatens patient 
safety and public health worldwide.  Your commitment to address this critical 
problem, during the November 2-3 U.S./European Union (EU) summit, provided 
the necessary gravitas that has been missing from past U.S. and global drug 
resistance action plans. 
 
Bad Bugs, No Drugs:  An ‘Impending Disaster’ 
The increasing number of multi-antibacterial drug-resistant infections worldwide 
and the diminishing number of new antibacterial drugs in development with the 
potential to treat these infections represent one of the world’s greatest health 
threats.  The World Health Organization (WHO) has supported this premise, 
identifying antimicrobial resistance as one of the three greatest threats to human 
health.  Two recent reports—one by IDSA1 and another by the European Centre 
for Disease Prevention and Control (ECDC) and the European Medicines 
Agency (EMEA)2—demonstrate that there are few candidate drugs in the 
pipeline to treat infections due to highly-drug-resistant bacteria.  The 
ECDC/EMEA report, for example, found only 15 antibacterial drugs with 
systemic administration in the development pipeline and only five of these had 
progressed to clinical trials to confirm clinical efficacy (Phase III or later).  
Unfortunately, based on past experience, we know that few of these drugs are 
likely to make it to market.  Resistance to the current library of antibacterial 
drugs is a serious problem in all parts of the world including the Asia-Pacific 
region, Latin America, Europe and North America.  Accordingly, the 





1 IDSA Report on Development Pipeline: “Bad Bugs, No Drugs, No ESKAPE” CID 2009:48  
(1 January 2009), Boucher, et al. 
(http://www.idsociety.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=13478) 
 




Prime Minister Fredrik Reinfeldt 
On behalf of the EU Presidency 
Swedish Government Offices 
SE-103 33 Stockholm, Sweden 
 
  
PAGE TWO—IDSA 10 X ’20 Letter to President Obama and Prime Minister Reinfeldt 
 
 
Global Commitment to Develop 10 Novel Antibacterial Drugs by 2020 (10 X ’20) 
The time has come for a “Global Commitment to Develop New Antibacterial Drugs” to address the 
emerging disaster caused by the confluence of increasing bacterial resistance and a stagnant 
antibacterial drug pipeline.  Despite the good faith efforts of many individuals, professional 
societies, governmental agencies, and philanthropic groups, the looming crisis has only worsened 
over the past decade.  The problem only can be solved by bringing together global political, 
scientific, industry, economic, intellectual property, policy, medical and philanthropic leaders to 
discuss and commit to a sustainable antibacterial drug research enterprise.  In IDSA’s opinion, our 
immediate goal should be the development of “10 novel antibacterial drugs by 2020”.  Key to 
advancing antibacterial drug development is the concomitant need to advance the development of 
improved diagnostic tests specific to multi-drug-resistant infections. 
 
Global stakeholders must capitalize on each other’s strengths to create a long-term, sustainable 
research and development (R&D) infrastructure model that provides incentives across the spectrum 
of the antibacterial drug and related diagnostics research enterprises.  Success would be of immense 
benefit to the health of the citizens of the world.  Further, the sustained infrastructure created to 
achieve this goal would help to recreate the highly skilled scientific workforce that was lost over the 
past two decades as many companies abandoned antibacterial drug development and would 
otherwise provide the necessary incentives for perpetual antibacterial drug discovery and 
development.  Microbial evolution causing antibiotic resistance is constant; our collective efforts at 
antibiotic discovery must be constant, or we risk being permanently overtaken by the microbes.  
 
The discovery of antibacterial drugs in the 1930s and 1940s represented a transformative moment in 
human history.  One of the leading physicians of the 20th century, who bore witness to the pre- and 
post-antibiotic era, has described the discovery and development of antibacterial drugs as an 
“awesome acquisition of power” for physicians and their patients.3  Now, 70 years later, in the U.S., 
EU, and around the world, the challenges posed by infections caused by the multiply-drug resistant 
pathogens continue to escalate, causing patient morbidity and mortality, as well as increasing health 
care costs.  As a global society, we have a moral obligation to ensure, in perpetuity, that the treasure 
of antibiotics is never lost and that no infant, child or adult dies unnecessarily of a bacterial infection 
caused by the lack of effective and safe antibiotic therapies.   
 
Lending your imprimatur to the creation of a Task Force that will focus on “strategies for improving 
the pipeline of new antimicrobial drugs,” among other important objectives, is a critically important 
first step.  Only after establishing a global commitment to address the antibiotic pipeline problem can 
global multifaceted solutions be instituted.   In 1961, U.S. President John F. Kennedy declared that it 
was possible for humans to walk on the moon.  Many thought the statement was only political and 
impossible to achieve.  History proved Kennedy’s dream was possible in 1969—less than 10 years 
after the President first committed to act. 
 
Antibacterial Drug Pipeline Work Group (“Work Group”) 
To make the Task Force most effective and to achieve our “10 novel antibacterial drugs by 2020” 
dream, we strongly recommend that the U.S. and EU Task Force establish an Antibacterial Drug 
Pipeline Work Group (“Work Group”) as a component of the Task Force.  The Work Group would 
focus specifically on the antibiotic drug pipeline problem as this problem requires expertise not 
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In our vision, the Work Group would: 
 
1. be established as a public/private entity including experts from the national and international 
scientific, industry (including small, medium and large pharmaceutical, biotechnology and 
medical diagnostic companies), medical, economic, intellectual property, reimbursement and 
other policy, public health, philanthropic and governmental communities.  Only through the 
direct involvement of such experts within and without government can true progress be made in 
this critical area; 
2. be co-established by the U.S. and EU, with the U.S. activities being administered from within 
the White House as a component of or working in close collaboration with the U.S. President's 
Council of Advisors on Science and Technology (PCAST) and engaging and relying upon the 
expertise of the White House’s National Council of Economic Advisors and with the EU 
activities being administered from within the European Commission (EC); 
3. be co-chaired on both sides by either a former or current political leader who has the capacity 
to assist in turning recommendations into actions or respected non-governmental and 
international, scientific/philanthropic leaders with an excellent understanding of the economics 
of the pharmaceutical, biotechnology and medical diagnostic industries; 
4. include among its members the heads of the U.S. National Institute for Allergy and Infectious 
Diseases (NIAID), U.S. Food and Drug Administration (FDA), and U.S. Biomedical Advanced 
Research and Development Authority (BARDA) as well as their EU counterparts within the 
European Commission’s (EC) Directorates General for Research (DG Research), Health and 
Consumers (DG SANCO), and Enterprise (DG Enterprise), including the EMEA.  NIAID and 
FDA are co-leads of the existing U.S. Interagency Task Force on Antimicrobial Resistance, 
along with the U.S. Centers for Disease Control and Prevention (CDC).  Moving forward, 
NIAID, FDA, BARDA, and the EC Directorates General and EMEA will be integrally involved 
in developing and advancing pipeline solutions;  
5. include CDC, ECDC, and WHO representation for public and global health expertise as well 
as representation from the U.S. Department of Commerce and its EU counterpart, the EC’s DG 
Enterprise, for expertise in intellectual property rights and the economics of the 
pharmaceutical, biotechnology, and medical diagnostics industries;  
6. explore and identify recommendations across a broad spectrum of policy options including 
those which address regulatory and financial disincentives that negatively impact the 
antibacterial drug and related diagnostics pipeline.  A review of the findings of a new EU-
commissioned report titled “Policies and Incentives for Promoting Innovation in Antibiotic 
Research,” drafted by a team from the London School of Economics and Political Science 
(LSEPS), will be helpful in this regard.  A draft version
4
 of the report was released at an EU 
conference held in Stockholm, Sweden in September 2009; the final report is likely to be 
published by the end of this year.  The LSEPS report provides a good starting point for 
discussion about the kinds of incentives that will be needed to reach the “10 novel antibacterial 
drugs by 2020” goal.  Related to this, the U.S. will need to commission a similar report that 
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7. identify scientific challenges that need to be addressed and consider new research opportunities 
that the U.S. and EU should fund to advance antibacterial drug and related diagnostics 
discovery and development; 
8. immediately examine U.S. and EU funding levels specific to antibacterial drug and related 
diagnostics discovery and development and recommend supplemental funding targets in this 
area consistent with the urgent needs; and  
9. be a transparent process—Work Group meetings/calls must be open to the public and meeting 
materials and transcripts must be made publicly available. 
 
The Task Force’s Other Critical Responsibilities:  Appropriate Use and Infection Prevention 
At the same time the Work Group focuses on the drug and related diagnostics pipelines, the U.S., 
EU, WHO and global community must continue to work towards attenuating the serious problem of 
drug resistance.  We strongly believe that aspects of recommendations 1 through 9 (above) also are 
relevant to the Task Force’s responsibilities related to: (a) the appropriate uses of antibacterial drugs 
in the medical and veterinary communities, and (b) prevention of both health care- and community-
associated drug-resistant infections.  For example, we believe the Task Force, as a whole, should be 
a public/private initiative with non-governmental experts directly represented, its focus should be 
global, and its processes should be transparent.  Also, of great importance, as with the drug pipeline 
problem, numerous components of the U.S. and EU governments will be necessary to tackle the 
appropriate use and prevention issues.  Indeed, the United States’ own Interagency Task Force on 
Antimicrobial Resistance has representation from eleven (11) different agencies representing six (6) 
U.S. departments.  For this reason, the idea of nesting the appropriate use and infection prevention 
efforts under a single department or directorate general likely will not take full advantage of the U.S. 
and EU governments’ breadth of expertise and abilities to respond effectively and would most likely 
result in an insufficient response.  To address these concerns, we believe the U.S. and EU Task Force 
activities, as a whole, should be administered from within the White House, perhaps in conjunction 
with PCAST, and the European Commission, respectively.  
 
Conclusion 
As the new Transatlantic Task Force gets underway, IDSA seeks a “Global Commitment to Develop 
New Antibacterial Drugs” from U.S., EU and other global leaders to take all necessary actions to 
ensure that 10 novel systemically administered antibacterial drugs will be brought to market by 2020 
and to compose the new Task Force in a way that makes this 10 X ’20 commitment a reality.  
Naysayers will immediately discount the 10 X ’20 commitment as radical, impossible, and 
unacceptable to political leaders in the U.S. and EU, industry, academe, governmental experts, and 
the international scientific and medical communities.  Objections are inevitable, but easily nullified 
by recognition of the magnitude of the problem and the moral imperative incumbent upon all 
stakeholders to make it happen.  Without a global commitment to create and maintain the necessary  
sustainable infrastructure, the inventory of safe and effective antibiotics will inevitably shrink as the 
bacteria grow ever more resistant.  This need not happen, if we all work together to make the  
10 X ’20 commitment a priority.   
 





 PAGE FIVE—IDSA 10 X ’20 Letter to President Obama and Prime Minister Reinfeldt 
 
 
IDSA stands ready and willing to work with the U.S. and EU governments and the Task Force’s 
members as this extremely important initiative advances.  Please contact Robert J. Guidos, JD, 
IDSA’s vice president for public policy and government relations, at  or by 
phone at 703-299-0202 should you have any questions or comments.  
 
Sincerely, 




cc:  Kathleen Sebelius, MPA, Secretary, U.S. DHHS 
Anthony Fauci, MD, FIDSA, Director, U.S. NIAID  
Margaret Hamburg, MD, Commissioner, U.S. FDA 
 Tom Frieden, MD, Director, U.S. CDC 
 Robin Robinson, Ph.D, Director, U.S. BARDA  
Robert Madelin, Director General, DG SANCO, EU Commission  
Heinz Zourek, Director General, DG Enterprise, EU Commission 
Jose Manuel Silva Rodriguez, Director General, DG Research, EU Commission 
Melody Barnes, JD, Director, Domestic Policy Council, The White House 
Dr. John Holdren, co-chair, PCAST; Director, Office of Science and Technology Policy  
    EOP, The White House 
Dr. Eric Lander, co-chair, PCAST; Director, Broad Institute of MIT and Harvard  
Dr. Harold Varmus, co-chair, PCAST; President, Memorial Sloan-Kettering Cancer   
    Center   
Göran Hägglund, Minister for Health and Social Affairs, Sweden 
John Monahan, Acting Director, U.S. HHS, Office of Global Health Affairs 
Rep. Henry Waxman, Chair, U.S. House Energy and Commerce Committee  
Senator Tom Harkin, Chair, U.S. Senate Health, Education, Labor and Pensions  
    Committee 
 
 
